Key barriers to antiretroviral (ARV) treatment adherence : Experiences of health care workers (HCW) and antiretroviral therapy (ART) clients in the uThukela district of KwaZulu-Natal. by Cele, Jabulani Reginald.
 
 
Key barriers to antiretroviral (ARV) treatment 
adherence: Experiences of health care workers (HCW) 
and antiretroviral therapy (ART) clients in the uThukela 
























Masters of Social Science (Masters by thesis)  
 
School of Applied Human Sciences 
Discipline of Psychology 
 
University of KwaZulu-Natal 
 
 
i | P a g e  
  
Declaration 
I would like to declare that this dissertation (Key barriers to antiretroviral (ARV) treatment 
adherence: Experiences of health care workers (HCW) and antiretroviral therapy (ART) 
clients in the uThukela district of KwaZulu-Natal) is my own work and all sources of 
information have been referenced. I am not aware of any study on the same phenomenon 
in the same area that may have been submitted for the same purposes at any university or 
college.              
 
Student Name: Jabulani Reginald Cele  






















ii | P a g e  
 
Acknowledgements 
I would like to send volumes of appreciation to Dr Mary van Der Riet, who, without her 
warm attitude, unshaken support and focus, this work would not have been this rich. 
Without her, I would not have gone this far. The road has been very tough, but with your 
support it was doable. Thank you for being available, even in times I would expect it 
would not be possible. To me, you have been something beyond a supervisor and a 
mentor. Thank you for that; you came across as an individual with an attitude that makes a 
scary load approachable and tolerable with joy.  
 
A heartfelt thank you goes to Sister (Sr.) Geetha Ganes Sarjoo firstly for opening the gates 
of the Injisuthi clinic as the operational manager for the facility through her prompt 
response with a letter of permission for this study to be conducted at Injisuthi clinic, a 
clinic that the KZN MEC for Health liked to mention a lot when preparing abstracts for the 
2016 world AIDS conference. Secondly, Sr. Ganes provided support that is beyond the 
words “thank you” when I was in the facility conducting interviews, providing a dedicated 
space for interviews, to an extent of sacrificing her office when she was out of the facility, 
just to ensure that I could comfortably conduct interviews without any disturbance in her 
absence. Sr. Ganes also offered to leave her management seat and ‘went down’ to be one 
of the research participants. The road has been tough, but through your kindness it all went 
well, and I thank you.  
 
T. P. Ngobese: a big word of thank you goes to ‘Tholah’, a HAST (HIV AIDS STI & TB) 
counsellor for Injisuthi clinic. She took the enormous task of recruitment of the clients 
using ARVs upon her shoulders, and ran with it like she was getting paid for it, tirelessly 
organising the interview space, ensuring that it was confidential and promoted the dignity 
of the interviewees. She communicated with all the staff, ensuring that the facility 
personnel were aware that there was a study going on within the facility, and ensured that 
the next research participant to follow was alerted when to follow when the interview was 
finished for the previous participant.  
 
I would also like to send a big thank you to Mr Sizwe Zondo who volunteered to provide 
admin support and be a messenger for this study. He ensured that, in this study, I only had 
to worry about core issues that related to the details of the study, and he took upon himself 
iii | P a g e  
 
work relating to making copies, and organizing and filling necessary documents while 
going to the field. He also ensured that there were enough money, pamphlets and leaflets 
for the researcher to distribute to the research participants, prior to departure to the 
research field.  
 
To Dr M. T. Zulu, the district director for uThukela health district, who made it possible 
for this study to be conducted within the health district under her directorship. She opened 
wide the gates for this study to be conducted, and threw in some necessary advice where 
needed, as well as support that is worth recognition. She was able to respond and 
coordinate that a letter of support for this study reached my hands within a week’s time 
upon her awareness of this study, while she was out of the office. 
 
Matron T. S. Hlongwa, who within two days after hearing about my intention to conduct 
this study in a facility that was under her management, made sure that I got a letter of 
support within a period of two days. This happened within her very tight schedule, since 
she had her duties, plus an action position as a CEO. On top of these, here I was asking her 
to provide me a letter of support as per the district director’s advice. Above all that, within 
two days, the letter of support was in my e-mail box. For that I thank you very much, since 
that was the last critical step for me towards going to Injisuthi clinic for data collection.  
 
Mr Sizwe A. Coka always travelled an extra mile and assumed a role of an emergency 
consultant when I was desperately in need of computer technology support, even late at 
night, when the computer started to became a barrier. He never got tired of me, and, where 
necessary, he would even drive to wherever I was to provide support so that I could 
continue writing.  
 
A gesture of gratitude also goes to Ms I. L. Nyembe, uThukela district ARV coordinator, 
who has always been willing to answer any question relating to ARVs, in support to this 
study. This sometimes happened even in informal consultations, in the parking in front of 
the shops, on social media or over the phone. Through your years of experience working 
on ARV programs and expertise, I went through this with confidence.  
 
Mrs J. L. Lubanga, uThukela health district pharmacy manager, who supported me with all 
the necessary pharmacological information and provided me necessary references in any 
iv | P a g e  
 
need that arose. Moreover, Mrs Lubanga would answer and attend to any question with a 
great demonstration of burning passion when I would have stopped her on her way rushing 
to somewhere to ask any ARV treatment-related question. For that, I would really, from 
the bottom of my heart, like to thank you.  
 
I would like to thank the three community care givers (CCGs) who participated fully in 
this study as research participants, while they came to the clinic for their reports. When 
they were asked to participate in the study, without any reservations, they participated. 
Their years of experience in supporting patients living with HIV at a community level 
brought some valuable and insightful information into this study. 
 
I would like to thank all three Injisuthi counsellors who participated in this study, your 
participation and openness in sharing information from your experience brought some 
tremendous light into this study. Your willingness and eagerness to share information and 
selfless participation in this study are highly appreciated. 
 
To the three Injisuthi professional nurses who participated in the study, you may not be 
aware of the level of the height and length of the value of the light in the information you 
shared. This contributed and made a strong pillar of the insight built around the human 
behaviour in relation to the use of ARVs. You have made me think the MEC for Health, 
Dr Dlomo, was correct in many aspects when saying: Without nurses with ARVs, we 
would not be where we are in the province.  
 
To all Injisuthi clinic staff who showed an understanding and cooperated in all aspects to 
ensure that interview processes conducted in their clinic ran smoothly, I thank you all for 
your cooperation, noticed and unseen. 
 
And last but not least I would like to send a heartfelt big thank you to the five research 
participants who are using ARVs. You responded positively and shared as far and as deep 
as you could, though you became aware of this at a very short notice. What you have 
shared will contribute a lot in the struggle against AIDS.   
 
Thank you Vivien ‘Viv’ Carol O’Neill for your wonderful work in editing this.  
 





It would only serve as some relief for me to dedicate this to a person who gave me courage 
and passion to work with people living with HIV: my late sister, Khanyisile Sweetness 
Cele, who slipped away, through HIV/AIDS, during the national roll out of ART, on the 
27
th
 of April 2004.  
 
It would be sober too, to dedicate this to all the people from all walks of life who are living 
with HIV, especially in South Africa. I hope it is not too long before an HIV-positive 























vi | P a g e  
 
Abstract  
In the fight against HIV and AIDS, the world managed to put more than 17 million people 
on anti-retroviral treatment (ART) in 2016. More than three million of the people on ART 
are in South Africa, and more than one million of them are in KwaZulu-Natal. South 
Africa is the epicentre of HIV and AIDS and has adopted the United Nations’ (UN) 90 90 
90 strategy to end AIDS and the World Health Organization’s (WHO) Universal Test and 
Treat Policy for people living with HIV. All this could be challenged by the level of 
adherence to treatment by the individuals put on antiretroviral (ARVs). This study sought 
to identify barriers to adherence for people using ARVs in a rural area in South Africa.  
    
The main aim of this study was to identify key barriers that make HIV-positive people who 
are using ARVs fail on ART. In total, 14 research participants were purposefully sampled 
and interviewed using semi-structured questions. Of the 14 research participants, five were 
clients who are on ARVs (two men and three women), three facility lay counsellors, three 
facility community care givers (CCGs) and three Nurse Initiated and Management of 
Antiretroviral Therapy (NIMART) nurses.  
    
Data from interviews were analysed using thematic analysis to identify barriers to 
adherence for ART. In this study, 12 barriers to adherence for Injisuthi clients who were 
using ARVs were identified. The barriers identified included: 1) side effects, 2) pill 
burden, 3) no improvement while on ART, 4) use of alternative (traditional) medicine, 5) 
improved health, 6) communication with health care workers, 7) practical problems/socio-
economic issues (poverty), 8) mobility and migration labour, 9) gender and social 
organisation (masculinity), 10) stigma and discrimination leading to fear of disclosure, 11) 
lack of community support, and 12) service delivery.  
 
In the rural context, it is critical for improved adherence to ART to establish interventions 
that tackle socio-economic, stigma and gender issues, together with providing appropriate 
continuous psychosocial support for clients using ARVs when they complain about side 
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Chapter 1: Introduction 
 
Three and a half decades have passed since AIDS (Acquired Immune Deficiency Syndrome) 
was discovered in the summer of 1981. At almost every corner, AIDS was met with fear of 
death, since there was no cure. According to van Dyk (2011), it was only in 1987 that the first 
antiretroviral drug was approved to treat the HIV (Human Immunodeficiency Virus), a virus 
that leads to the AIDS condition if left untreated. That breakthrough was then, however, met 
with resistance from the virus (HIV), as it mutated. Endeavours continued to make treatment 
for HIV better until a set of three drugs was developed to treat HIV; this was called Highly 
Active Antiretroviral Therapy (HAART). According to van Dyk (2011), HAART was 
introduced in 1995, but in South Africa the use of HAART only commenced in March 2004, 
in the Gauteng province, followed by a nationwide rollout in April of the same year.  
 
In 2016, the whole world celebrated meeting a target of 15 million people initiated on ART. 
In the event, this target was exceeded by over two million, since there were more than 17 
million people initiated on ART by 2016. In South Africa, there were more than 3.5 million 
people initiated on ART in 2016, while KwaZulu-Natal celebrated reaching a target of 
putting over one million people on ART, which is the highest number ever seen on ART in 
the country among all the provinces. This made KwaZulu-Natal the only province in the 
country with more than a million people on ARVs. This also shows that KwaZulu-Natal is 
the province with the most people living with HIV in South Africa.  
 
Policies have been changed globally and locally to allow more and more people to be put on 
antiretroviral treatment and new targets are being set. The World Health Organisation (WHO) 
devised a policy called 90 90 90 which identified specific targets for countries to adopt. This 
means countries have to ensure that 90% of the people living with HIV know that they are 
living with HIV; put 90% of the individuals living with HIV on ARVs; and ensure that 90% 
of those on ARVs adhere to treatment to have their viral loads suppressed. In 2016, criteria to 
put individuals on ART improved to accommodate every individual living with HIV, and this 
is known as the Universal Test and Treat policy (UTT) policy (NDoH, 2016a). Starting all 
individuals who are living with HIV on ART regardless of their CD4 count is a 
recommendation by the WHO Guidelines on ART. According to the WHO Consolidated 
guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (2015, 
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p. 6), “efforts should be made to reduce the time between diagnosis and ART initiation to 
improve health outcomes”. Starting all HIV-positive individuals on ARVs is seen as 
contributing to improving health outcomes, thus reducing mortality and improving life.  
 
However, the main threat to the success of the use of ART to control HIV and to curb AIDS 
is how people use ARVs. Taking the lessons learned from tuberculosis (TB), which is 
curable, one will see that the misuse of TB treatment led to resistant types of TB and, 
consequently, TB is still the number one cause of death in the country (Statistics South 
Africa, 2017). This is the case in uThukela District (health plan) as well (UThukela District 
Health, 2014). Most of the resistant strains of TB have resulted from poor adherence to TB 
treatment.  
 
With ARV treatment, there are also people who used ARVs but failed on them and were 
changed onto a second set of pills which are said to be less tolerable and more expensive 
(WHO, 2011). This shows that taking ARVs is not just a smooth journey for individuals 
using them. The taking of pills is not what people do under normal circumstances. People 
have to start taking pills daily because of the need to control their HIV, which means a 
change in their normal day-to-day behaviour. To make that change of behaviour to 
accommodate taking of pills is difficult, and there are a numerous barriers to taking ARV 
treatment.  
 
This study explored the barriers that are hindering taking of ARVs by people who are living 
with HIV in the rural setting of Injisuthi clinic in the uThukela district in the province of 
KwaZulu-Natal. To achieve this, this study examined the experiences of clients who used 
ART and failed on the first-line regimen, and the experiences of the health care workers who 
support them (nurses, lay counsellors and community care givers).  
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Chapter 2: Literature review 
 
2.1 Introduction  
This chapter looks at the burden of HIV in South Africa and provides motivation for this 
study on adherence in the uThukela district of KwaZulu-Natal. This chapter also looks at the 
goals of ART in light of how far the country has travelled towards meeting these goals. The 
state of adherence in the country is attended to through looking at the policies and strategies 
that were supporting adherence previously, as well as the current strategies and policies.  
     
Some of the frameworks on barriers to adherence are explained, interrogated and compared 
with each other. The Department of Health (DoH) national adherence guidelines (NDoH, 
2016b) are also used since they also contain a list of barriers to adherence to TB/HIV and the 
treatment of non-communicable diseases. How the current theories are falling short in giving 
specific information about barriers to adherence at a local level will also be discussed.  
 
2.2 Burden of HIV 
More than 36 million people in the world are living with HIV (UNAIDS, 2016). While AIDS 
was first discovered in the United States of America, its weight has been resting on Africa, 
especially sub-Saharan Africa and more specifically on South Africa. In the ranking of the 
top ten countries in terms of HIV prevalence, South Africa is leading, contributing 18% to the 
world’s people living with HIV, followed by Nigeria at 9% and India third, contributing 6% 
(Piot et al., 2015). In South Africa, the Human Sciences Research Council (HSRC) has 
reported the national prevalence to be at 12.2% (HSRC, 2014), and KwaZulu-Natal has been 
leading among the nine provinces of South Africa (UNAIDS, 2013). The KwaZulu-Natal 
Department of Health (KZNDoH) reported HIV prevalence at 16.9% in 2016 (KZNDoH, 
2016b). According to the antenatal sentinel surveillance report (NDoH, 2013), the uThukela 
district within KwaZulu-Natal (KZN) had an HIV prevalence of 46% in 2009, a prevalence 
never seen anywhere else in the world. This report also indicates that there has been a drop 
from 46% to 40% in the prevalence in this district in 2013. However, the uThukela district 
still remains one of the districts with the highest prevalence of HIV in the province of 
KwaZulu-Natal.  
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Given the burden of HIV in the country, South Africa is at the forefront of the fight against 
the AIDS disease. South Africa should therefore demonstrate leadership coming from insight 
gained from local studies that are conducted from within the country. This might provide 
hope for better control and management of the epidemic. 
 
2.3 Antiretroviral therapy  
The main goal of antiretroviral therapy (ART) is to control HIV. Since its discovery, HIV has 
been a life-threatening virus that has been known to cause AIDS and eventually death. Until 
the discovery of treatment to control HIV, there was no hope for people with this infection. 
HIV replicates itself within the human body while destroying its key defence mechanism, 
thereby exposing the infected individual to other infections. With the discovery of treatment, 
some hope was restored for people who are both infected and affected by the virus. The 
Southern African HIV Clinicians Society (Maartens, Venter, Meintjes & Cohen, 2008) 
identified four main primary goals for antiretroviral therapy: 1) the improvement of quality of 
life, 2) reduction of HIV-related morbidity and mortality, 3) maximal and durable 
suppression of viral load, and 4) restoration and/or preservation of immunological function. 
However this may be threatened by inability to adhere to ART. Van Dyk comments that 
“only 40% of the respondents were able to reach the optimum adherence level of 90% or 
above” (van Dyk, 2010, p. 235). 
 
2.3.1 Improvement of quality of life 
Before the introduction of ART in South Africa, HIV and AIDS meant getting very ill, 
experiencing despair, fear and a sense of doom, and eventually death. A decision to make 
ART accessible to individuals living with HIV renewed hope and improved the quality of 
health care, since it meant that HIV could now be managed. There has been a dramatic 
improvement in the quality of life of those with HIV since the introduction of ART. Even the 
transmission of HIV has been reported to be in decline. According to the Global AIDS report 
(UNAIDS, 2013, p. 12), studies have provided evidence that “antiretroviral therapies can 
reduce the risk of HIV transmission by as much as 96%”. The South African National 
Department of Health on its ART Universal Test and Treat (UTT) fact sheet (NDoH, 2016a) 
indicates that putting HIV-positive people on ART improved general life expectancy in South 
Africa in 2011 by three years for men (from 54 to 57.2) and by five years (from 55.5 to 62.8) 
years for women. The impact of ARVs on improving the duration of life is clear.  
5 | P a g e  
 
2.3.2 Reduction of HIV-related morbidity and mortality 
Rolling out of ARVs in the world has changed the picture of HIV infection from that of 
inevitable death to a chronic and manageable disease. There has been a 43% global decline in 
AIDS-related deaths from 2003 to 2016. In the Southern and Eastern African regions, AIDS-
related deaths have been reported to have been reduced by 36% (UNAIDS, 2016). There is 
hope that if ARVs are used correctly, the world will be in a position to put an end to AIDS, 
hence the ambitious 90 90 90 strategy as ‘a call to end AIDS’ (UNAIDS, 2013). Van Dyk 
(2011) comments that the impact of the inaccessibility of ART is seen in the estimated loss of 
about 330 000 lives in South Africa in about three years prior to the national public rollout of 
ART. In the UTT fact sheet, the South African Department of Health claims that the 
breadwinners and parents living with HIV are now able to lead their lives free of the fear of 
death and of leaving behind their children as orphans (NDoH, 2016a).  
 
If ARVs are used correctly, countries are in a better position to reduce HIV-related illnesses 
(morbidity) and deaths (mortality). This is even more critical for countries that are carrying 
the burden of HIV such as South Africa. ARVs could help reduce AIDS and deaths, if used 
correctly, meaning proper adherence by those who are put on ART programmes. If the clients 
who are put on ARV treatment adhere, the virus could be suppressed, and the third 90 of the 
90 90 90 goals could be met.  
 
2.3.3 Maximum and long-term suppression of viral load 
The third 90 of the UNAIDS ‘90 90 90 by 2020’ goals urges countries to ensure that at least 
90% of the clients who are taking ARVs should have an undetectable HIV viral load 
(UNAIDS, 2014). However, when one looks at what people usually do when they are put on 
treatment, it becomes hard to determine how the third 90% goal is going to be achieved. The 
majority of people fail to complete a seven-day treatment course of antibiotics despite the 
message written on the box encouraging them to “finish the course”. What people do is 
critical when it comes to the use of medicine to control viruses, bacteria, and parasites (van 
Dyk, 2011). Van Dyk (2011) comments that when using antimicrobial drugs to control 
viruses, bacteria and parasites, one of two things will happen – the microbes will either die or 
adapt.  
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TB treatment has become less effective over time, and it is important for that not to happen 
with HIV treatment. While TB is easily curable compared to HIV, it has adapted to treatment 
and remains the number one killer in the country (Statistics South Africa, 2015). ARV 
treatment reduces HIV viral load. Viral load suppression is expected to curb HIV 
transmission. We have seen this in the reduction of mother-to-child transmission (MTCT) of 
HIV. According to Montaner (2011), sustained optimum ART could reduce HIV 
transmissions and thus reduce HIV incidence in a country. Putting more people on treatment 
is a strategy to tackle HIV transmission in communities through suppressing HIV viral loads 
at a community level (van Dyk, 2011). This strategy is echoed in the South African 
government’s UTT fact sheet (2016a). When more people are put on treatment, it suppresses 
the community viral load. One of the major contributory factors to viral load suppression is 
adherence to ART. In 2016, the Department of Health added another goal of ART: the 
prevention of HIV transmission. The Department of Health saw the benefit in suppressing the 
communal viral load by ARVs as part of preventing the spread of HIV (van Dyk, 2011). 
 
2.3.4 ARVs and the restoration of immunological function 
HIV is known as a virus that damages the immune system, thus opening the gates for 
opportunistic infections and leading to AIDS. ARVs are known to suppress viral replication 
(or the self-multiplication) of HIV. If HIV is stopped from multiplying while destroying cells 
that are crucial to the functioning of the immune system, known as CD4 cells, this allows the 
immune system an opportunity to recover if it has been already damaged.  
 
2.4 South Africa’s ARV programme 
Treatment of HIV by using ARVs is an important intervention that does more than 
controlling HIV in an infected individual. It has been pointed out that “HIV treatment is a 
unique tool in the AIDS response, preventing illness and death, averting new infections and 
saving money” (UNAIDS, 2014, p. 3). Since ARVs are one of the key interventions in the 
fight against AIDS, more and more individuals who are living with HIV are being put on 
ART. South Africa has the largest number of people living with HIV in the world and the 
largest ARV programme in the whole world. According the Global AIDS update (UNAIDS, 
2016), the world is reported to have 17 million people on antiretroviral therapy and three 
million of these people are in South Africa. This makes South Africa number one in terms of 
the number of people on ART. Out of over three million people who are on ART in South 
7 | P a g e  
 
Africa, the province of KwaZulu-Natal is leading amongst other provinces. In 2016, 
KwaZulu-Natal had more than a million people on ARVs.  
 
ARVs are used in South Africa, like elsewhere in the world, as a means to control HIV 
spread from the infected individuals. ARVs are also used in South Africa to prevent further 
spread of HIV in four ways. Firstly, ARVs are given to pregnant HIV-positive women to 
prevent HIV being transmitted from the pregnant mother to her unborn child. Secondly, they 
are given within 72 hours to anyone who may have had an unintended exposure to HIV, as a 
means to prevent HIV replication and infection after the incident, regardless of the situation 
(NDoH, 2016a). This is known as post-exposure prophylaxis (PEP). Thirdly, ARVs are given 
to the most vulnerable groups, such as sex workers, prior to exposure to HIV. This is done to 
prevent infection by HIV, where an HIV-negative individual is given ARVs for a certain 
period of time before he/she gets exposed to HIV. This is known as pre-exposure prophylaxis 
(PrEP) (NDoH, 2016c). Lastly, ARVs are now given to all individuals who test positive for 
HIV. This comes from the knowledge that, in the presence of ARVs, replication of HIV in 
the body of an infected individual becomes suppressed. This will lead to an infected 
individual having a very low HIV viral load.  
 
However, to achieve this low level of virus in the body of an infected individual, one needs to 
adhere to taking ARVs as prescribed. This means taking ARVs every day, at the specific 
times. If the viral load is low or at a level known as an undetectable viral load, there is a very 
slim chance of infecting others with HIV. Now the government is putting every HIV-positive 
individual on ARVs regardless of their CD4 count in the hope of controlling the further 
spread of HIV (NDoH, 2016a). In this strategy, individuals are expected to start treatment 
(ART) immediately after they are discovered to be HIV positive. For this programme to be 
successful, it will need the individuals to adhere to the treatment given to them.  
 
2.5 ARV adherence  
Adherence is defined by van Dyk (2013, p. 493) as “tak[ing] every dose of medication 
strictly as prescribed”. While the country is doing well in initiating HIV-positive clients on 
ARVs, there is a need to ensure that the individuals on ARVs are adhering to ART. This is 
very important to avoid the mutation and resistance of the HI virus. According to the 90 90 
90 targets, the second 90 is about ensuring that 90% of the people who have discovered that 
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they have HIV are initiated on ART. The third 90 focuses on ensuring that the viral load of 
those who are put on ART is suppressed (UNAIDS, 2014).  
 
Adherence plays a vital role in viral load suppression. According to Kgasi (2017, p. 3), 
“[v]irological failure is almost always related to poor adherence”. It is hard to ensure that 
people who are using treatment are continuing to do so, in order to be certain that a desired 
level of viral load suppression will be attained. While there is a need to focus more on long-
term adherence (WHO, 2015), the National Department of Health has been observing a 
decline of ‘retention in care’ for the clients who are using antiretroviral therapy, with low 
rates of adherence to ARVs, of only 35% in adults at 48 months (NDoH, 2016b). If the viral 
load suppression is currently at 35%, it means there is a long way to go in order to reach the 
goal of a 90% viral load suppression. One of the most important aspects for achieving viral 
load suppression is adherence to ART. This also means that, of the people who are using 
ARVs in South Africa, about 65% of them are not adhering to their treatment. If viral load is 
not suppressed, there are also increased chances that the HI virus will adapt and be able to 
continue multiplying itself in the presence of ARVs. When this happens, there is a risk of 
spreading that resistant strain of the virus to others in the country.  
 
The South African Department of Health is currently changing policies around how HIV is 
managed in the country. These changes include the implementation of a new strategy for 
adherence, with improvements in HIV testing services (NDoH, 2016b) and ensuring that 
HIV-positive clients are initiated on ARVs without being delayed by the ARV literacy 
classes (NDoH, 2014b).  
 
2.6 A need for adherence to ART  
Even though ART clients are not expected to adhere 100%, there is an expected degree of 
adherence in order to achieve better treatment outcome. According to Nsimba, Irunde and 
Comoro (2007, p. 1), a “‘[n]ear-perfect adherence’ should be defined as 95% and above 
adherence”. Studies have so far shown contrasting findings on the state of adherence in the 
sub-Saharan region. According to Mills, Nachega, Buchan et al. (2006, cited in Watt et al, 
2009, p. 1794)  
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Initially, findings about adherence to ART regimens in sub-Saharan Africa have been 
promising. A meta-analysis found that a pooled estimate of 77% of patients in African 
settings achieved adequate adherence (most often measured as taking 95% of 
prescribed pills), compared with just 55% of patients in North American settings.  
 
On the other hand, in her study on clients on ART since the rollout of the ART programme in 
South Africa in 2004, van Dyk (2011, p. 121) discovered that only 40.1% of the clients 
“attained a 90% level of adherence, which is an ideal level of adherence required for 
treatment success”. In the context of HIV and AIDS in South Africa, adherence remains a 
pillar of HIV and AIDS control. Van Dyk’s findings seems to be in line with the Global  
report (UNAIDS, 2013) which demonstrates that in terms of HIV viral load suppression, 
which is an outcome of good adherence, sub-Saharan Africa is only at 29%, which leaves 
71% of people with an HIV level that is not suppressed. Since sub-Saharan Africa is the 
region with the highest HIV prevalence in the world, and KwaZulu-Natal has the highest 
prevalence in the country, this creates a particular problem in dealing with HIV. If adherence 
is not addressed, the control of HIV in South Africa as a whole could be seriously affected, 
since poor “treatment adherence has been closely correlated with viral suppression, while 
non-adherence has contributed to progression to AIDS, the development of multidrug 
resistance, and death” (Weiser et al., 2003, p. 282). 
 
One more problem could be the development and spread of a resistant strain of HIV as is 
currently the case with tuberculosis (TB). Studies have demonstrated that lack of adherence 
can lead to the spread of resistant strains of HIV, treatment failure, more opportunistic 
infections for people that are living with HIV, and ultimately an increase in the death rate in 
the country (Kagee, Swartz & Swartz, 2013). If there is poor adherence to ART, it means that 
the HI virus may get a chance to adapt and replicate itself in the presence of ARVs. Once this 
happens, it means that the virus will start replicating itself regardless of the presence of 
sufficient ARVs.  
 
While adherence to treatment has recently been given more attention, there is still more to 
learn if we are to provide relevant support for people living with HIV. As a country (South 
Africa), we have a very limited choice when it comes to controlling HIV/AIDS. The 
Department of Health and other institutions that are giving ARVs to people living with HIV 
are enrolling individuals into ARV programmes with the hope that they will do as they are 
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told. Van Dyk (2010, p. 244) states that “it is of utmost importance that our ‘access to all’ 
ARV campaigns also include an ‘adherence by all’ component in order to avoid the serious 
health problems we are currently facing in Africa with extreme drug-resistant tuberculosis, 
for example”. The reality is that, in most cases, treatment does not go according to the plan of 
the clinicians. ARV users try, but various barriers prevent them from sticking to the plan 
proposed by the clinicians.  
 
2.6.1 The use of literacy classes to promote adherence to ART 
From 2004, when ARVs were rolled out widely in South Africa, there used to be ARV 
literacy classes. This was done because of a belief that, if users of ARVs are educated about 
the medicine they are taking, adherence to treatment may be better. ARV literacy classes 
comprised three sessions that were attended by the clients who had tested HIV positive before 
embarking on their treatment. These classes used to be a prerequisite for ARV initiation for 
clients living with HIV. They empowered clients with, among other things, knowledge about 
HIV, dealing with issues of disclosure, dealing with stigma, dealing with side effects, dealing 
with opportunistic infections and strategies to adhere to ARV treatment.  
 
Since 2014, there have been changes to this educational support for people who need 
treatment. The new guidelines stated that these classes are no longer a prerequisite before 
starting ARVs, but could rather run concurrently with the taking of ARVs (NDoH, 2014b). 
Van Dyk (2011) says that education in a group or individual form is important for treatment 
adherence. For now, however, clients who test HIV positive are put on ARVs without the 
information they would have received from these classes. It is hoped that they will get such 
information along the way, as they carry on with taking their treatment.  
 
2.6.2 HIV pre-test counselling  
From 1998 to 2016, there used to be an extensive pre-test counselling process in the 
Department of Health to establish some level of readiness prior to testing for HIV. This is no 
longer recommended by the Department of Health (NDoH, 2016c). This means that since 
2016, clients testing for HIV could be tested without pre-test counselling, this if they have 
attended a group information session and seem not to have any concerns before testing. These 
guidelines recommend that provision of information in a group setting is sufficient for a 
client to be tested for HIV. Extensive counselling is only requisite as post-test counselling, 
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that is, after the client has tested. However, this might be affected by the emotional response 
to the HIV test results. In a case where a person tests positive, it may not be a good time to 
bombard that person with information that is important for him/her to adhere to treatment.  
 
In pre-test counselling, a person used to get enough information that could support him/her to 
live with HIV. Now with the current lack of emphasis on pre-test counselling, this 
opportunity to prepare a person for adherence is taken away. This means that many people 
are currently put on ARVs, with scanty or no psychosocial preparedness. This is also 
worsened by taking away the three ARV literacy classes that have been referred to above. 
Removing both literacy classes and pre-test counselling, combined with a very short period 
before a person is expected to start treatment (i.e. same day after testing HIV positive), may 
negatively affect later adherence.  
 
2.6.3 New adherence guidelines of 2016 
The South African adherence guidelines (NDoH, 2016b) provide guidance on what is 
supposed to be done from when a person is discovered to be living with HIV until he/she is 
given treatment. When the person has been enrolled to take chronic medication, he/she is 
expected to take his/her treatment from the clinic and be seen by a clinician monthly for a 
period of six to 12 months. If a person using ARVs has taken the medication correctly, and 
appears to be doing well on ARVs or any other chronic medication, he/she is given an 
opportunity to choose one of three methods of getting their medication that are thought to be 
much easier.  
 
The new South African adherence guidelines seem to be dealing with a barrier that relates to 
ARV clients accessing ARVs. These guidelines specify three ways in which clients may 
access their treatment easily. The first one is called ‘spaced fast lane’. This means that the 
clients can now take their ARVs straight from the clinic pharmacy, without joining any 
queues and without seeing a clinician for a period of about six months. The second one 
involves the ‘adherence clubs’. Adherence clubs are run by a community care giver (CCG) 
who is expected to bring medicine from the clinic to the community for all chronic illnesses 
for people who were registered for this programme. The CCG or adherence club facilitator 
would bring their pre-packed medication and provide health education. These clubs are 
expected to meet once in two months. This method allows the clients using ARVs to access 
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their ARVs in the communities where they live, without any need for them to travel to the 
clinic to collect their medication. They can get a two-month supply in order to limit the 
number of trips it takes to access their treatment. Within these adherence clubs there is health 
education, but the guidelines have limited details about what exactly needs to be done within 
the adherence clubs to enhance adherence.  
 
The third strategy is the use of ‘pick-up points’. This allows stable clients on ART and on 
other chronic medication to access their medication from an accredited (approved) pick-up 
point of their choice (NDoH, 2016ba). A pick-up point could be any place that has been 
assessed and seen as qualifying to store medication, taking account of the safety of the 
medication and that of the clients who would be accessing their medication from that 
particular pick-up point. In all these three methods, there is an ease of access to treatment, 
which addresses some of the barriers to adherence. However, there are some barriers that are 
minimally or not at all addressed by this national adherence strategy. A number of barriers 
that have been identified and may not have been addressed by the national adherence 
guidelines are provided in the discussion below.  
 
2.7 Barriers to adherence 
In order for one to support people who are HIV positive and using ARVs to control it and live 
healthily, one would need to understand the factors that prevent them from adhering to their 
treatment. There is a need to understand how people come to fail on their therapy. Before 
developing interventions to support people on therapy, one needs to gain a deeper 
understanding of barriers to adherence. A number of studies about barriers to adherence are 
summarised in Table 1 below. This information will be merged with van Dyk’s (2013) 
framework of barriers to adherence to form an overarching framework. Although barriers to 
adherence have been given attention, there is still inadequate information about what makes 
people fail on ARVs in various contexts. For instance, there are hardly any studies conducted 
in the province of KwaZulu-Natal about barriers to adherence 
 
2.7.1 Van Dyk’s (2013) framework of barriers to adherence  
Barriers to adherence have been proposed, categorised and ranked in various studies. In the 
literature, barriers vary, perhaps due to context. The framework of barriers to adherence that 
will be used for this study is adapted from research conducted in South Africa in 2011 by van 
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Dyk (van Dyk, 2013). Van Dyk (2013) identified barriers to adherence and classified them 
into eight main barriers: 1) psychosocial or person-centred barriers, 2) practical problems, 3) 
relationship between client and health care worker, 4) medication-related barriers, 5) service 
delivery-related barriers, 6) stigma, 7) health control, and 8) cultural aspects. In this listing, 
the numbering has no value for frequency of the barriers; therefore, it does not mean that the 
barrier labelled as number 1, is more dominant than any other.  
 
To compensate for issues that may not have been covered by van Dyk, barriers from a cardio-
vascular therapy framework are included. As much as this framework focuses on a different 
health issue, it provides a comprehensive framework of barriers to adherence. According to 
the National Heart Foundation of Australia (2011), barriers to medicine adherence and 
treatment strategies can be categorised into five issues: 1) condition-related, 2) therapy-
related, 3) patient-related (intentional), 4) patient-related (unintentional), and 5) social or 
economic factor issues.  
 
Most of the barriers identified above also appear in the South African adherence guidelines 
for HIV, TB and non-communicable diseases (NCD) (NDoH, 2016b) as barriers to linkage, 
adherence and retention in care. In these guidelines, barriers to adherence are classified into 
three main categories, which are: 1) patient-related, 2) provider-related, and 3) structural 
barriers. The three main categories also have their own sub-categories. Most of the issues 
mentioned under these guidelines match the issues mentioned above. A summary of the 
barriers is provided in Table 1, after the barriers from a variety of studies have been 
discussed. Frameworks from other studies will later be merged to form a single framework 
(see Table 2), which will be used to interpret the results from this study.  
 
2.7.1.1 Psycho-social or person-centred barriers 
Van Dyk (2013) understood psychosocial or person-centred barriers to relate mostly to what 
a person does when on ART. According to van Dyk (2013), psychosocial or person-centred 
barriers include forgetting (to take the medication); treatment fatigue; alcohol abuse; sharing 
ARVs; having no intention to adhere; poor support; and failure to disclose.  
 
Forgetting to take treatment may be aggravated by substance abuse. Van Dyk (2011) 
comments that 21% of the ARV users who defaulted claimed that they forgot to take their 
treatment when they used alcohol. Under this category, van Dyk (2013) also mentioned 
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sharing of ARVs as a threat to adherence. ARVs are distributed such that they are enough to 
cover an individual patient for a month. This means that when ARVs are shared with a friend, 
partner, or anyone else, for any reason, they will be insufficient to cover the person who is 
sharing them for the whole month.  
 
Van Dyk (2013) also mentioned that lack of support from significant others is one of the 
challenges that affects adherence for people on ART. Treatment fatigue could mean that 
some individuals may stop taking ARVs just because they are tired of doing so. Van Dyk’s 
(2013) framework also mentions lack of intention to use ARVs by the client. This may be the 
case where a person living with HIV may have been pressured to do so either by the health 
care worker or a family member. Failure to disclose because of stigma and fear of 
discrimination is dealt with in more detail in the section about stigma below.  
 
The cardiovascular framework (National Heart Foundation of Australia, 2011) on the barriers 
to adherence expands this concept of person-centred barriers. In this framework, this barrier 
is split into two sub-categories, in which the intention of the person on therapy is considered 
(i.e. intentional or unintentional) (National Heart Foundation of Australia, 2011). According 
to this framework, patient-related intentional barriers can be sub-categorised into lack of 
symptoms; perceived side effects; rejection of diagnosis; not understanding the importance of 
medicines; interpersonal skills; loss of faith in medicines; and costs and burden of therapeutic 
regimen medicines (National Heart Foundation of Australia, 2011). However, some of the 
sub-barriers mentioned under person-centred in the cardiovascular framework (National 
Heart Foundation of Australia, 2011) fit very well into other of van Dyk’s (2013) barriers to 
adherence and they will be dealt with as complementary in those barriers.  
 
Lack of symptoms in this framework is referring to the situation when a client feels well and 
therefore thinks there is no need for medicine. In this category, the patient believes that, for 
instance, high blood pressure is not as serious as the clinicians say, since the client sees no 
symptoms. As most people take treatment because they want to see symptoms disappear, if 
there are no more symptoms, it could be easy for them to just forget and eventually stop 
taking treatment. Alternately, when the symptoms have disappeared because of the 
medication, clients may be tempted to stop medication, for they may now be feeling well.  
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Perceived side effects, according to this theory, could be a barrier to adherence. This National 
Heart Foundation of Australia (2011) framework lists factors that may influence the client’s 
perceptions such as media reports, belief that there will be side effects because the clinicians 
talked about them, experiences of side effects from other medications, misinterpretation of 
symptoms as side effects, patients insisting that the treatment they are taking is causing side 
effects, and incorrect interpretation of the consumer medicine information (CMI). With 
ARVs, almost all of these could be applicable. For clients, it could be easy to misinterpret the 
CMI because of illiteracy, and that information may be provided in a language that is not the 
client’s home language. In addition, often the information is provided using medical and 
pharmacological jargon. Clients might therefore find it difficult to follow instructions and 
information provided in the packaging material of the medication.  
 
The rejection of diagnosis is seen as a barrier to adherence in the cardiovascular barriers to 
medicine theory. This also relates to clients who are undergoing ART. Clients who are 
diagnosed with HIV, in most cases may deny the fact that they are living with the virus. 
According to the theory of the stages of grief by Dr. Elizabeth Kübler-Ross, denial and shock 
are part of the common reactions when one is experiencing loss. These are mentioned as part 
of the stages toward acceptance of loss or diagnosis (van Dyk, 2013). If one is in denial or is 
rejecting the fact that one has been diagnosed with HIV, there may be a chance that one 
might reject anything that is associated with the diagnosis. Therefore, this may lead to poor 
adherence.  
 
Loss of faith in medicines comes when the clients start feeling that the medicine is doing too 
little to improve their health condition. This may work in support of the above-mentioned 
barrier (i.e. not understanding the importance of medicines). If the client is not aware of the 
importance of taking the medicine, it is easy to lose faith in the medicine and try other 
alternatives. For example, if clients continue to see symptoms while taking the medication, 
there are chances that their faith in the medication may be lost and they may perceive the 
medication as not working.  
 
Many issues in the cardiovascular framework (National Heart Foundation of Australia, 2011) 
overlap with issues mentioned by van Dyk (2013). However, some of the overlapping issues 
are discussed under this heading for comparison purposes.  
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2.7.1.2 Practical problems and challenges  
In the van Dyk (2013) framework, practical problems and challenges include such things as 
transport to the clinic, not having food with which to take the ARVs, robbery (e.g. losing the 
whole month’s supply through this), working shifts, and failure to keep enough supply of 
ARVs when not going to be at home during time for treatment. These barriers relate to a set 
of barriers identified in another study conducted in South Africa. Thus, Knight, van Zyl, 
Sanne, Basset and van Rie (2015) also identified leaving the house without tablets, running 
out of tablets between visits, and lack of transport money as some of the eight reasons they 
identified for sub-optimal adherence to ARV medication. The mention of transport to the 
clinic is not specific in van Dyk (2013). However, Knight et al. (2015) indicate that lack of 
transport money could be a barrier to adherence for individuals on ART.  
 
2.7.1.3 Relationship between client and health care worker 
According to van Dyk (2013), problems in terms of relationship between client and health 
care worker may include lack of support and poor sharing of information with clients (e.g. 
viral load and CD4 count results) so that clients will know when they are doing well (or not) 
and relate this to their previous adherence. An issue about sub-optimal skills of the health 
care professional is emphasised as a barrier to adherence in the cardiovascular framework of 
barriers to adherence (National Heart Foundation of Australia, 2011). However, in their 
classification of barriers, this is listed under socio-economic barriers. The communication 
skills of the health care practitioner are very important when dealing with clients who are 
expected to adhere to treatment for a very long time.  
 
Both van Dyk (2013) and the National Heart Foundation of Australia (2011) found that the 
relationship between client and health care worker could negatively affect adherence to 
treatment. However, this seems to be based more on poor communication skills from the care 
worker’s side. Under patient-related: intentional barriers, the cardiovascular framework 
(National Heart Foundation of Australia, 2011) refers to the interpersonal skills of a patient. 
According to the cardiovascular framework, interpersonal skills could be a barrier in a 
situation where the client fails to communicate how he or she understands and experiences 
his/her condition to the clinician who prescribes the medication. This could be because the 
client does not want to offend the clinician or because of a language barrier.  
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These two aspects together may leave the client not wanting to go back to the health facility 
and they therefore become a ‘loss to follow-up case’ in the health care system. A loss to 
follow-up case, according to the National Department of Health, is a phrase used to describe 
clients who are no longer coming to the clinic, while all the means to trace them and bring 
them back to the clinic for care have failed. According to this, a person becomes a loss to 
follow-up case after a period of three months, over which time all strategies would have been 
used to find the client who is no longer coming to collect his/her medication. This could be 
the case where the clients experienced reprimands from the clinic. According to Campbell et 
al. (2015), reprimands are linked to poor adherence to ART and poor adherence to clinic 
times.  
 
Another aspect in the relationship between the health care worker and the client on therapy 
could be a lack of trust. According to Dale, Bogart, Wagner, Galvan and Klein (2014), 
general medical mistrust was seen to be contributing to low adherence and thus poor health 
outcomes in African American males living with HIV in America. In the cardiovascular 
framework (National Heart Foundation of Australia, 2011), mistrust could be related to 
barriers such as lack of confidence by a patient in a prescriber; sub-optimal interpersonal 
skills for the health care professional; and when the health care worker has insufficient 
knowledge about the health condition he/she is managing.  
 
2.7.1.4 Medication-related issues 
For van Dyk (2013), medication-related issues include such things as side effects, for 
example lipodystrophy, a condition where body fats get redistributed and an individual will 
appear to be changing shape physically. Alternately, one may have been put on a regimen 
that is difficult to follow, such as a regimen that requires taking medication an hour before 
food. This requires planning for both food and medication on a daily basis. In the 
cardiovascular framework (National Heart foundation of Australia, 2011), medication-related 
barriers are referred to as therapy-related barriers.  
 
The therapy-related barriers, according to this cardiovascular framework, include multiple 
doses per day, side effects and frequent changes in medicines (National Heart Foundation of 
Australia, 2011). This class of barriers relates to the pills themselves, as well as the procedure 
for taking them. 
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Multiple doses per day may mean that the client has to remember different times and 
different pills, and the amount of pills to take on a daily basis at different times. For example, 
in the patients who are using ARVs, in the first-line regimen in South Africa prior to January 
2015, one had to take three types of pills. Out of these three pills, two had to be taken in the 
morning and in the afternoon, 12 hourly, at the same time every day, and in the afternoon, the 
client had to remember to take the third pill as well as in the evening. This is because the 
third one is effective for 24 hours, and need to be taken only once a day. Usually the first line 
regimen contains a drug called efavirenz (EFV) which is known for making ARV clients to 
feel drugged(NDoH, 2015). This becomes even harder if the client also had to take other pills 
for other conditions.  
 
Side effects differ in their manifestations. With ARVs, there are side effects that may make 
the client uncomfortable, as is the case with cardiovascular illnesses. Clients on ARVs may 
experience mild to moderate side effect such as headaches, dizziness, an upset stomach, sharp 
pain, nausea, and vomiting (van Dyk, 2011). In addition, there are side effects that could have 
an impact on the client’s lifestyle, such as severe skin rash. This may affect the way one 
looks. Side effects may also change the shape of an individual who is using ARVs. This may 
be due to a redistribution of the body fats in a condition medically termed lipodystrophy 
(Lekhuleni, Mothiba, Maputle & Jali, 2013). This condition was known to be caused by 
Stavudine, one of the three pills prescribed for new users of ARVs as first-line regimen prior 
to 2011 (Lekhuleni et al., 2013).  
 
In a study conducted in Limpopo, South Africa, the clients on ARVs expressed their 
“concerns related to side effects of the antiretroviral drugs” (Lekhuleni et al., 2013 p. 80). 
One man commented: “Since I have started the ARVs, I have developed breasts and this 
caused embarrassment and I was reluctant to continue with ARVs” (Lekhuleni et al., 2013, p. 
80). If clients are experiencing these side effects, this could be a barrier to adherence. If 
clients are feeling ashamed or feel discomfort caused by ARVs, the chances may increase for 
clients to abandon ARVs. Renal problems have been associated with use of Tenofovir for 
individuals who are using ARVs (Brennan et al., 2014). Tenofovir is a drug that is included 
in the set of pills used currently and as a first-line regimen in the country since 2010 
(Brennan et al., 2014).  
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Frequent changes in medicines, according to the cardiovascular framework (National Heart 
Foundation of Australia, 2011), relates to changes of the dosage, or maybe the regimen. On 
ARV, changes often come with the implementation of new guidelines, or if a client is 
experiencing severe side effects related to the medicine.  
 
In the adherence guidelines (NDoH, 2016b), medication-related barriers are mentioned as 
well. According to these guidelines, medication-related issues include pill burden and 
regimen complexity, treatment adverse effects, medicine toxicities or cross-interactions with 
other drugs, and medication palatability or the taste of the medication.  
 
Burden of therapeutic regimen relates closely to how the amount of medication which needs 
to be taken is a barrier to taking medicine. In the theory related to treating cardiovascular 
conditions (National Heart Foundation of Australia, 2011), large amount of medicines relates 
to the fact that the client may be expected to adhere to lifelong therapy, and may have other 
infections or other conditions for which he or she is taking treatment. The amount of 
medicines becomes a barrier when the client is expected to take many medicines, either a 
combination of drugs (regimen) for one condition, or other drugs for other treatments. An 
example of the large number of medicines for people living with HIV would be that, prior to 
the fixed dose combination (FDC) era, a client was expected to take a combination of three 
drugs for HIV. If there was co-infection or presence of other opportunistic infections such as 
TB, a client would also have to take additional medication.  
 
In a study that looked at the impact of the combination of antiretroviral therapy initiation on 
adherence to anti-tuberculosis treatment, results showed that clients adhered to TB treatment 
prior to being initiated on ART (Knight et al., 2015). However, when the clients were 
initiated on ART, an 8-10% drop was observed according to pill count in their adherence to 
TB and an 18-22% drop was observed when measured by an electronic Medication Event 
Monitoring System (eMEMS). This shows how a large amount of medication can become a 
barrier to adherence. Depending on the number of other conditions and the treatments to be 
taken, the client may feel overburdened and therefore adhere poorly to their treatments. 
According to Hodes, Vale, Thabeng, Toska and Cluver (2016, p. 12), “…heavy pill-burden is 
associated with ART non-adherence”. 
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2.7.1.5 Service delivery issues  
In van Dyk’s (2013) framework, service delivery-related barriers would include bad-
mannered staff, clinics or hospitals closing early and therefore preventing access of clients to 
medication, industrial strike action which means clinic employees are not available to give 
medication to their clients, treatment stock-outs and incarceration (e.g. when one is in prison 
and access to treatment may be delayed). The National Heart Foundation of Australia (2011) 
mentions health system or health care team-related barriers. These include such things as the 
patient does not know how to take her/his medication, the patient lacks confidence in the 
prescriber, the patient visits different facilities and the patient miss appointments (National 
Heart Foundation of Australia, 2011).  
 
2.7.1.6 Stigma 
In van Dyk (2013), the stigma barrier leads to fear of disclosing one’s HIV status or the fact 
that one is taking ARVs. This might mean hiding of medication (making it easier to forget to 
take it) and fear of rejection by those surrounding an individual living with HIV, including 
significant others. This may lead to secrecy and thus poor support from others for they may 
not be aware that one is in need of support. The fact that HIV is often stigmatised means that 
people living with HIV may not like to disclose their status in order to avoid being 
discriminated against by others.  
 
According to adherence guidelines, the stigma that is attached to the diagnosis and disclosure 
of one’s status, in this case of living with HIV, is a barrier to treatment adherence (NDoH, 
2016b). In the South African adherence guidelines, stigma is listed as a barrier to adherence 
under a sub-category of barriers called affective barriers. These include depression, anxiety, 
lack of motivation, reduction of self-worth, fear of violence, stigma, and abandonment. 
Stigma has also been pointed out in the literature as one of the causes of poor adherence. 
According to Kehler, Mthembu, Ngubane-Zungu, & Mtambo, (2012) females in Cape Town, 
South Africa feared to disclose their status to their male partners due to stigma and 
discrimination (gender base violence against them). Studies in the United States of America 
have demonstrated that stigma attached to HIV is related to poor adherence to HIV treatment 
(Li, Murray, Suwanteerangkul & Wiwatanadate, 2014). In a study that was conducted in 
Thailand, it was concluded that HIV-related stigma “is a stronger predictor of treatment 
adherence than any type of stigma alone” (Li et al., 2014. p. 6). It is clear that HIV-related 
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stigma could still be a strong barrier to ART adherence despite the fact that HIV has been 
known for more the 30 years. 
 
2.7.1.7 Health control 
Health control barriers in van Dyk (2011) involve a poor will to live, feeling that one has less 
control over what is happening in one’s life (external locus of control), and feeling powerless 
and helpless over one’s health and life (e.g. a “What can I do?” attitude). There is little 
information on health control barriers available in the literature. This relates to the health 
beliefs and attitude barrier in the cardiovascular framework of barriers (Heart Foundation of 
Australia, 2011). However, this is listed under socio-economic issues in this framework. 
What comes out clearly is that the attitude and beliefs of the person about the health condition 
that he/she may be expected to take medicine or therapy for could be a barrier to adherence.  
 
2.7.1.8 Cultural aspects 
Lastly, in van Dyk’s (2013) framework are the cultural aspects which include religious 
beliefs. This barrier includes use of alternative-medicines, for example, traditional medicines 
from unapproved sources who claim to either cure AIDS or to be able to ‘boost one’s CD4 
count’. Research in three African countries (Tanzania, Zambia and Uganda) in 2011 indicated 
that consultation with traditional healers posed a threat to adherence for clients who are using 
ARVs (Wanyama et al., 2017). When the data were further analysed to explore the 
characteristics of the clients who consulted the traditional healers, it was discovered that 
clients who accessed their treatment from a facility that has a traditional healer nearby, and 
clients who had fewer symptoms and had been on ARVs for more than five years, were more 
prone to consult with traditional healers and were therefore at greater risk of failure to adhere 
to the ART (Wanyama et al., 2017).  
 
2.7.1.9 Condition-related barriers 
This set of barriers is not directly mentioned in van Dyk’s (2013) framework, but many of the 
issues pointed out in it are valuable for adherence. According to the cardiovascular 
framework (National Heart Foundation of Australia, 2011), condition-related barriers include 
long duration of therapy. Long duration of therapy refers to the duration of time the client is 
expected to adhere to treatment. As is the case with many chronic disease therapies to 
maintain health, this applies to people who are living with HIV and are using ARVs to 
control it so as to stay healthy for as long as possible.  
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2.7.1.10 Socio-economic issues (poverty)  
Social or economic factors include categories of barriers such as high costs of treatment, and 
poor health literacy (Heart Foundation of Australia, 2011). If people living with HIV are to 
succeed in adhering to their medication, something may need to be done to address poverty. 
In the cardiovascular framework, poverty is mentioned partially under social or economic 
barriers. Poverty (or socio-economic issues) also appears in other categories as lack of food 
and transport money to the clinic (see table 1 below) 
 
The South African adherence guidelines (NDoH, 2016b) also refer to the issue of socio-
economic status as a barrier to treatment adherence. This is mentioned under a cluster of 
patient-related barriers as a socio-demographic barrier. This refers to issues of age, sex and 
socio-economic status of the individual expected to take treatment. Costs of medication can 
also be a barrier to adherence. However, in South Africa, with the decentralisation of ART 
from the public hospitals to primary health care (PHC) facilities, cost of ARVs has been 
eliminated. All the services that are given through PHC clinics are free of charge. This 
includes HIV care and ARVs.   
 
While cost of the medications has been eliminated as one of the barriers in medication 
adherence, there are costs involved in travelling to where the medication is available. Clients 
are still travelling long distances in South Africa to fetch their medications, either because of 
unavailability of health care services in their area or because of stigma attached to HIV. If the 
treatment is accessed a long distance away from where the person lives, this means that the 
users of ART will have to have transport money to the public health facility.  
 
2.7.1.11 Gender and social organisation  
There is no category for gender issues in the Van Dyk (2013) framework. However, there is 
some mention of gender issues when commenting on stigma and discrimination affecting 
adherence (van Dyk, 2011). Van Dyk (2011, p 14) comments that: 
 
Some, especially women, kept their HIV status as well as their ARV-taking behaviour a total 
secret from their sex partners. Of those who kept it a secret from their sex partners, only 21% 
could reach optimum adherence levels. Fear of blame, rejection, losing their children, 
violence and even being killed were some of the reasons given by participants for their 
silence.  
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Clearly in this comment by van Dyk (2011), stigma and discrimination are closely related to 
gender-based violence. It is also clearly shown how this stigma affects adherence by females 
in particular, where females have to hide the fact that they are taking ARVs based on their 
fear of being discriminated against by their male counterparts. In the South African context, 
one would expect gender to play a role in the uptake of treatment since some studies have 
demonstrated differences in terms of gender in health-seeking behaviour. Men seem to be less 
active in taking up HIV-related services compared to women (Skhosana, Struthers, Gray & 
McIntyre, 2006). This poor health-seeking behaviour for men, according to the CAPRISA 
AIDS treatment programme, leads to them accessing treatment at a very late stage of having 
HIV, which contributes to a high mortality rate in men when they are initiated on ART 
(Naidoo et al., 2017).  
 
While it is often not clear why men seem to be reluctant to seek HIV-related services, some 
studies point to masculinity issues. In a study conducted in Zimbabwe, it was observed that 
the “notion of masculinity that required men to be and act in control, to have know-how, be 
strong, resilient, disease free, highly sexual and economically productive” contributes to this 
(Skovdal et al., 2011). In the African rural setting, it is generally accepted that men have the 
last word on most issues, and appear as decision-makers in the families in which they live. If 
men are not taking part in finding out about their HIV status, it is possible that they could 
also influence their partners not to access health care services. Table 1 below shows a 
summary of barriers to adherence discovered by other researchers from 2003 to 2017.  
 
In van Dyk’s (2011) work in the South African context, there is no indication of which 
barriers to adherence seem to be more common than the others. An insight into which barriers 
are dominating in a particular community may assist health care providers and decision-
makers to direct their efforts in the right direction. It might also lead to the development of a 
better-tailored psychosocial support framework for people living with HIV while improving 
adherence to ART and consequently it would lead to better treatment outcome. The following 
section describes the framework of barriers from studies that attempt to identify the most 
dominant barriers to adherence.  
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Table 1: Barriers to adherence 
 
 
2.7.2 Most dominant barriers to ARV adherence  
Some of the studies did not only discover barriers to adherence, but also identified which 
ones were found to be more dominant than the others. It is important for the health care 
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dominant. This helps the health care workers to be in a position to know the issues they 
should screen for and be talking about when seeing their clients.  
 
In a study conducted in Botswana, findings indicated that “[p]rincipal barriers to adherence 
included financial constraints (44%), stigma (15%), travel/migration (10%), and side effects 
(9%)” (Weiser et al., 2003, p. 28). In this study, it was concluded that “if cost were removed 
as a barrier, adherence is predicted to increase from 54% to 74%” (Weiser et al., 2003, p. 28). 
Financial constraints seem to dominate in this study (Weiser et al., 2003), and stigma seems 
to have been number two in the barriers to adherence in Botswana. However, in a study in 
Nigeria that that looked closely at stigma as a barrier to adherence, the authors concluded that 
the effect of stigma and feelings of discrimination were not significant to HIV-positive clients 
who were taking ARVs (Atibioke & Osinowo, 2015). However, other studies still see stigma 
as an important factor influencing poor adherence in the sub-Saharan region. According to 
Campbell et al. (2012), in Zimbabwe, poor adherence in most cases resulted from stigma for 
ART users of all ages.  
 
Most of the barriers identified and ranked in the Botswana study mentioned above were 
common in the Zimbabwean setting. According to Campbell et al. (2012), barriers that often 
appear to be obstacles to the use of ART in Zimbabwe include costs and high clinic fees. This 
shows that in countries where clients pay clinic fees, costs could result in being a serious 
barrier. This is different for South African citizens, where public clinic services are free of 
charge. In the South African context, however, costs (socio-economic issues) could become a 
barrier when clients have to use transport to the point where ARVs are to be accessed. Thus, 
long distances to the clinic where ARVs are to be accessed by the users in the South African 
context could still be a challenge and therefore a barrier to adherence. In Zimbabwe, transport 
and long distances to the clinics are also still a challenge for the clients who are taking ART 
(Campbell et al., 2012).  
 
A recent study has also been conducted looking into the barriers and facilitators to adherence 
in sub-Saharan Africa (Croome, Ahluwalia, Lyndsay, Hughes & Abasa, 2017). This study 
looked into barriers that have been identified from 2005 to 2016 and ranked them in order of 
frequency. According to this study, the most frequently identified barriers (in descending 
order) are: 1) forgetting, 2) lack of access to adequate food, 3) stigma and discrimination, 4) 
side effects 4), and being outside the house or travelling (Croome et al., 2017). The main 
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issue in this study was clients forgetting to take their pills. In the literacy classes held in the 
past, clients were encouraged to choose and use reminders to overcome forgetting.  
 
A second barrier was not having adequate food while on ART. As much as there are no clear 
rules that ARVs must be taken with food, ARV users mention unavailability of food as one of 
the challenges for not taking their medication. According to van Dyk (2011), 37% of the 
ARV users who were not adherent mentioned that they did not have food and therefore could 
not take their ARVs. Stigma and discrimination were also barriers to adherence. Experience 
of the side effects from the ARVs is mentioned as the second-last dominant barrier, followed 
by being away from the house without treatment. This set of barriers is similar to the ranking 
in the Botswana study (Weiser et al., 2003). However, the only difference is that the most 
dominant issue was forgetting to take medication, while in the Botswana setting the main 
issue was financial constraints.  
 
In a study conducted in the Gauteng province in Johannesburg on barriers to ART adherence 
in the South African setting, several reasons for poor adherence were identified. In their study 
of the impact of combination ART and TB treatment on adherence, Knight et al. (2015, p 37) 
discovered that:    
Leaving house without tablets (n = 8) and running out of tablets between visits (n = 8) were 
the most frequently stated reasons for missing doses, followed by forgetfulness (n = 3), 
dosing errors (n = 3), taking medication as prescribed whilst not using the eMEMS lid (n = 3), 
distractions (n = 2), medication side effects (n = 2), and lack of transport money (n = 1). 
 
Most of the barriers identified in Knight et al.’s (2015) study are in line with what Van Dyk 
(2013) refers to as person-centred barriers. 
 
Since there are quite a number of issues that have been suggested by various sources and 
covering different aspects, there is a need for a merged framework for this study. A number 
of barriers to adherence available in the literature are provided using van Dyk’s (2011) 
framework as a master framework, while issues identified by other frameworks to cater for 
the issues that may not have been mentioned in van Dyk’s work have been added. This is 
represented in Table 2 below. 
  
27 | P a g e  
 
Table 2: Framework of barriers to adherence (adapted from van Dyk, 2011) 
 
 
From the above discussion of the literature review, I have indicated that South Africa is 
overburdened with HIV and has the largest number of people on ARVs. South Africa should 
be leading in finding solutions to deal with HIV. In order to reach the United Nations 90 90 
90 targets, South Africa will have to ensure that barriers to adherence are addressed. In this 
section, a set of barriers to ART from a range of studies was presented and then merged into a 
framework to be used for the basis of understanding the results of this study. In the next 
section, the theoretical framework for this study will be presented.  
 
  
BARRIER TO ADHERENCE  EXAMPLES/SUB-BARRIERS  
Psychosocial or person-centred 
barriers 
Relationship between patient and health care worker; treatment fatigue; 
pill burden; forgetfulness; lack of health care support; bad planning and 
running out of ARVs; lack of symptoms; sharing ARVs with friends; 
alcohol abuse; no personal intention to adhere; non-disclosure of status; 
and lack of sharing information with the patient. 
Practical problems/socio-
economic issues (poverty) 
Transport problems to get the clinic; not enough food to eat with 
ARVs; difficulty in planning ahead to have enough ARVs; mugging 
and robbery of ARVs; and working shifts. 
Medication/therapy-related 
barriers 
Side effects; difficult treatment regime to follow; pills too big to 
swallow; multiple medicines for one disease state or several conditions; 
frequent changes in medicines; no improvement; loss of faith in 
medicine; not understanding significance of the medicine; and long 
duration of therapy. 
Service delivery-related barriers Hospitals and clinics not having enough stock; health care workers on 
strike; poor discipline in clinics (bad service and early closure); being 
imprisoned (access to treatment). 
Stigma and discrimination Secrecy; fear and lies; hiding of pills; non-disclosure; no support 
groups due to secrecy and fear of community rejection; and rejection of 
the disease. 
Health control   No control over own health; fatalistic attitude (“Nothing I can do will 
make a difference.”); external locus of control; poor health literacy. 
Cultural aspects  Using medicines from traditional healers with ARVs without 
disclosing to health care worker.  
Communal life style reduces privacy for stigmatised infection such as 
HIV. 
Gender and social organisation 
(masculinity) 
Men have need to maintain masculinity; avoiding health seeking; 
women have less power in relationships with men, making decisions 
including about health seeking.  
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2.8 Theoretical framework   
Various health behaviour theories were considered for this study; however, they had 
limitations. Some of these theories focus on the individual and issues affecting adherence to 
medication. However, focus on the individual and their cognitions in relation to adherence is 
insufficient to explore the range of processes which impact on adherence. For example, the 
behavioural learning theory perspective (Munro, Lewin, Swart & Volmink, 2007) posits that 
the patient’s behaviour depends on the consequences such as punishment or reward. 
Communication theory (Munro et al., 2007) puts forward the patient-practitioner relationship 
as a factor that influences adherence. The cognitive perspective focuses on what is in the 
mind of a patient (perceptions and beliefs) about the disease itself and taking medication, as a 
facilitator or barrier to adherence and, lastly, the self-regulation perspective, like cognitive 
theory, focuses on the individuals’ perceptions of the disease as a threat or not (Munro et al., 
2007).  
 
However, most of these theories have not been developed for a specific context, such as a 
rural African context which is the focus of this study. The focus on the individual and 
individual cognition does not give sufficient explanation for adherence practices which might 
be related to the circumstances surrounding an individual. In a rural context such as that of 
the community in which this study was conducted, there are many other issues outside of the 
individual which influence expected behaviours from the people.  
 
Barriers to adherence, especially in a deep rural setting in an African country, may include 
issues beyond the individual, which are group or community related. Van Dyk (2013) 
cautions counsellors and health care workers to consider collective existence when 
counselling and providing health education to Africans in a traditional African setting. In an 
African perspective, one’s individual behaviour (and consequently adherence to treatment) 
may rather be influenced by the surrounding individuals. This is the basis for the Zulu saying: 
“umuntu ngumuntu ngabanye abantu” (loosely translated as a person is a person through 
other persons).  
 
This collective existence in the African traditional context often contributes to the decisions 
to be taken by individuals, including decisions about health and treatment. Diseases like 
AIDS may be kept as a secret at a wider community level and only disclosed in a smaller 
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group like a family, sometimes not to all family members, therefore affecting taking of 
treatment. With HIV in the African setting, there may be family, partner and community 
issues which may not have been taken into consideration by the health care workers when 
giving medication to their clients. Although these issues may not be significant for the 
practitioners, they may be very important for their clients and thus affect adherence to 
medication. When concluding on the failure of the health behaviour theories to provide a 
single simple solution to medicinal adherence, Munro et al. (2007, p. 14) said: “to understand 
and overcome the barriers to treatment adherence, considerable research is needed”.  
 
Seeing that health behaviour theories focus mostly on individual aspects of adherence to 
medication, frameworks of barriers were seen as more appropriate for this study. The barriers 
identified in a variety of studies were merged to formulate one framework which was used in 
understanding the findings of this study.  
 
2.9 ART and behaviour change   
The taking of treatment is not what people normally do but is necessitated by a need for 
survival in the face of medical challenges. In the presence of HIV, like with many other life-
threatening diseases, behaviour change is needed, which is a challenge on its own. For 
example, the WHO (1988) recommends condom use to prevent the transmission of HIV. 
However, despite the risk, people do not easily change their behaviour to use condoms in 
sexual interactions. In a Tenofovir gel study conducted within the uThukela district (as one of 
the nine sites), it was reported that only 35% of the clients (women) adhered to condom use 
(Qhakaza Mbokodo, 2015). This was despite adherence counselling provided on a monthly 
basis and condoms being given to them. Non-adherence to condom use and other sexual risky 
behaviours such as unprotected sex with multiple partners, of HIV-negative or unknown HIV 
status, has been associated with poor adherence to ART.  
 
According to Frank and Duncan (2009, p. 2) it was found that “patients who reported a 
significantly greater number of sexual partners, greater rates of unprotected vaginal 
intercourse, including with partners who were HIV negative or of unknown status, were more 
likely than others to be non-adherent” to ART. This makes it clear that factors that may have 
led to non-adherence in condom usage could be linked to non-adherence to ART as well.  
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ART, too, is expected to contribute as a prevention strategy. This has been the case ever since 
it was discovered that, by suppressing the communal viral load by putting all who are HIV 
positive on ART, there are greater chances of reducing viral transmission (van Dyk, 2011). 
However, it is disappointing that only about 40% of the people on ART manage to achieve 
the desired above 90% adherence. According to van Dyk (2011), studies have shown that, 
like in other chronic treatments, adherence to ART is at around 40% in the sub-Saharan 
region and in South Africa. 
 
Treating HIV requires that an infected individual takes ARVs and adheres to the specific way 
of taking them, as prescribed by the clinicians. Doing exactly as expected and following all 
the procedures proves to be difficult for people at times. The strict adherence to treatment that 
is expected from an individual taking ARVs is sometimes beyond that of other medications 
that are familiar to people. Before 2014, a person using ARVs in South Africa had to 
remember specific times to take their treatment in the morning as well as in the evening, and 
specific pills to take in the morning and in the evening. For example, someone on the first-
line regimen (the first set of pills to start with for everyone being put on ARVs) had to take 
two different types of tablets (Stavudine and Lamivudine) in the morning and in the evening 
the same two types of pills and a third one (called Efavirenz). If one decided to take these 
pills at seven o’clock in the morning, it means one has to take the evening pills at the same 
time in the evening, at seven o’clock. This was so because if an individual is not strict with 
these times, there are chances for HIV to continue multiplying itself and thus creating a 
resistant type of itself. However, since 2014 up to today this challenge does not apply for 
clients on a regimen one with the availability of fixed dose combination (FDC). FDC is only 
available for clients on regimen on in the public health service, thus if an ART client is losing 
regimen one he/she would also be losing a benefit of FDC.  
 
It is clear that taking treatment requires commitment and an extra effort since this introduces 
changes from what an individual normally does. Much more caution needs to be exercised for 
an individual to meet the strict expectations that come with taking ARVs for a person living 
with HIV, to ensure that the virus stays under control. This will also need psychosocial 
support for an individual who is committing to this change of behaviour. For this support to 
be targeted at the right place, there needs to be information available about what may make 
local people fail to maintain this new behaviour (adherence to ARVs) in their lives. 
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2.10 Need for more insight on barriers to ARV adherence  
It is becoming clear now that even with the best treatment available, adherence remains 
important, if not more important than, the medicine itself. This study seeks to explore the 
issue of adherence and barriers to adherence in a particular rural community. There has been 
no such study conducted within the uThukela district since the roll out of ARVs in 2004. In 
most of the districts in KwaZulu-Natal, there is a need for such information to be available. 
Given the highest HIV prevalence and number of people on ART compared to other 
provinces, a focus on this geographic area is important. 
 
Putting clients on treatment is very expensive, and this is also a lifelong therapy. Treatment 
requires a vigilant and easy-to-implement psychosocial support process that is informed by 
evidence from the local context. The results of the study may also give some insight into non-
adherence to other forms of treatment and to other health care interventions such as condom 
use, family planning and TB treatment.  
 
Focusing on adherence and minimising barriers to adherence may be vital in the fight against 
HIV, AIDS and TB, and may help sustain the impact of any other treatment or therapy since 
there is consensus that ART clients’ high viral load is attributable to non-adherence before 
any other factors may come into play. Wasti, Simkhada, Randall, Freeman & van Teijlingen, 
(2012, p. 1) pointed out that “poor adherence can lead to the virologic failure of patients 
using cheaper first-line treatment regimens and the spread of drug-resistant forms of the 
virus, resulting in a public health calamity”. Thus, a study that focuses on exploring barriers 
to adherence could assist in avoiding future devastating effects of HIV infections.  
 
Identifying the most common barriers in the local community may also assist in provision of 
psychosocial support for individuals who are supporting ARV users. This is particularly 
useful within the context of fast-tracking clients and the strain on human resources in the 
health care sector. Knowledge of key barriers to ART adherence is necessary for the nurses 
when in consultation with clients already on ART, to screen for poor adherence. This could 
prove of value since the luxury of having lay counsellors to provide adherence counselling is 
falling away with the KZN policy for career-pathing lay counsellors (KZNDoH, 2013), 
implemented in 2013.  
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Identifying barriers that are most likely to lead to non-adherence for clients who are on ART 
may also assist health care providers in dealing with loss to follow-up (LTFU), which, 
according to the KZNDoH HAST quarter four report, is at 27% (per 12 months cohort) in the 
province of KwaZulu-Natal, while the target is no more than 10% of the clients who are on 
ART (KZNDoH, 2016a). This LTFU has been increasing gradually over the past four years. 
According to this report, in the 2011/2012 fiscal year it was at 15.1%, in 2012/2013 at 17.1%, 
2013/2014 at 24.5%, and in 2014/2015 it was at 27.5% (KZNDoH, 2016a).  
 
2.11 Value for money 
The ART regimen 1 is cheaper than regimen 2, while regimen is 2 cheaper than regimen 3. 
This shows that the cost value escalates with the regimens that a client is re-initiated on. 
According to WHO, in an early warning indicator (EWI) workshop conducted by Dr 
Jacqueline Pienaar, it was shared that it costs $115 to put one client on the first-line regimen; 
$330 for the second-line regimen and $1 500 for the third-line regimen per year in South 
Africa. Keeping clients on the first-line ARV regimen could help save the country money 
which could be invested in other challenges that the country is facing. To keep ART patients 
on the first-line regimen, reasons for poor adherence should be identified and addressed.  
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Chapter 3: Aims and objectives 
 
3.1 Aim of this study 
The aim of this study was to identify key barriers to adherence for the clients who are using 
ARVs at Injisuthi clinic, in the uThukela district of KwaZulu-Natal province. 
 
3.2 Objectives of this study 
The objectives of this study were: 
1. To explore the reasons for non-adherence for clients who use ART. 
2. To discuss barriers to adherence to ART from the perspective of health care workers 
involved with clients who are using ARVs. 
3. To identify barriers that play a major role in poor adherence in clients who are on 
ART.  
4. To compare barriers to ART experienced by clients on ART with barriers reported by 
the health care workers who are involved with ART clients.  
 
3.3 Research questions  
This study attempted to answer the following research questions: 
1. How do clients come to fail to adhere to ART treatment? 
2. What makes it difficult for ART clients to adhere to treatment? 
3. Which are the most common barriers to ART adherence experienced by local clients? 
4. How do health care workers perceive barriers to adherence for their clients on ART?  
5. How does the perception of barriers to adherence by clients on ART differ from that 
of the health care workers? 
6. How do challenges of living with HIV relate to poor adherence?  
  
34 | P a g e  
 
Chapter 4: Methodology 
 
4.1 Research design  
The study used a qualitative approach. According to Nieuwenhuis (2008, p. 51), qualitative 
research involves “a research methodology that is concerned with understanding the process 
and the social and cultural contexts which underlie various behavioural patterns and is mostly 
concerned with exploring the ‘why’ questions of the research”. This approach provides an 
opportunity to gain in-depth knowledge of the phenomenon since, when working with 
research participants, it is able to “focus on the ‘emic’ perspective, the views of the people 
involved in the research and their perceptions, meanings and interpretations” (Holloway & 
Wheeler, 2010, p. 3). This study seeks to develop an understanding of the reasons for poor 
adherence to ART for the individuals who are using ART to control HIV once they are 
infected by it. A qualitative approach helped in developing an understanding of the subjective 
experiences of research participants.  
 
4.2 Location of the study 
The study was conducted at the Injisuthi clinic in the uThukela district because the Injisuthi 
clinic is one of the clinics under Estcourt Hospital, which is the sub-district with the second 
highest number of clients on regimen 2 amongst the four sub-districts of the uThukela 
district. The Injisuthi clinic is a high-volume clinic within the uThukela district.  
 
A programme manager for HCT at HAST unit advised me to contact Dr Lutge, who is the 
head of research within the KwaZulu-Natal Department of Health to find out the procedures 
for obtaining permission for this study. Dr Lutge’s response is attached as Appendix one. 
Permission to conduct the study at the facility was received from the Injisuthi clinic’s 
operational manager (see Appendix two).  
 
4.3 Sampling  
In criterion sampling, according to Nieuwenhuis (2008), the researcher decides the criteria to 
be met by the research participants to be selected for the research. The number of the 
participants and their characteristics are decided upon prior to the study. Criterion sampling 
was used for this study, since the client research participants had to meet important specific 
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criteria: 1) HIV-positive individuals, 2) have a history of using antiretroviral treatment 
(ART), 3) have failed on the first combination of ART, and 4) still continuing to come to the 
clinic (on a different combination set of antiretroviral treatment). The number of clients on 
ART interviewed was five as this is a sufficient number for an in-depth qualitative study.  
 
The criteria for the health care workers were also set prior to data collection. Participants who 
met the criteria were selected and interviewed. This study included three nurses involved with 
HIV-positive clients on ART and three HIV lay counsellors involved with the provision of 
psychosocial support to clients who are on ART and living with HIV. In addition, the study 
include three community care givers (CCGs) linked to this clinic, as they are also involved 
with community support for clients who are on ART.  
 
4.3.1 Recruitment of ARV clients 
Lay counsellors from the facility, since they are already aware of their client’s HIV status and 
whether they meet the criteria, were asked to identify and recruit potential participants. Prior 
to recruitment, lay counsellors who opted to participate in the recruitment process were 
provided with training on how to conduct briefing and recruitment of the participants on 
ARVs while taking care of ethical issues. In this training, the rights and autonomy of clients 
to participate in the study were discussed. The information sheet for participants, which was 
available in both English and isiZulu (see Appendix three A – English and Appendix three B 
– isiZulu), was given to the counsellors for use while recruiting. The rights of a client to 
choose not to participate and to withdraw from participating during the study without any fear 
of consequences were discussed. Clients’ right to privacy and confidentiality was 
emphasised.  
 
When recruiting participants, lay counsellors gave potential participants a copy of an 
advertisement (Invitation to participate in a study). This invitation was also available in the 
local language, isiZulu (see Appendix four A – English and Appendix four B – IsiZulu). The 
participants who were willing to participate were taken through the information sheet, 
described above. The lay counsellor helped clients with understanding the content of the 
information sheet and addressing any questions as they came. Participants who were still 
interested after going through the information sheet were then booked for a research 
interview time slot by the counsellor.  
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4.3.2 Sampling and recruitment of health care workers 
When recruiting health care workers (lay counsellors, community care givers and nurses), the 
researcher asked the operational manager (OM) of the facility (during a briefing meeting with 
her) to identify two or three nurses who met the criteria for the study (i.e. nurses who are 
directly involved with clients who are on ART). The OM was herself willing to participate in 
the study, since she fulfilled the criteria. She then identified another two nurses who met the 
criteria. All three lay counsellors at the clinic met the criteria since they were all directly 
involved with the provision of psychosocial support to clients who are living with HIV and 
on ART. CCGs were at the clinic on the first day of data collection for their report meeting. 
They were approached by the lay counsellor who was involved in recruiting the ART clients 
and asked if they were willing to participate in the study. Three CCG’s agreed to participate.  
 
4.4 Data collection methods 
Semi-structured interviews were used to interview the five participants on ART, as well as 
the nine health care workers. Nieuwenhuis (2008, p. 87) defines a semi-structured interview 
as “a two-way conversation in which an interviewer asks the participants questions to collect 
data and to learn about the ideas, beliefs, views, opinions and behaviours of the participant”. 
This data collection method was suitable for this study for it allowed participants to narrate 
their experiences of the barriers to treatment adherence at their own pace and share 
information they were willing to share. Semi-structured interview schedules were used for 
this study with probes for clarification where necessary. Two sets of semi-structured 
schedules were used and translated into isiZulu. The first schedule was used for participants 
on ART (see Appendix five A – English and Appendix five B – isiZulu), and the second one 
was used for the health care worker participants (see Appendix six A – English and Appendix 
six B – isiZulu). Data were collected from participants from the 2
nd
 to the 11
th
 of November 
2016.  
 
The interviews were conducted in a private space; some in the operational manager’s 
consulting room and others in the Emergency Medical Services (EMS) team room in the 
clinic. Prior to the interviews, the researcher first established whether the client had agreed to 
participate in the study and understood the contents of the information sheet. For the 
participants using ARVs, the researcher ascertained the ART regimen the client was on, and 
confirmed that the client had been on another ART regimen prior to the current one. 
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The researcher further explained the purpose of the study, disclosed the information about the 
institution he is working under and the contacts of the relevant persons in the institution 
(UKZN). The researcher also explained the rights of the participant in the study, emphasising 
voluntariness of participation and the right to stop participating without fear of negative 
consequences,  as well as the right not to answer questions should they not wish to do so. The 
informed consent form was read to all the clients in the language of the client (isiZulu) and 
signed by the clients (see Appendix seven A – English and Appendix seven B – isiZulu). 
Permission to audio-record the interview was obtained from all participating clients (see 
Appendix eight A – English and Appendix eight B – isiZulu), and written informed consent 
was obtained prior to interviews.  
 
ART research participants were asked to respond to open-ended questions about the 
discovery and disclosure of HIV status; source and kind of support (from the clinic 
community and other); personal reasons for needing ARVs; health status prior to ART; what 
happened immediately after ARV initiation; duration on ART; challenges experienced on 
ART; the most difficult times on ART; ensuring taking ARVs even when they were to travel; 
what they used/are using to remind themselves when it is time for ARVs; storage of ARVs 
when at home; their reasons for being switched from the first-line regimen and what they 
were doing to ensure that they did not run out of medication (see Appendixes Five A and B). 
This was accompanied with probes where necessary.  
 
All the health care workers were interviewed using semi-structured questions with probes for 
clarification where necessary. Health care workers responded to questions about services they 
offer to HIV-positive clients; duration of time they have spent working with people living 
with HIV in their lives including before their current occupation; average number of HIV-
positive people they offer services to and people who use ARVs they meet per day; type of 
services they offer to their clients; difficulties and reasons for stopping ARVs they may have 
been told by their clients; and their own opinion of what makes their clients stop taking 
ARVs (see Appendixes Six A and B).  
 
Interviews were conducted in isiZulu, the mother tongue of the participants. The interview 
with the OM of the clinic was conducted in English. All participants were encouraged not to 
mention their names and identifiable features of themselves during data collection. The 
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clients were asked their age in terms of range rather than a specific age (e.g. between 30 and 
35, or between 35 and 40).  
 
All collected data were transcribed verbatim and translated by the researcher. To check the 
validity of this translation, the English version transcription was given to a fluent isiZulu- and 
English-speaker (with a post-graduate qualification) to back-translate, that is, to translate 
back into isiZulu. The researcher then checked the translated transcript for consistency of the 
original translation with the back-translation and made adjustments where necessary.  
 
All 14 participants were compensated at the rate of R75 per participant (including the nurses, 
lay counsellors and CCGs) for transport costs and their time spent in the research. This was 
only disclosed to participants at the end of the interview. Participants on ART also received a 
variety of health information and educational material in the form of booklets and pamphlets. 
 
4.5 Data analysis  
Thematic analysis, according to Braun and Clarke (2006), is a method that is used in 
qualitative research to identify, analyse and report patterns (also known as themes) within 
data. Data for this study were analysed using this method. Braun and Clarke (2006) further 
state that thematic analysis involves six phases in which the researcher familiarises 
him/herself with his/her data; generates initial codes; searches for themes; engages in theme 
reviewing; defines and name themes; and produces the report out of the themes identified. 
These phases are not meant to follow any serial process (Braun & Clark, 2006). 
 
In this study, the researcher started getting some sort of familiarisation with data during data 
collection from research participants and data transcription from audio-recordings. Further 
familiarisation with data occurred during data translation from isiZulu to English. This was 
followed by reading and re-reading data while generating codes across the data set. Issues 
were coded during data reading and re-reading at the time they were recognised or seen as 
important prior to interpretation (Fereday & Muir-Cochrane, 2006). This process was 
followed by identifying themes among participants who use ARVs, where patterns were 
identified based on the codes that were given in the previous phase. This was followed by 
identifying patterns for health care workers in their respective categories (i.e. lay counsellors, 
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community care givers, and lastly the NIMART nurses, who initiate and manage clients on 
antiretroviral therapy).  
 
Identified themes were labelled and presented to a fellow student who is also doing a 
master’s degree in psychology at another university and to the researcher’s supervisor, in 
order to review identified themes so as to ensure objectivity in these themes. Adjustments 
were done where necessary as per the fellow student’s and supervisor’s suggestions. 
Identified themes were also compared across all four categories of the research participants in 
order to establish the perspectives of the research participants. This was followed by 
comparing themes that were identified in this study with the ones that were identified and 
discussed in the literature review. Lastly, the discussion of themes was produced from the 
analysed themes and presented to the supervisor as the first draft for a review, and 
adjustments were made as per the supervisor’s recommendations and advice. This research 
report follows a structured framework that was formulated from a number of studies 
identified during literature review in which van Dyk’s (2013) framework was used as an 
overarching framework.  
 
4.5.1 Credibility  
Credibility is defined as the degree to which the research represents the actual views of the 
research participants and not those of the researcher (Moon, Brewer, Januchowski-Hartley, 
Adams & Blackman, 2016). Credibility seeks to ensure that research claims are as objective 
as possible and free from the researcher’s bias. In this regard, Nieuwenhuis (2008) further 
comments that, if qualitative researchers speak about research validity and reliability, they 
mean the credibility and trustworthiness of the research. These aspects were achieved in this 
study by ensuring that data were collected from participants who were involved in many 
aspects in antiretroviral therapy. This combination of participants with a variety of 
backgrounds included people who used ARVs and defaulted but were still on the ARV 
programme; nurses who initiated clients on ARVs and monitor their progress; lay counsellors 
who tested people for HIV, linked them to an ARV programme and supported them to adhere 
to their treatment; and CCGs who supported people living with HIV in the community 
through home visits. This variety was aimed at ensuring that this phenomenon was looked at 
from a variety of perspectives. 
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Interviews were conducted through semi-structured questions which were made available 
both in English and isiZulu (see Appendixes five and six) until saturation was reached. This 
was done to limit the language barrier during interviews that may have limited the quality of 
the data. The researcher took steps to ensure that data transcription was done verbatim from 
the audio-recording, and compared with notes taken during interviews. Translation and back-
translation were used to confirm that the meaning was not lost during translation from 
English into isiZulu. Lastly, analysis and interpretation were done as closely as possible to the 
data and through going back and forth from themes to the data to confirm the analysis. 
Furthermore, the researcher was assisted by a post-graduate student from another university 
and a study supervisor to decide on some of the issues and to make conclusions from the data.  
 
The researcher also made sure compensation for time and travelling costs (for clients who 
travelled to the venue of the study) was only disclosed and provided at the end of the 
interviews, in order to ensure that this did not influence what the participants had to say 
during the interviews.  
 
The researcher possesses more than 17 years of experience working in the field of HIV, 
teaching, coordinating prevention programmes, counselling, supervising, as a programme 
manager, and working for the Department of Health. This means that the researcher had to be 
extra sensitive when interviewing participants who were on ARVs, allowing them enough 
time to respond to the questions and offering additional time should they wish it, in order to 
guard against leading the participants towards favourable answers or influencing either ARV 
clients or clinic staff. 
 
4.5.2 Dependability 
Dependability of an enquiry “refers to the consistency and reliability of the research findings 
and the degree to which research procedures are documented, allowing someone outside the 
research to follow, audit, and critique the research” (Moon et al., 2016, p. 2). This was 
achieved in this study through a comprehensive and thorough description of the data 
collection, the data analysis procedures, and steps taken to guard against any other 
interference that may have influenced the outcomes of this study. Furthermore, tools that 
were used during data collection are attached as appendices in this report. 
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4.5.3 Transferability 
Transferability is defined by Moon et al. (2016, p. 2) as a kind of external validity that “refers 
to the degree to which the phenomenon or findings described in one study are applicable or 
useful to theory, practice, and future research”. Maree (2008) points out that the aim of the 
interpretive study is not necessarily the generalisation of the study to other populations, but 
rather to gain rich descriptive perceptions of the research participants of a particular study. In 
this study, the accounts of the research participants in the form of transcribed and translated 
data are presented as extracts in support of the themes identified during data analysis. The 
context of the study was provided including the demographic information of the participants 
(see Tables 3 and 4 in the following chapter), and their backgrounds were also described to 
ensure that all these characteristics be considered in terms of transferability of the findings.  
 
4.6 Ethical considerations 
It is very important to consider ethics when one is conducting a study that involves human 
beings in order to protect research participants from any harm, ensure they are free from 
abuse and to ensure that as they participate in the study, their welfare is guaranteed. 
According to Terre Blanche, Durrheim and Painter (2006), what led to the growth of research 
ethics were the problems and consequences of the abuses committed by the Nazi medical 
researchers in the times of World War Two in Germany. Therefore, in order to make sure that 
there are no more abuses of research participants while researchers are conducting their 
studies, ethical guidelines were created, research ethics committees (RECs) were formulated, 
and legal acts that protect research participants from abuse were passed and incorporated into 
the constitutions of most countries. An example of this would be the South African Health 
Act (Act 61 of 2003, Chapter 9, Section 71). This act prescribes that all research that involves 
human participants must be approved by an independent accredited research ethic committee.  
 
Approval of this study from the Humanities and Social Sciences Research Ethics Committee 
was received (see Appendix nine). This approval was followed by approval to conduct the 
study from the KZN Department of Health (see Appendix ten). Approval was also supported 
by letters from the uThukela district manager, Dr M. T. Zulu (see Appendix eleven) and Mrs 
T. S. Hlongwa, the acting chief executive officer (CEO) of the Estcourt Hospital as a mother 
hospital to Injisuthi clinic (see Appendix twelve).  
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According to Terre Blanche et al. (2006), ethical research is guided by four philosophical 
principles: beneficence, non-maleficence, justice, and autonomy (which includes respect for 
individuals’ dignity).  
 
4.6.1 Beneficence 
Beneficence ensures that individuals, as far as possible, should be asked to participate in 
studies that will in one way or the other benefit them. Participants in this study were made 
aware of direct and indirect benefits from this study. This information is included in the 
information sheet and was explained in the interview.  
 
4.6.2 Non-maleficence 
Non-maleficence as a principle ensures that research participants are not going to experience 
any direct or indirect harm as a result of them participating in a research study. Care was 
taken in this study that all participants were not asked to respond to offensive or embarrassing 
questions during their interviews. Participants were made aware of their right not to respond 
to some of the questions should they wish not to do so. In addition to this, their names were 
not linked to the study or study findings, and their identity was kept confidential through the 
use of codes in the reporting of the data.  
 
4.6.3 Justice  
Justice denotes the presence of fairness during the course of the research. The rights of the 
clients who participated in this study were taken care of and clients were made aware of 
them, including the right to participate in the study or not. Interviews were conducted in a 
way that was as fair as possible to the participants, and participants reserved their right to 
stop participating in the study should they have felt that the study was no longer fair to them.  
 
4.6.4 Autonomy and respect  
Autonomy and respect for research participants’ dignity is a philosophical principle that is 
there to ensure that individuals are neither forced nor coerced to participate in the research. 
They could opt to withdraw from the study at any time should they wish to do so, without 
negative consequences to them; they could give their consent to participate in the study; they 
were informed of the details of the study; their identity was protected; and their participation 
was voluntary. 
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Participants were given details of the authorities (researcher’s supervisor and university 
research ethics committee) to contact should they have questions, or should they have felt 
there was a need to contact relevant people with matters arising from the study being 
conducted. Information about the purpose and the process of the study was given to the 
participants prior to their participation (see Appendices three A, B, and C for the information 
sheets). Written informed consent was obtained for both participation in the study and for 
audio-recording of the research interview. Raw research data linked to participants’ names 
were not disclosed to any other person before it was anonymised, transcribed and translated. 
Participants were made aware of this procedure which protected their identity. Furthermore, 
interviews took place in a private room/office and nurse’s consultation room as there was 
only an interviewer and the research participant. Participants on ART were encouraged not to 
use their full names during their participation. Participant’s names were not included in either 
the research data or when the research report was written.  
 
4.7 Storage of data  
Data will be stored securely in a locked filing cabinet with my supervisor (Dr Mary van der 
Riet) for a period of five years. When the period of five years has lapsed, all collected data 
will be destroyed. Paper-based, transcribed and translated data will be shredded. Electronic 
audio and written data have been deleted from all electronic systems including data storage 
devices.  
 
4.8 Dissemination of the results 
Research participants were made aware that the results of this study would be made available 
in various forms, and presented to a variety of platforms without mention of their names or 
any identifiable features to protect their right to privacy and confidentiality. This might 
include conference presentations and/or possible journal publications.  
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Chapter 5: Results 
 
In this chapter, the findings of this study will be presented. I will first give a brief description 
of the participants of this study and then the thematic analysis of the data is presented. 
 
5.1 Research participants 
Research participants for this study included people from a variety of backgrounds: people 
living with HIV and using ARVs; lay counsellors; community care givers (CCGs); and 
nurses. 
 
5.1.1 Antiretroviral therapy (ART) clients 
Five clients who were using antiretroviral treatment (ART) were interviewed. All of the five 
clients who were using ART had been changed from the first-line regimen to another 
regimen. Some had been switched once and put on the second-line regimen, while others had 
been changed twice. Two of the five participants on ART were men, and the remaining three 
were women. Four participants were married. All of the participants on ART were above the 
age of 18. Table 3 presents a summary of demographic information for participants on ART. 
 
Table 3: Demographic information for participants on ART 
Participant Age Period on ART Gender Race  Employment status 
01 30-35 2 years Male African Unemployed 
02 55-60 >3 years  Male African Unemployed 
03 40-45 8 years Female African Unemployed 
04 30-35 Not available Female African Unemployed 
05 30-35 9 years Female African Unemployed 
 
 
5.1.2 Health care workers (HCWs)  
Nine health care workers who are involved with people living with HIV participated in this 
study. These health care workers were in three categories (lay counsellors, community care 
givers and nurses). 
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Lay counsellors are employed by the Department of Health. They work in the clinics to 
provide psychosocial support in HIV. Their work includes counselling and testing for 
individuals who want to know their HIV status and provision of ongoing counselling and 
psychosocial support for clients who test either HIV positive or negative. Ongoing 
counselling also includes adherence counselling for clients who are using ARVs. Three lay 
counsellors participated in this study (see Table 4). Their knowledge is valuable, since they 
talk to clients who are using ARVs from the point where they got to know their HIV status, 
up to where they have failed on their treatment.  
 
CCGs are also employees of either the Department of Health or the Department of Social 
Development, employed to provide health care support for patients at household level. Their 
normal work is to go to the community to provide health education, and assess the state of 
health for individuals at home and refer them if necessary. Three CCGs employed by the 
Department of Health participated in this study. At the time of their interviews for this study, 
they all had more than ten years of experience in the community, supporting people who are 
living with HIV and the ART clients in this study.  
 
Nurses who are helping HIV-positive individuals with ARV initiation and further support 
were also interviewed. Three nurses who are trained in NIMART (Nurse-Initiated 
Management of Antiretroviral Therapy) participated in this study (see Table 4). They are 
based at the clinic to provide, amongst other services, HIV-related services to HIV-positive 
individuals. Information from these nurses is also valuable for this study, for it is part of their 
work to start clients on ARVs and talk to them very often when they come to the clinic to 
collect their medication; when they are sick; when they experience side effects; and when 
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Gender Race  Services provided to clients living with HIV 
and on ART according to the health care 
workers (HCW) 
06 CCG +/- 16 years Female African Health education; counselling on treatment 
adherence; education on the importance of 
adherence to clinic appointment dates; nutrition.  
07 CCG +/- 11 years Female African Counselling on disclosure; healthy eating; and 
substance abuse.  
08 CCG +/- 21 years Female African Family HIV education; counselling on HIV, 




+/- 10 years Female African ARV education; ongoing counselling; adherence 
counselling (including screening for side 
effects); education on blood check-ups; 




+/- 13 years Female African disclosing blood results (CD4 count and viral 




+/- 12 years Female African Disclosing blood results (CD4 count and viral 




+/- 10 years Female Indian Facility management; provision of treatment; 
counselling; address questions on HIV and 
treatment; education about ARVs; management 
of children on ARVs.  
13 NIMART 
nurse  
+/- 6 years Female African Provision of treatment; counselling; initiation on 
ARVs; TB and STI screening; address questions 
on HIV and treatment; education about ARVs. 
14 NIMART 
nurse 
+/- 5 years Female African Provision of treatment; counselling; initiation on 
ARVs; TB and STI screening; address questions 
on HIV and treatment; education about ARVs. 
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5.2 Key barriers to adherence   
In the analysis of the data, it is clear that the different participants in the study highlight 
different issues in relation to adherence. The findings will be presented and discussed in 
terms of how the four groups of participants highlighted particular issues (i.e. participants 
who are using ARVs; lay counsellors who are supporting them from the clinic; CCGs who 
support them from the community; and nurses who put them on ARVs and provide ARVs to 
them while attending to their other clinical needs).  
 
In the process of data analysis, a number of themes were identified. The following twelve 
issues were dominant in the transcripts: 1) side effects, 2) pill burden, 3) no improvement 
while on ART, 4) use of alternative (traditional) medicine, 5) improved health, 6) 
communication with health care workers, 7) practical problems/socio-economic issues 
(poverty), 8) mobility and migration labour, 9) gender socialisation and organisation 
(masculinity), 10) stigma and discrimination leading to fear of disclosure, 11) lack of 
community support, and 12) service delivery. These themes will be presented using extracts 
from the data, commencing with problems mentioned by the participants that are medicine 
related.  
 
Extracts from the research participants are used in this section to illustrate the issue that is 
being identified. Where necessary, brackets are also used to give an interpretation of what 
was said by the clients if it was in isiZulu and was hard to translate. In this case, the extract 
would include what was said by the client in isiZulu in italics with an interpretation put in 
brackets. To illustrate parts of the transcript which were left out, an ellipsis is used. Some 
sounds that were made by the participants while thinking before responding to a question are 
written in italics like: Uhhh ...; ah ...; errr; ehhh. Exclamation marks were included when 
participants were talking in a raised tone of voice, implying exclamation. Pauses were 
indicated in brackets. 
 
Extracts from research participants are presented without their original names but with codes, 
for example: ‘Participant 01 (MC 30-35)’, where M stands for male, C for client using ARVs 
and 30-35 is the age of the participant. In the case of a female participant, an F is used 
making the descriptive code look like ‘FC 35-40’. In the case of health care workers, three 
different codes are used: 1) ‘Participant 09 (L/C)’ is used for a lay counsellor at Injisuthi 
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clinic; 2) in the case of CCGs, it might be ‘Participant 06 (CCG)’; and 3) in the case of the 
NIMART nurses at Injisuthi clinic, it would be ‘Participant 14 (NN)’.  
 
5.2.1 Side effects  
All five participants who were antiretroviral therapy clients complained about side effects 
when they were asked about their most difficult time on ARVs. The side effects mentioned 
included: changing of body shape/growing and hardening of the stomach, feeling drugged by 
the medication, vomiting, and producing excessive urine (“they made me pass a lot of 
urine”), losing weight, and dizziness. Participant 01 (MC 30-35) said: 
The time that was the most difficult to continue with taking medication...? Ehh... I would just 
tell the truth, you see … the first day… ehh... just the first week, when they were drugging 
me. 
 
Participant 02 (MC 55-60), when asked about the most difficult times on ART, said: 
I did not see it that badly ... it was just that condition I have experienced … but now it has 
stopped … that thing of having dizziness like that. 
 
On the same question, the female participants also mentioned side effects. Participants 03 and 
05 complained about their stomach growing. Participant 03 (FC 40-45) and Participant 04 
(FC 30-35) complained about the pills making them vomit. When asked about the most 
difficult times on ART, Participant 04 (FC 30-35) said: 
On the first ones? Errr … ukuthi ayengiphalazisa-ke lawo! [The thing is they made me vomit, 
those ones!] They really made me vomit uhhu. 
 
When asked the same question, Participant 03 (FC 40-45) said: 
 Hha …! Ukuphalaza! hha …! [Vomiting …!] I saw it as the most difficult one. 
 
This was expressed with fear of imminent death, saying: 
... when you vomit, you could see that you are going straight away hhayi! … no I could see 
that I was losing power, phela ukuphela kwamandla uyahamba! Ukuphela kwamandla, 
uyahamba! [If you are losing power, it means you are dying!]  
 
In their narratives, clients talked about the side effects and how these disturbed their lives. 
For almost all the clients, side effects seem to have played a vital role in non-adherence. The 
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next sub-topic is about how side effects for ARVs interfered with the daily lives of the people 
who use ARVs, thus affecting adherence.  
 
5.2.1.1 Side effects affected life routine 
The side effects of taking ARVs affected different aspects of the clients’ lives. When clients 
were not getting support and appropriate guidance in order for them to cope with side effects, 
they made decisions that affected adherence. This included reducing dosage, not taking the 
pills for some time, or even abandoning ARVs for a while. The two male clients complained 
about a noticeable increase in the need to urinate, interfering with work and travel. Participant 
02 (MC 50-55) says:  
Now if I were to travel by car, they bother me such that I must go and stop the car, now and 
then for passing the urine … Things use to happen like this, they make me urinate a lot. If I 
am to travel, maybe I am supposed to go to eGoli [Johannesburg].  
 
It is interesting that both male participants complained about a noticeable increase in the need 
to urinate; however, it was not clear what treatment regimen they used, and therefore the 
relevant cause could not be established. Participant 01 (MC 30-35) said:  
Ukuchamake kade ngichama impela … hhayi mfowethu angifuni ukuqamba amanga [passing 
of urine, no, my brother, I don’t want to lie] cishe u two litre kade ugcwala [approximately, I 
would make two litre full]. Approximately two litres would be full of urine! Every day in the 
morning, two litre, every day in the morning two litre [repeating and indicating by his hands 
to emphasise this one]! Engichamisa! [… making me to pass a lot of urine!] – [with a high 
tone of voice now]. Engichamisa [making me to pass urine]. 
 
 
Participant 01 (MC 30-35) did not mention how a noticeable increase in urine affects his 
taking of ARVs; however, Participant 02 (MC 55-60) did comment on this, mentioning that 
he does not take them at all when he is to travel, in order to avoid disrupting the journey for 
the need to urinate.  
 
Participant 01 (MC 30-35) also complained about feeling drugged, and this interfered with 
his university studies. He mentioned that the pills would keep him feeling drugged for a long 
period of time, preventing him from studying at night.  
But those ones [the previous regimen], I was no longer studying because, kade ongathi 
ngingalidla lingidakwe mpelampela [the time I took it, it would really – really drug me] as 
from 10:00, I would look at time, after two hours it would start becoming a drug to me, 
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drugging me … it would be until morning until maybe it is about 3:00 … 4:00. Engidakiwe 
nje [just drugged] … while I want to study.
 
 
He continued mentioning how the side effect of feeling drugged impacted on his academic 
performance, saying:  
… Manje nje [right now] you see now … 2015 eyi! You can see my results [academic ones] 
they are not really, really, really not good angithi manje nje ayikho into ekade ngizoyenza 
uma kuthiwa “dlana”! Dlana! [The thing is now, there is nothing I could do; if they say 
“eat!” You must eat!] 
 
Clearly, these side effects affected the participants emotionally. This is considered in the 
following section.  
 
5.2.1.2 Emotional dimension of the side effects 
Some of the participants associated the side effects with death, saying that, with the dizziness, 
and the vomiting, they felt that they were dying. Participant 01 (MC 30-35) said: 
... they would drug me such that I would see that no ... I am really going to fall now here, I 
would fall hitting the ground with my face, now that is what was making me scared, ehhe, I 
used to have dizziness [and] hold onto the house to maintain balance ... These pills are strong; 
I could see that, no I am going to go [meaning I am going to die].  
 
Participant 03 (FC 40-45) commented that she had reported the vomiting and feeling of dying 
to the health care worker:  
I said hhayi bo! Wentombazane [Hey, young lady], I am dying I can see, if I am not even able 
to raise the head! I am dying! Ngiyafa nje qoboqobo! [I am really dying] and you are still 
pushing me to it!
 
 
Here it becomes clear how the lives of the individuals taking ARVs appeared to be 
interrupted and in some cases threatened by the experience of side effects. There were 
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5.2.1.3 Response to complaints about experiences of the side effects  
Three of the clients reported that when they complained about these side effects to family 
members and health care workers, they were told that they will eventually get used to them. 
Participant 01 (MC 30-35) said: 
... because now, I am looking at life, I have been hearing them saying “uzowajwayela, 
uzowajwayela” [you will get used to them, you will get used to them]. And as am saying that 
at home, I made them aware, and my sister, my sister is already eating them, now she kept on 
saying “hhayi uzowajwayela, uzowajwayela uzowajwayela [no, you will get used to them, 
you will get used to them, you will get used to them]. 
 
He commented that he tried to get used to them, but found it very difficult: 
Eyi! While I am trying, at school, hoping that I will get used to them, I will get used to them, 




A health care worker responded similarly to Participant 03 (FC 40-45):  
When I came here to the clinic, no I was still fetching them from Emtshezi [Estcourt hospital]; 
the lady there said uzowajwayela [you will get used to them].
 
 
What has been mentioned by Participants 01 (MC 30-35) and 03 (FC 40-45) “uzowajwayela” 
(you will get used to them) is a rather encouraging response. However, when the clients 
realised that these side effects were persisting, they made their own decisions about ARVs.  
 
Some of the responses to these complaints were not very supportive or encouraging. When 
Participant 5 (FC 30-35) complained about painful feet and her growing stomach, she said 
that the health care worker’s response was:  
“Ngesikhathi uqala amaphilisi sakutshela nje ukuthi amaphilisi anama side effects, manje 
uthi senzeni-ke thina?” [“We have told you when you started to take pills that the pills have 
got side effects! Now, what do you want us to do?”]  
 
This shows that there is a lack of empathic support from some health care workers. The users 
of ARVs continued experiencing side effects despite the responses from their supporters, 
professional and non-professional, and in most cases this affected their adherence to ARVs. 
Clients then responded to side effects in various ways.  
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5.1.2.4 Clients’ responses to side effects  
In response to their experience of the ARVs, all of the clients interviewed made their own 
decisions about their ARV treatment. These included abandoning ARVs for a while, not 
taking them at certain times, reducing the dosage, seeking alternative treatment, or continuing 
them. Participant 2 (MC 55-60), who complained about increased urination, said: 
... the urine ... it happens frequently such that if I am to travel by car ngivele ngingawathinti, 
ehhe, ngize ngiwathinte ntambama [I just don’t even touch them until afternoon] … ngize 
ngiwathinte kusasa,… mhlambe ngeqise usuku nje lonke ... ngoba kufanele ngiwathathe 
ekuseni ngiphinde ngiwathathe ntambama [Or until tomorrow … maybe I skip the whole day 
... because I am supposed to take them in the morning and in the afternoon as well]. But then 
... it means maybe it happens when maybe I am to take a long journey … it is just that, maybe 
it could be one day maybe two days … yebo. 
 
When asked about the most difficult times on ARVs, Participant 03 (FC 40-45) mentioned a 
loss of power. Rather than continuing to complain about this side effect, she decided to 
reduce her dose:  
If you are losing power, you are dying, yes I would lose power! They said you are going to 
get used to it ngathi woh ukukhuluma ukuhlupha angivele ngithule, [I then said, oh ... if I talk 
it’s like I am nagging them ... let me just keep quiet], I will put aside the big ones and just 
take the only other one. 
 
 
When Participant 01 (MC 30-35) saw that the ARVs were interfering with his studies, he 
decided to stop them: 
The thing is now I was seeing that ... ehh! Ngiwamise [I would stop them] ehhe! You see if I 
stopped them today, I would be able to study at night [with a faster pace and higher tone of 
voice now] ... it would be possible to study at that time. 
 
 
When she was talking about the difficulties experienced by her clients taking ARVs 
Participant 09 lay counsellor (L/C) said:  
Sometimes I can see that it is ... maybe not easy for them to take their treatment because 
others would say, the treatment makes him/her vomit … That is what they would say.
 
 
It is interesting that some of the clients were still complaining of the side effects even on the 
regimen they were using currently. Some had already made adherence-related decisions. For 
example, one of the participants who is already on the second-line regimen, and still 
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complains about side effects, has decided to take only the evening dose to avoid vomiting. 
She mentioned that since she is only taking the evening dose, she is no longer vomiting 
during the day. This differs from the expected treatment dose of pills which is twice a day, in 
the morning and in the evening.  
 
In addition to the side effects, pill burden and treatment fatigue were issues which affected 
adherence.  
 
5.2.2 Pill burden and treatment fatigue 
Two of the clients used expressions that show that they feel overburdened by the number of 
pills they have to take and prefer a single dose treatment in the form of a fixed dose 
combination (FDC), which are three pills in one tablet. Participant 02 (MC 55-60) said:  
 ... ngashintshelwa kuyo le nqumbi esengiyiphuza manje [I was changed to this heap I am 
drinking now] … ehhe. 
 
 
Participant 03 (FC 40-45), after an unsuccessful attempt to be switched on to the single dose 
(FDC), said: 
 … ngiyeke kuso lesi siwakla. [Let’s leave it alone, I will have to take this bundle.] 
 
 
Both of these participants expressed their dissatisfaction with taking a number of pills rather 
than a single dose. Isiwakla and inqumbi (heap) are both labels that exaggerate the amount of 
pills. To express his unhappiness about the number of pills and preference for the FDC, 
Participant 02 (MC 55-60) said: 
... because they are too much, these pills I am eating … they are not like those ones … [pause] 
that one I was taking, it was just one pill … now they are two. 
 
Participant 05 (FC 30-35) commented: 
I don’t know if I had no appetite because I was consuming a lot of pills or the other doctor’s 
pills or the Procydin [an antioxidant] itself, but I was drinking or consuming lots of pills. 
 
While the clients using ARVs expressed their dissatisfaction with the number of pills they 
were taking, there was also an experience of being tired of taking treatment for a very long 
time. This is referred to as treatment fatigue. The following extracts demonstrate how taking 
treatment for a long time becomes tiring and thus a barrier to adherence. Participant 09 (L/C), 
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when she was still talking about the difficulties her clients expressed about taking ARVs, 
said: 
Someone would report that he/she cannot drink the pills every day … yes it would be better if 
they would have a break on their treatment.
 
 
Participant 10 (L/C) referred to clients stopping treatment for a similar reason. She 
commented:  
People always have their own reasons … but when you talk to him/her nicely, someone may 
tell you that ... someone said that “it is just painful to know that at 20:00 you must take the 
pills”; others are complaining about fatigue, that it is just tiring. 
 
 
The same issue was also highlighted by Participant 12, a NIMART Nurse (NN):  
It is because it’s a long time treatment; it’s not like treatment of six months like TB, you 
know. HIV is not curable, they have to take this treatment lifelong and sometimes, ah.
 
 
Another medicine-related barrier involved a lack of improvement on the ART. This 
potentially led to loss of faith in ARVs, likewise affecting continuing with the medication.  
 
5.2.3 No improvement while on ART 
Some clients took the ARVs for a number of years but did not see an improvement. Some 
believed that after taking ARVs for a while, there should be a difference and they should no 
longer be bothered by symptoms like severe loss of weight or serious diarrhoea.  
  
Participant 03 (FC 40-45) said:  
Years had gone by just about three … four years, there was supposed to be a difference there 
but there was no difference, the only thing I was getting thinner, nakhu ngizofa ngihamba [I 
could see that I was dying while I was walking] Hhayii [laughing]... I could see that I was 
going now [dying]. They kept on saying “Don’t you see that you are going?”. 
 
Participant 02 (MC 55-60) said: 
Ayi, what started was Ngivele ngikhishwe yisisuke mfowethu [I started now having running 
stomach, my brother], I had a running stomach! [ending with a high tone of voice and pause] 
It was March! Ngakhishwa yisisu ukubhubha [I had a severely running stomach - like it was 
an end of the world]. I had a running stomach, running stomach! Running stomach! Running 
stomach! [repeating four times emphasising with hands and a fist] while I was there in Free 
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State, I went to their clinic there, errr the, Phuthaditjhaba clinic. Even there they tried to help 
me, kodwa nje kwashaya eceleni [it didn’t work]. The running stomach never stopped, it 
never let me alone … the stomach never let me alone, until I came to this clinic. I told them 
that the stomach is really giving me a problem. They said to me let us check the CD4 count 
and check the viral load as well. Eyi! They checked me [they did my check-ups]; they said to 
me “Hey man, your CD4 count has dropped here. It is not going well. And your viral load is 
high, it is at about 23 000”. Yah! They said to me, no, it is not going well. And then from 
there I rushed to doctor Mzinyane [snapping a finger].
 
 
These extracts illustrate the difficulties the participants had in taking ARVs. Although they 
did not directly link this to poor adherence, these experiences may lead to doubts about 
effectiveness of ARVs.  
 
All the medicine-related issues discussed above may also have played a role in one way or 
another in the search for and use of alternative-medicines.  
 
5.2.4 Traditional medicines 
Some of the clients talked about resorting to traditional medicine when they did not 
experience any improvement while on ART. They seemed to be doing this to deal with some 
of the symptoms such as loss of appetite or when they did not feel well. However, only two 
participants mentioned use of alternative medication while on ART. These two participants 
mentioned use of Procydin and okwesintu (traditional medicine). Participant 02 (MC 55-60) 
said:  
I would not know how it is going because ngibuye nami ngiphuze iziphuzo lezi zesintu, ehhe 
... angimile nakuzo. [I sometimes drink these drinks traditional medicines … ehhe … I have 
not stopped using them either.] Ngiyapeyta, ngiyaphalaza ngenze zonke izinto lezi [I take 
enema, induce vomiting, and do all the other things]. 
 
 
Participant 05 (FC 30-35) mentioned the use of Procydin, which according to Lekhooa (2015) 
is a herbal traditional immune booster. Participant 05 (FC 30-35) said “I once used 
Procydins” and the participant went on describing why she used Procydin and that it, at some 
stage, proved to be too expensive for her:  
I once used Procydins in the mornings but since Procydins were over my budget, I stopped 
using them because I had no money anymore. I heard that Procydins help a lot ... Yes, 
Procydins help because I had no appetite, but after using Procydins, I had appetite once again 
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I don’t know if I had no appetite because I was consuming lot of pills or the other doctor’s 
pills or the Procydin itself.
 
 
The use of alternative treatment together with ARVs was also mentioned by a counsellor and 
a community care giver; these health care workers linked this use of alternative medication 
with ART interruption. Participant 07 (CCG) mentioned the use of traditional medicines as 
one of the barriers that leads to defaulting. They commented that the clients’ use of traditional 
medicine seems to be motivated by looking for a cure:  
... while believing that the pills are working, but something on the other hand you would see 
that hhayi … they have that faith that something else on the other side can help and end up 
stopping the pills ehhe. You would find that after that they default errr … you would find that 
most of the people basebenzisa izimbiza lezi abakholelwa kuzo ukuthi yizo ezisebenzayo noma 
ngabe … ayingasali ngiyawadla amaphilisi kodwa imbiza ethile angiyithole nayo… [are 
using traditional medicine which they believe that it is working even if they do eat/take the 
pills, but a certain traditional medicine should not be left behind, I should also get it] errr … 
most of the times it is … izimbiza [traditional medicine].  
 
And Participant 09 (L/C) commented: 
… Others, more especially in the past year, they were reporting mostly the story of going to a 
person whom they were saying is helpful. When they have gone to that person they come 
back saying he said he is going to help them … the healer … a traditional healer.
 
 
When this was followed up, exploring whether her clients were really getting ‘helped’ when 
consulting the traditional healer, she said: 
I would say they were not getting helped because they would quickly come back here … and 
sometimes a person would come back … you find that a person has some illness … when 
he/she comes back, he/she would say … when being asked why he/she was no longer coming 
to collect treatment, then he/she would say, no I was there.
 
 
The traditional healer’s advice was in contrast to medical advice from the clinic: 
… They were … saying … they said … he said to them, they must stop taking pills and drink 
his medicine because his medicine will eradicate the virus. 
 
The inclination to stop ARVs seemed to be coming from the healer him/herself, with claims 
that her/his medicines will cure the HI virus. A nurse emphasised how the use of traditional 
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medicines affects adherence and how this relates to clients’ search for a cure. Participant 13 
(NN) comments about this usage and how it affects adherence:  
Okunye kukhona lokhu ababuye bathembisane kona ezindaweni zokuhlala izigubhu lezi 
ababuye baziphuze zesintu [The other thing is that there is that thing which they promise each 
other, where they stay, these traditional medicine, these bottles which they also drink] ... by 
the time they are taking that, so often that they would stop taking the pills ... by the time they 
are taking that, so often that they would stop taking the pills, because when you ask others 
what happened exactly, they would say that, no there is something that they have tried which 
it was believed that it finishes/cure the virus [HIV].  
 
She comments that clients seemed to go to traditional medicines, and when they are not 
effective, they come back to the clinic, leading to poor adherence and interruptions in the 
treatment regimen: 
You would find that they have stopped on the other side [referring to pills/ART] and focus on 
the other side amabhodlela omuthi wesintu [traditional medicine], and after they have realised 
that it doesn’t work for them, they come back to us … others would miss the due date. 
 
Some clients used alternative treatment in combination with ARVs and did not abandon 
ARVs. However, the nurse’s account illustrates how use of alternative treatments can lead to 
the client abandoning ARVs.  
 
If seeing no improvement while using ARVs led to poor adherence and even to the search for 
alternative-medicines, one may expect that if there is improved health, adherence would also 
improve. Sadly, the data highlighted the opposite. When the medicine was taken and health 
conditions improved, some users of ART stopped taking their treatment. 
 
5.2.5 Improved health  
The results highlighted that some of the clients seem to have had a poor understanding of the 
need for ongoing treatment when they have recovered from the opportunistic diseases they 
may have had because of HIV infection. This reason for failure to adhere was pointed out 
mostly by the health care workers.  
 
Participant 09 (L/C) mentioned that some of the clients may not come up with serious reasons 
as to why they have stopped taking ARVs. She said: 
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A person would just say no, he/she just saw that he/she was better now and then he/she 
stopped taking them … and then he/she abandons them … when he/she feels better and say I 




When Participant 13 (NN) was responding to a question about clients’ reasons for non-
adherence, she said: 
Others would say “I saw that I was better”, but then when he/she started the treatment, he/she 
was told that he/she’s going to take the pills for rest of his/her life … “I saw that I was better, 
then I stopped” ... Umhh … the others ehhee … the other thing which make them to stop is 
this thing where a person would say that “I saw that I was better” and stops. 
 
For Participant 14 (NN), this was one of the main reasons for lack of adherence:  
... others stop them due to that he/she no longer likes to drink/take them anymore. Yes, there 
are those who say so … they say they did not like to … because he/she was well. 
 
She also mentioned that clients may have wanted the ARVs to treat a specific condition and 
when that condition is gone, the client may stop taking them:  
Others would start because they are facing a certain problem … for now maybe he/she’s 
having a non-stop diarrhoea and start ARVs and become well, he/she will see that he/she’s 
well … well ….well [drawn out]. 
 
She commented that clients were influenced by others in the community who may have 
stopped taking ARVs themselves:  
When he/she’s having a conversation with others, they would mislead him/her, telling 
him/her that “I also stopped them [ARVs]; nothing will happen, after two years you will be 
fine, you won’t have anything”. Eventually, he/she stops them for real and come back again.
 
 
In these accounts, improved health and the influence of peers become barriers to adherence.  
 
Communication between the health care workers and their clients is critical because health 
care workers are the ones who are expected to communicate all the critical information about 
taking medication, support clients on ART, and counsel them on the challenges that may be 
experienced by the users of ARVs. The success of ARVs may be hampered if there is a poor 
relationship and communication between the health care worker and the client using ART.  
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5.2.6 Communication with health care workers 
Some of the lay counsellors commented on the relationship between the clients and the health 
care workers. They said that some clients avoided coming to the health care service because 
of the way they would be treated, for example, being shouted at for missing appointments or 
for defaulting their treatment. A lay counsellor (Participant 09 (L/C) commented:  
… and then he/she decided not to come at all because he/she thinks that he/she would be 
shouted at, and then he/she ends up not coming at all … and come back when he/she is 
seriously ill … when he/she is avoiding being shouted at … If he/she does not get shouted at, 
you would see that she/he gets better. 
 
Nurses also mentioned that problems with communication affected treatment adherence. 
Participant 13 (NN) mentioned that clients may not come for treatment after defaulting 
because they thought the nurses would shout at them:  
Others would miss the due date; they would say “No I was afraid that you would have shout 
at me!” Why would we shout at them [raising voice]? Because these people are old, isn’t it? 
We are not shouting, siyabonisana [we are just having a conversation with each other]… 
Sometimes you are trying to dig out the answers from the person, wanting to know what 




In this account, the nurse positions the client as not understanding the nurse’s probing 
questions. However, another nurse, Participant 12 (NN), referred to the clients as lying to 
them and providing incorrect cell phone numbers:  
... but sometimes they give us the wrong numbers, they give us the wrong numbers. Patients 
are ... are … I don’t know whether ehh. Whether, what they think we are gonna do with their 
cell numbers, because they sometimes even give us the wrong cell numbers themselves, 
because sometimes when you try like emhhhmm … for example, we trying to do the loss to 
follow babies, the phone numbers are not going through. It’s the wrong numbers that they 
have written on the files, so we don’t know how to trace these patients, we don’t.
 
 
This participant showed her distress and frustration with clients:  
We don’t know whether they are really living at those areas or they lied to us. So we believe 
what the patients tells us, but it difficult for these transfer-ins because mostly they come from 
Johannesburg, far in those Soweto clinics there … [dragging the word]. They say, no they 
were on treatment. 
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Another nurse also commented on clients ‘lying’ to them. Participant 14 (NN) expressed her 
exasperation with this behaviour: 
There are, those mothers who stop the pills while they are HIV positive and continue 
breastfeeding the baby; others would even lie when they come here at the clinic … “Is the 




She added saying: 
… she would say no, while you are busy writing that a baby is being formula fed, formula 
fed, whereas she knows that she is breastfeeding the baby, ehhe ... You would be surprised 
when the child is HIV positive, when you follow her story thoroughly and accordingly, you 
would find that she was not only breastfeeding the baby, but she was mix feeding the baby.
 
 
And she added that: 
... they say one thing and do the other. It seems as if they don’t actually see the danger 
[giggling]. 
 
This introduces the question of trust between the health care worker and the patient. In an 
earlier extract, a nurse commented that clients feared that they could be “shouted at”. From 
the above narratives, one could see that there is an issue about communication, as well as 
issues of trust between the nurses and the clients. Clients seem to fear the nursing staff, and 
nursing staff are frustrated at the client not telling them the ‘truth’ about their health 
practices.  
 
The next section presents the issues that are not medicine or person related but rather relate to 
access. The clinic in this study serves a relatively remote rural community. Access to 
treatment affects the economy of households in the area. The next section will discuss socio-
economic issues and how poverty affects access to treatment and adherence to medication.  
 
5.2.7 Socio-economic issues (poverty) 
Poverty appeared to be affecting adherence negatively through lack of funding for transport 
to the clinic to collect ARVs, thus making ARVs inaccessible. Poverty also affected the 
availability of food in the household, affecting adherence. Some of the participants spoke at 
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length about how lack of money for transport affects access to ARVs, while some 
participants felt that it is not easy to take ARVs without food.  
 
5.2.7.1 Difficulties relating to taking ARVs on an empty stomach 
Two of the participants using ARVs talked about the challenge of taking pills on an empty 
stomach. Participant 02 (MC 55-60) said:  
I have to eat early [pause] because now if I take them without food ... ayangigqilaza [they 
enslave me/they give me problems]. Ayangikhweba nje impela [it becomes a real problem] … 
[pause] … ehhe angiqeda amandla [they make me feel tired].
 
 
Participant 03 (FC 40-45) commented how lack of food made her skip doses:  
Yes, there are difficulties because you would not just take them without eating and just take 
them like that, just saying that because now they are available, you are taking them ... I would 
not take them, I would leave them alone ... I would tell myself that I would not die in just one 
day by missing one dose. 
 
5.2.7.2 Money for transport to the clinic 
When responding to the question about reasons for non-adherence, a nurse (Participant 12 
NN) commented that the clients said that they could not pay for transport to the clinic: 
Also, it’s like ehh ... ehh ... they would say they don’t have transport, they don’t have money 
for transport come to the clinic.
 
 
She also believed that this was the reason for defaulting on ART:  
All the time, I think it’s more about the transport mhh ... and the clinic is ... is like far for 




She also commented on the nature of the rural context and the distances clients had to travel 
to the clinic:  
And the very deep rural …so they can’t access the clinic; they have to pay like I don’t know 
... 30 something like 30 Rands or something to come. Single trip is 20 aahh ... or 30 Rands 
between 30 or 20 Rands to come to clinic, yah. 
 
She elaborated that the limited transport options also affected their clinic attendance:  
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... and then the transport come early in the morning and then it goes early, so if they come 
early and they not even seen at the clinic, they need to catch the taxi back, so sometimes it’s 
you know! It’s difficult for them because the, the ... the far-out areas, they leave early from 
Bolton to go to that maybe ehh ... ehh ... that place Sinikamehlo you know far … it’s very far 
mmhh … It’s very far out.
 
 
Another nurse, Participant 13 (NN), also highlighted the challenges of rural clients getting to 
the clinic:  
... they usually say maybe a person haven’t come for collection, or he/she does not adhere to 
the treatment accordingly, when you look at his/her viral load and ask where the problem is, 
others would tell you that they had no money for transport, then I couldn’t come on due date.
 
 
The lay counsellors and the CCGs also pointed out the challenges relating to transport money 
to go to the clinic. Participant 09 (L/C) commented: 
Others would complain about the transport … you would find that one did not get the money 
to come on that day and then he/she decided not to come at all.  
 
Poverty thus affects access to treatment and adherence to treatment due to lack of food. In the 
next section, mobility and migrant labour as disruptions to adherence to ART will be 
discussed. 
  
5.2.8 Mobility and migrant labour  
Since the communities around the Injisuthi clinic are rural and poverty stricken, many of 
them travel far from their homes in search of work. This is also the case for the clients who 
are taking ARVs. Most of the health care workers highlighted that adherence is affected by 
the fact that people move around in relation to job opportunities, which affects their access to 
treatment and therefore adherence. 
 
Participant 12 (NN) said: 




Participant 13 (NN) commented: 
... others would say I got the job maybe in Bloemfontein, ay ... then [drawn out], you see …? 
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The third nurse, Participant 14 (NN), also commented on this: 
Ohhhhh ... o ………… others they stop because they went to work - a person would say I got 
a job in Johannesburg … ehhe, then he/she didn’t take a transfer letter, he/she didn’t have 
time … saying that he/she didn’t get time because he/she had already gone to work ... 
sometimes they are working like far as domestic workers, so they don’t get off all the time to 
come back home, to come and collect treatment, uhhumm.
 
 
Working far away from the clinic meant that they would need to take time off from work to 
visit the clinic. Participant 13 (NN) said: 
Others would complain that they are at work on that side, so they don’t want to be absent.
 
 
These people would not attend the clinic near their work. A nurse argued that they preferred 
the familiarity of their own clinic. Participant 13 (NN) said: 
And that a person is not familiar with the place; he/she would be scared to even go to the 
clinic, a person would want something that he/she is familiar with … that he/she knows that I 
will do this and that ... until they get their treatment in that way.
 
 
Some clients would have their treatment collected on their behalf, and have it sent by taxis to 
Johannesburg or Durban. Participant 13 (NN) referred to a mother who opted to collect the 
treatment for her child and send it in this fashion, after her child defaulted and became ill. 
She said: 
... because their pills are collected by their mothers most of the times, I would ask why 
doesn’t she collect near where she is working from? Her mother would say she had once done 
that but she ended up not taking her pills and my child came back home severely sick … Now 
I am making sure she gets her pills; now I am actually the one who sent them as a parcel to 
her; those are the appearing reasons.
 
 
The lay counsellors also commented on how migrating for work reasons affected adherence. 
Participant 10 (L/C) said: 
Someone will tell you that eyi! “Me I have found a job at eGoli [Johannesburg]”, the way … 
the the … the place, eyi! “I was not able to take the transfer letter” … errr … someone would 
say eyi! “It is the kind of a job that I am doing; I travel as a trucker, as I travel with a truck 
sometimes I send someone, and you would find that when I send someone, the person that I 
would have sent would come back saying ‘Ayi! They now need you to come personally, it has 
been a long time being a sent … sent … sent …’ … but I can tell the reason … that it is the 
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working conditions I am working under, of which Ngigxamalazile [I have one leg in the other 
situation and the other on another]. I cannot abandon the job, while I do want to continue 
taking my treatment … yebo, and the job is here waiting for me”. 
 
Three work-related issues that seem to be coming up here are: 1) finding a new job as far as 
400 km away in Johannesburg; 2) the type of job that one is doing (e.g. being a trucker); and 
lastly 3) not being able to go to the clinic for treatment, because of working hours.  
 
Apart from work-related travelling, health care workers highlighted travelling and being 
away from home as one of the reasons mentioned by their clients for stopping ARVs. 
Participant 13 (NN) commented 




She said that someone might disappear for three to five months and come back later on. 
When the nurse asked why this was, the client might say: 
That is the thing … I had visited somewhere then I wasn’t able to collect ... It is just those 
things they use to say, my brother. 
 
When users of ARVs were away from home, because of work or social reasons, their 
adherence was affected.  
 
The data also show that there are issues of gender in various forms that appeared to have 
affected taking of ARVs. 
 
5.2.9 Gender and social organisation (masculinity) 
Certain forms of masculinity played a role in ARV adherence for both men and women. 
Participant 10 (L/C) highlighted that the difficulties with ART adherence are different for 
men and women said: 
It differs with gender … the challenges for males and females are not the same … ehheee.  
 
She went on to deal with challenges for men on ART saying: 
Males … usually it is the behaviour change that the problem they are having … the change is 
that there are things which they have to stop when they start the treatment … things which are 
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She also went on to talk about how a man is perceived in the community, and how he might 
avoid being seen as ‘sick’: 
Something else, it depends on areas. As for these places where we are, which are rural areas, 
they look at it as if the man is not a real man if they drink pills; they believe that a male 
should just have live naturally.
  
 
This need to be seen as ‘well’ rather than ‘sick’ might relate to maintaining a particular image 
of being a man and not being associated with HIV which is stigmatised. She said: 
... others see themselves as not normal when they must drink the pills ... They would want to 
be normal just like everyone else because he/she sees him/herself better.
 
 
Another aspect of the social organisation of gender in rural contexts is how female clients on 
ART were affected by being under the control and supervision of other people. If they were 
married, they might find it difficult to continue taking ARVs for they feared being 
stigmatised and discriminated against by their husbands and in-laws.  
 
Participant 13 (NN) mentioned that a client may default because the husband is in denial, 
which could lead to conflict that may prevent the female partner from fetching ARVs from 
the clinic, thus defaulting:  
Others will tell you about the arguments/problems between them and their husbands, that they 
don’t want them to take the pills, so as he was home, maybe he works in Johannesburg: “As 
he was present at home. I then couldn’t come for collection.” 
 
The denial of HIV as well as the stigmatisation of the illness was evident in men’s exertion of 
control over their wives’ movements Participant 13 (NN) said:  
… because they say that he says that he doesn’t want any HIV news in this home, and the 
mother/women will end up not collecting her pills and you will find out that she is 
breastfeeding at the moment.
 
 
Participant 14 (NN) also commented on these tensions within the family which affected ARV 
adherence:  
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... the husbands do not want them to take ARVs. They [husbands] still have that belief, that 
they themselves don’t have HIV. Even if the female/mother does have it, they believe that 
they don’t have it [HIV].
 
 
Participant 13 (NN), also comments on a ‘problematic’ husband affecting a mother’s 
practices. Continuing with breastfeeding might put the child at risk of HIV infection. With 
sadness, she said: 
We find out that others are breastfeeding the children. They’ve tested and given FDC [fixed 
dose combination – a combination of three ARVs in one pill] and as time goes on, she 
stopped collecting but she still continues with breastfeeding the child and tell you about her 
problematic husband … It is just those things just [drawn out], which we usually come across.
 
 
Another nurse, Participant 14 (NN), also commented on the ‘problematic husband’: 
Ehhee ... yes it is at times really difficult, especially here in rural areas because the women are 
married and their husbands are problematic, usually others will verbalise it … mostly the 
females, the problem is the husbands, the husbands do not want them to take ARVs. A person 
would default, defaulting because her husband doesn’t want her to come and collect ARVs, 
ehhee. 
 
Stigma related to HIV was also a factor in ARV adherence. It affected disclosure of one’s 
status and the taking of ARVs.  
 
5.2.10 Stigma, discrimination, non-disclosure affecting adherence 
It has been highlighted that taking of ARVs is affected by stigma, discrimination, and non-
disclosure. Most of the participants highlighted that there is still a lot of stigma around living 
with HIV in the communities where they live. Because of fear of being stigmatised and 
discriminated against, most of the people opt not to disclose that they are living with HIV and 
therefore taking ARVs. This means that, very often, people who are taking ARVs do so alone 
and without support, which affects their adherence to treatment. Participants on ART 
highlighted their preference to disclose to their families. However, they were afraid to 
disclose to the community and even to the CCGs. This fear seems to be coming from stigma 
and therefore fear of being discriminated against.  
 
Only one participant on ART mentioned the non-disclosure of her HIV status and two 
participants on ART referred to issues relating to stigma and fear of being discriminated 
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against. Participant 04 (FC 30-35) mentioned that she was taking her treatment (ARVs) in 
secret and feared to take her ARVs openly because of the fear of being stigmatised. She 
mentioned that during that time, taking ARVs was still seen as a shame, saying: 
Eyi I was hiding them [referring to ARVs] … [giggling and pause] I was hiding them, maybe, 
maybe I would hide them in the bag, I would not be able to put them maybe in the wardrobe 
you see ehhe ... for them to just stay in the hidden place … errr… it is just that, it [living with 
HIV and therefore taking ARVs] was not that widespread, I don’t know how, there were still 
very few people using them [ARVs], and that I would see it [using ARVs] as a shame, 
something like that [pause] uhhu. 
 
This participant commented that, nine years ago, it was difficult to take ARVs when one had 
not disclosed, due to fear of being discriminated against. She refers to the shame of taking her 
medication: 
You would be scared even to drink them … it was 2008. You would be scared … You see 
then ... [giggling] … you would fear the people. You see, maybe you were just sitting in the 
house; then you would fear to stand up take them and drink them, now, hhayi.  
 
Participant 05 (FC 30-35) also commented on how people would stigmatise those on 
treatment:  
Uhh … nothing. Besides that people like talking badly … you will find that in your presence, 
while you are on these pills, they would be talking about someone else, saying so and so has 
HIV and udla amaphilisi [is taking ARVs], things just like that.  
 
Participant 14 (NN) also mentioned the presence of stigma when she was responding to the 
question about the challenges she often heard from her clients, saying: 
... because no! Coming daily to the clinic hhayi-i ... they say it turns out that people watch 
them … stigma is still there. 
 
This stigmatisation affected her emotionally and made her keep her status a secret: 
... they would talk badly about other people who are taking pills, while you yourself, you 
know that you are also taking them … That would make one feel pain, but it is just that there 
is nothing one can do, you would just keep quiet while they are saying what they are saying 
… The ones who know that they are still negative, they would talk badly about the ones who 
are already positive.  
 
68 | P a g e  
 
Her fear of disclosing was reinforced when she observed how people with HIV were 
stigmatised:  
… hhayi, there is still stigma … it is still there because it is just not easy to tell a person about 
your status, because you would not know if he is stigmatising others or not. Sometimes you 
would find that, when you are just going, you would hear them stigmatising others. 
 
 
One of the CCGs also commented on how stigma and fear of discrimination led to non-
disclosure which affects adherence to ARVs. Participant 06 (CCG) said: 
Let me just say, the youngsters, the thing what makes some of them not to take the pills, 
ukusaba ukuphumela obala nakubangani bakhe axoxe ngesimo ayisona [it is being afraid of 
coming out and disclose to friends his/her [HIV] status]. 
 
Another Participant 07 (CCG) commented that it was mostly men who did not disclose. This 
affected their adherence:  
The males, most of the times, what they usually do is that they hide it, they do not disclose. 
They hide it too much; that’s what makes them to default, they are secretive … That is what I 
usually come across with mostly, they hide it.
 
 
Secrecy around one’s HIV status prevented clients from getting appropriate information 
related to HIV and adherence to ARVs. Participant 08 (CCG) commented that she could not 
provide health education when she went to the household: 
You may find that someone else is still keeping it as a secret... but he/she needs information, 
… while having it, but still keeps his/her status as a secret… ihhi. 
 
Participant 08 (CCG) also mentioned that some of the clients do not like others to know that 
they are living with HIV. This affected their participation in support group meetings:  
When you say that they should meet you, you will find that the other is afraid of being seen 
by the other, that he/she is living with this illness, you see?
 
 
This CCG also commented that this fear of being stigmatized and discriminated against 
affected married women and indicated how this affects adherence to ART, saying: 
It was very difficult for people to come and collect their treatment, and they were looking at it 
as serous disgrace to have that illness and to follow the treatment routine … they were afraid 
in a way you can never imagine. 
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Participant 09 (L/C) also commented on this stigmatisation: 




She went on, elaborating that a female client would miss an appointment while hiding her 
HIV status. When she asked the client why she had not come: 
... and a person tells you that no, ngasuke ngifica u…mnakwethu ngase ngiyajika [when I 
came here, I bumped into the lady whom I share my husband/boyfriend with] and then I went 
back. When the person has come to the clinic to collect the treatment.
 
 
Participant 10 (L/C) referred to the stigma and people’s “negative attitude” to HIV as 
affecting treatment adherence She said: 
I think it is their own attitude towards HIV ... they still have a negative attitude to HIV. There 
is still that thing that a person who get it [HIV], is someone who is misbehaving. 
 
She explained how HIV is associated with sexual immorality, saying: 
... uke ubone mhlambe uma uthesta abantu abadala athi hhayi ngizotester nje phela mina 
angisagijimi [you would see/notice that, maybe, when you are testing adults, he/she would 
say, no I am here just to test because I am no longer running [sexually active]], ehhee.
 
 
While still commenting on the difficulties for the clients on ART, a nurse, Participant 12 
(NN), referred to the gender issues in these communities. A married woman (a makoti) is 
under the supervision of her husband and her mother-in-law. Married women would not 
reveal their status to their in-laws:  
... most of them, I would say majority of them, haven’t disclosed at home because they are 
makotis at home; they don’t want their in-laws to know that they are positive, you know. 
 
 
Participant 14 (NN) also commented on how non-disclosure made it difficult for married 
women to attend the clinic. They would be questioned by their in-laws about their frequent 
clinic visits: 
Ehhee ... and that they are scared of their mothers-in-law because they live with them, and the 
sisters-in-law, since we have extended families here in rural areas, now if you go repeatedly 
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Lack of disclosure to family might mean that clients lacked support in taking treatment. 
Participant 09 (L/C) commented:  
I usually talk to them; maybe you find that someone has a problem when he/she has to start 
treatment, he/she doesn’t know how to take his/her treatment because they haven’t told 
anyone where they live about their HIV treatment.
 
 
Married women were not free to attend the clinic or take medication if they had not disclosed 
to their husbands. Participant 09 (L/C) commented: 
You may find that a person would tell me that her husband has arrived, so she hasn’t 
disclosed to him, and then she will be unable to take her pills. 
 
 
This lack of adherence to ARV treatment by married women was also commented on by 
Participant 10 (L/C): 
For females, in most of the times it is disclosure; it’s the disclosure with their partners, you 
will find out that she didn’t tell her partner then; now there is problem that she has to hide the 
pills when she has to drink them … nakuma-in-laws kulaba abasuke beganile [and to the in-
laws to those who are married, or to the family to those who are not married].
 
 
Non-disclosure by female clients was related to fear of losing the relationship: Participant 11 
(L/C) said: 
… if I and Cele (the researcher’s name), we are in the relationship, but it is difficult to tell 




Disclosure by female clients to their husbands was very difficult. Participant 07 (CCG) 
commented that: 
Others state that it becomes difficult especially those that are married, who are daughters-in-
law; they used to say that it becomes difficult to tell their husbands because the husband usho 
kuqala ukuthi [is the first one to say] “If I could find out that you have this disease/virus, I 
would kill you” ehhee … angithi [isn’t it?]. 
 
 
Participant 07 (CCG) commented that from her support groups she has learnt about how 
mothers in-law pose a challenge for married women in terms of disclosing, as well as clinic 
attendance. She said:  
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It then becomes difficult, sometimes mother-in-law/the husband’s mother would be a problem 
ehhe ... then the wife wouldn’t be able to say that “I am like this” [referring to HIV] because 
it would be said that she is the one who came with this thing and my child was very clean/had 
nothing [no HIV], ehhhe.
 
 
There seems to be a stigma-related issue around carrying ARVs in their containers as they 
make a noise and clients feel it could be noticed that they are carrying ARVs. One of the 
participants on ARVs mentioned this aspect, which was interesting and hardly, if ever, 
appearing in the literature. This creates a need for further research on the issue. When audio-
recording was stopped, Participant 01 (MC 30-35) said:  
But eish! The pills are making noise when travelling with them, even when they are inside the 
bag [and laughed].  
 
From the extracts above, it is clear that in the communities surrounding the Injisuthi clinic, 
there is still stigma around HIV. Thus, people who are using ARVs fear that they could be 
discriminated against by others and therefore they will choose not to disclose that they are 
HIV positive. This means that they will also have to hide the fact that they are taking ARVs. 
If their status is not public, and they are not alone in the household when they need to take 
their medication, this will affect their treatment adherence. Another issue which affected the 
use of ARVs was the lack of support for people living with HIV.  
 
5.2.11 Lack of support (community, clinic or home) 
This issue is closely related to the issue of stigma that is still dominant in the community. All 
of the clients reported receiving support from their families and people in the clinic setting, 
but not from the community. Participant 05 (FC 30-35) said: 
From the community, I don’t get any support because, I don’t know if they know or what, I 
never disclosed to the community that I am taking the pills [dragging the word]. 
 
 
Support from the community seems to be blocked by the issues of stigma and fear of 
discrimination, and therefore, clients opt not to disclose that they are living with HIV. Some 
participants pointed out that ‘talking’ (leading to fear of being stigmatised and discriminated 
against) was a barrier to sourcing support from the CCGs, while stigma seemed also to be a 
barrier when asked about support from the general community. 
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When responding to a question about community support and CCGs, Participant 04 (FC 30-
35) commented on their lack of confidentiality: 
Hhayi bayasekana nabo, they are supportive, they are supporting too [giggling] uhh … 




Participant 03 (FC 40-45) commented on why she would not disclose her status to the CCGs. 
She described how she avoids them in order to keep her HIV status a secret, saying: 
Now you cannot tell him/her something because sometimes we will have conflict with each 
other. If they come to enquire, I would say “No, I am not sick at all; just go and look for the 
ones that are sick, me I am fine” [laughing]. 
 
 
This lack of disclosure (because of the fear of stigmatisation) might prevent access to 
community-level support provided by the government through the CCGs.  
 
On the other hand, one of the CCGs, Participant 07 (CCG), commented about challenges 
relating to non-disclosure (due to stigma and fear of being discriminated against) at home, 
especially the married females, and said that the clients on ARVs are getting pressure (instead 
of support) from their in-laws: 
The home … where she is married to ehhee … where she is married to, most of them here are 
married, unenkinga yokuthi uzo...manje njalo aye-eclinic njalo aye-eclinic usuyokwenzani 
[she will be having a problem of always going to the clinic, going to the clinic … the question 
now would be, what are going to do [at the clinic]?] They are under that pressure, you would 
find that she … they end up defaulting, that pressure of “What are you now going to do at the 
clinic; each and every month, you are going to the clinic”!! Until they default, to the others 
the problem will be … that as she has hidden her status, at home.... 
  
The lack of support in the communities where the clients using ARVs live was also 
highlighted by a nurse. Participant 12 (NN) said: 
I feel that with the community ... they have a very poor support system because most of them, 
if you look at it, they don’t have their parents living. Some of them, their parents are living 
out of town because of work purposes, so they don’t have [dragging the word] a good support 
system for them to lean on. 
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In addition to this lack of community support, the delivery of health services also affected 
access to treatment and, consequently, adherence to treatment.  
 
5.2.12 Service delivery  
Health systems for service delivery at public health facilities affected adherence for clients 
who are using ARVs. The long waiting times, non-availability of ARVs for clients who are 
serviced by a mobile clinic, and the need for clients to come monthly for treatment all 
contribute to poor adherence. Incarceration also appeared to be playing a role in accessing 
ARVs.  
 
The length of time it took to get the ARVs had an effect on the clients’ adherence. Before 
2010, clients were only getting their ARVs from the hospitals. In 2010, the government 
changed ARV policies for managing patients on ARVs. Nurses were trained to initiate and 
manage patients on ARVs, and this made it possible for the hospitals to send their clients on 
ARVs to their nearby clinics. Over time, more clients were initiated on ARVs by the clinics, 
adding to the number of people who were already using the clinics. This increased pressure 
on the clinic services affected the time it took the clients to get their ARVs. In 2016, the 
government implemented a policy which made it easy for the clients to access their treatment 
from the community and places other than the primary health care (PHC) clinics. The 
rationale for this policy was to help reduce waiting times for clients at clinics and to improve 
adherence. However, the process to implement this policy has been going very slowly.  
 
Two of the participants on ARVs mentioned long waiting times as a challenge for them. 
Participant 03 (FC 40-45) on ART said:  
While I was still fetching them from here [in this clinic], I would come at about 06:00am; 
12:00 pm would come and pass without getting them and we would have just done nothing at 
all. While we were still fetching them from here, it was really difficult, to a point that I hated 
myself, saying why had they brought me back from Emtshezi [Estcourt hospital] because 
there it was better than here! 
 
 
Participant 04 (FC 30-35) commented that sticking to her clinic appointments was easy but 
the waiting time was very long: 
It is easier, but it is just that you will have to know that you will come back late … [giggling]. 
You will come back at night; you get here in the morning and go back at night [laughing] … 
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Participant 13 (NN) mentioned that the clinic is too often full. Some of the clients would 
come and wait but give up and go back without consulting the staff. She said: 
... and also our overcrowded clinic, others would go back ... when [drawn out] … what would 
I say? They … [pause] a person would say “I came and went back, because the clinic was 
full”, not because he/she couldn’t come inside because he/she saw that people were many and 
decided that he/she should just go back home.
 
 
She also added that they try to serve all the clients that have been to the clinic despite the 
clinic being full: 
... it is, yes it is that at the end of the day who is inside we make sure that we leave the clinic 
while he/she have been given his/her pills. There is no single person whom we send back 
home and say come back the next day. No! … We do not do that.  
 
Some of the nurses felt that the rules related to medication distribution are also a barrier to 
adherence. During the time of this study, nurses were only allowed to supply medication for 
one to two months. However, the nurses who initiate and manage clients on ARVs suggest 
that, if their clients should be given a three-to-four-month supply of medication, the situation 
would be better. Participant 14 (NN) commented that: 
At a time even when a person is stable … a person should at least come in two months, or one 
month; that causes a person to come to the clinic repeatedly. Kanti ukube abantu banikezwa 
amathathu noma awu - four ngabe bayezake abadoji [while if the people were being given 




Although there is also a policy on the provision of health services through mobile clinics, 
ARVs were not yet accessed from the mobile clinics during the time of the study. Participant 
08 (L/C) mentioned that clients have requested ARVs be available through the mobile clinics: 
 ... yes they really do have that request … the mobile [mobile clinic] does not come with 
ARVs … yes it does come with other pills but not with ARVs …. Now, we did ask from the 
nurse requesting … but he/she said no, it is still not authorised. Umhhh. 
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Participant 12 (NN) commented that, if a client was imprisoned, their treatment might not be 
continued, and this affected adherence:  
Some I would say that they were arrested [and] in prison so when they tell the sisters there in 
prison, they don’t believe them that they are on ARVs, so that’s how they default … They 
come out of prison, you know like they are awaiting trial whatever prisoners and then they 
come to the clinic afterwards when they already have defaulted, so those are some of the 
reasons. 
 
From the above, it is clear that service delivery could also be a contributing factor to poor 
ARV adherence. From the above issues it is clear that the health systems, although developed 
to serve the communities, can be a factor contributing to poor adherence. 
 
This section has reported the many issues that impact on adherence to ART. These barriers 
were mentioned by some or all of the participants, and the barriers also clearly relate to each 
other in various ways. Figure 1 is a diagram representing the interplay of the barriers to 
adherence and their relationship, as observed from the analysis of the data. The barriers as 
identified by the participants are mapped out, and each barrier is linked to the participants 
who mentioned it. Most of these issues do not occur in a vacuum but inter-relate with and 
influence one another.  
 
In the diagram (Figure 1) below, issues that were identified in the data are presented in boxes 
(in different colours to represent different themes) with an indication of who mentioned such 
an issue (the participants are listed in a box below the main box). This is done for comparison 
of the perceptions of the barriers among types of participants. In the diagram (Figure 1), 
pointed arrows represent the relationship observed among the issues. A double-pointed arrow 
indicates that the issues affect or influence each other, while a single-pointed arrow indicates 
that a particular issue leads to the one that is pointed to. In the discussion chapter, the 
significance of some barriers being mentioned by certain participants and not others will be 
discussed. 
 
Following diagram figure 1 below, the themes identified in the data are presented.  
 
  
































Figure 1:  Representation of barriers to adherence and their inter-relationships (issues that 
are affecting adherence for clients taking ARVs at Injisuthi clinic)  
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In this diagram, it is clear that in terms of barriers to adherence, for example, when side 
effects (mentioned by all clients, plus one lay counsellor) are experienced by a client on ART, 
communication with health care workers (mentioned by clients, lay counsellors, and nurses) 
will influence how these side effects will be managed. Poor management of side effects may 
lead to clients feeling overburdened by treatment and experiencing treatment fatigue 
(mentioned by clients and lay counsellors, especially when they see little or no improvement 
(mentioned by clients, CCGs, and nurses) while taking ARVs.  
 
A combination of side effects (mentioned by all clients and by one lay counsellor) combined 
with feeling overburdened by the treatment (mentioned by clients and lay counsellors) could 
lead to clients seeking alternative treatments such as traditional medicines (mentioned by 
clients, CCGs, and nurses). Some of the clients seek alternative-medicines in order to see 
symptoms disappearing quickly or to cure HIV. This could be also motivated by seeing no 
health improvement while using ARVs (mentioned by clients, CCGs, and nurses). The use of 
alternative-medicines or traditional medicines also affects the clients economically because it 
is paid for and most of these medicines may be very expensive. The use of traditional 
medicines in many cases includes abandoning ARVs.  
 
On the other hand, it is not only seeing no health improvement that leads to abandoning 
ARVs and seeking alternative-medicines. While some of the clients on ART take traditional 
medicines because they do not see improvement on their health when using ART (as 
discussed above), improved health (mentioned by lay counsellors and nurses) can also lead 
directly to poor adherence.  
 
Another link between the barriers is the fact that HIV is still stigmatised (mentioned by 
clients, lay counsellors, CCGs, and nurses). Stigma leads ART clients to fear that they may 
be discriminated against should others find out that they are using ARVs; therefore, they hide 
this fact. Experience of stigma seems to be more severe depending on gender (mentioned by 
clients, lay counsellors, CCGs, and nurses). Married women are most stigmatised and often 
fear that they may be discriminated against by their in-laws as well as their husbands who 
want to maintain their masculinity and therefore do not come to the clinic to learn about their 
HIV status. Should a woman find out first that she is HIV positive, HIV would be blamed on 
her by either her husband or in-laws, which may justify the discrimination against her. Young 
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married women are under surveillance from their in-laws and might take their medication in 
secret, miss clinic treatment dates and default on treatment.  
 
On the other hand, the husbands and men who travel for work opportunities (mentioned by 
lay counsellors and nurses), fail to go to their nearest clinics due to stigma (mentioned by 
clients, lay counsellors, CCGs and nurses), and inability to communicate with health care 
workers (mentioned by clients, lay counsellors, and nurses).  
 
It also appeared that some of the clients fail to access treatment when travelling due to 
challenges related to service delivery (mentioned by clients, lay counsellors, CCGs, and 
nurses), where there are long queues and waiting times while they have limited time to wait. 
This led to clients not collecting treatment from the nearby clinic when away for work, nor 
from the clinic back home because they are far away from the clinic they used to go to. Thus, 
these clients on ART will stay without medication and therefore default on their treatment. 
Most people from the area go far away for work opportunities because the area is rural and 
there are few economic opportunities.  
 
Socio-economic issues (referred to by the CCGs and nurses) also impacted negatively on 
adherence to ART due to lack of funds for transport to attend clinic appointments and due to 
lack of food to eat while on ARVs. Participants on ART mentioned that side effects are more 
severe if ARVs are taken without food. In the community, there is also very limited support 
(as was pointed out by clients, CCGs, and nurses). As most of these issues happen in the 
community, without adequate support, individuals using ARVs fail to adhere to treatment.  
 
5.3 Summary 
From the above analysis of data, it becomes clear that effectiveness of ARVs or ART 
depends not only on the efficacy of the pills, but also on many personal and social issues that 
may facilitate or hinder adherence. ARVs are made, tested and tried in a laboratory, a 
controlled and easy-to-manipulate environment. It is clear that the end-users of the ARVs 
themselves, when using the treatment, are confronted with a number of challenges which 
become barriers to them but which may not have been considered on the scientific-, 
production- and health-system levels. These barriers influence one another to produce an 
environment which is not conducive for individuals to adhere to ART. 
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In this chapter, I discussed the themes that were identified through data analysis and 
demonstrated how they seem to be influencing each other. I used a diagram to present these 
themes while demonstrating their relationships with one another. I linked the category of 
research participants to identified themes to demonstrate the source of the perspectives. In the 
next chapter, I will discuss these findings while comparing them to the barriers to adherence 
identified from the literature review. I will also discuss the perception of barriers to 
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Chapter 6: Discussion 
 
This study investigated the reasons for failure to take treatment for HIV by people who are 
living with HIV. Understanding this is crucial for the improvement of support for people 
living with HIV and using ARVs. Support for people using ARVs is necessary to improve 
adherence, thus contributing to the United Nations 90 90 90 targets to combat AIDS.  
 
This study investigated how clients fail to adhere to ART treatment, what makes it difficult 
for ART clients to adhere to treatment, the most common barriers to ART adherence for local 
clients, and the perceptions of barriers to adherence by clients on ART compared to those of 
the health care workers. In this chapter, the findings of the study will also be compared to 
issues that were identified in the literature reporting similar studies.  
 
To do this, a framework that resulted from the merged frameworks of barriers to adherence 
will be utilised. The merged framework of barriers to adherence (see Table 5) consists of the 
following headings identified as barriers to adherence to antiretroviral therapy (ART): 
psychosocial/person-centred barriers, practical problems/socio-economic issues, medication/ 
therapy-related issues, service delivery-related issues, stigma and discrimination, health 
control, cultural aspects (traditional medicines), and gender and social organisation 
(masculinity). This table also includes examples or sub-themes. In this table, an extra column 
has been added to indicate the category of participants who commented on the issues in the 
first or second column. This table (Table 5) plays a significant role in the discussion 
hereafter, for it represents barriers to adherence from the literature integrated with the 
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Relationship between patient and health care worker; 
treatment fatigue; pill burden; forgetfulness; lack of health 
care support; bad planning and running out of ARVs; lack 
of symptom; sharing ARVs with friends and alcohol 
abuse; no personal intention to adhere; non-disclosure of 
status; and lack of sharing information with the patient. 
CCGs 




economic issues (poverty) 
Transport problems to get to the clinic; not enough food to 
eat with ARVs; difficulty in planning ahead to have 









Side effects; difficult treatment regime to follow; pills too 
big to swallow; multiple medicines for one disease state or 
several conditions; frequent changes in medicines; no 
improvement; loss of faith in medicine; not understanding 
significance of medicine; and long duration of therapy. 
All ART clients  
Lay counsellor  
Service delivery-related 
issues 
Hospitals and clinics not having enough stock; health care 
workers on strike, poor discipline in clinics (bad service 




Stigma and discrimination Secrecy; fear and lies; hiding of pills; non-disclosure; no 
support groups due to secrecy and fear of community 
rejection; and rejection of the disease. 
ART clients 
Lay counsellors  
CCGs  
Nurses 
Health control   No control over own health; fatalistic attitude (“Nothing I 
can do will make a difference”) and external locus of 
control; poor health literacy. 
None  
Cultural aspects  Using medicines from traditional healers with ARVs 
without disclosing to health care worker. 
ART clients 
Lay counsellors  
CCGs 
Nurses 
Gender and social 
organisation (masculinity) 
Men’s need to maintain masculinity and avoid health 
seeking; women have less power in relationships with men 
making decisions including about health seeking.  




82 | P a g e  
 
What follows is a discussion of the findings of this study. To do this, barriers identified in the 
merged framework (Table 5) will be used as sub-headings for this discussion. In this 
discussion, barriers identified in the literature, and part of the merged framework, are 
compared to the findings of this study. Throughout the discussions, each barrier is also 
discussed in terms of the perspectives of the research participants in their respective 
categories.  
 
6.1 Psychosocial/person-centred barriers 
Person-centred barriers, according to van Dyk (2013), include treatment fatigue; 
forgetfulness; lack of health care support; bad planning and running out of ARVs; sharing 
ARVs with friends and alcohol abuse; no support from significant others; no personal 
intention to adhere; non-disclosure of status; and lack of sharing information with the patient. 
In the cardiovascular framework (National Heart Foundation of Australia, 2011), patient-
related barriers to adherence include lack of symptoms and burden of therapeutic regimen; 
these aspects also overlap with other barriers mentioned in van Dyk (2013).  
 
In this study, participants commented that the pills were ‘too strong’ and ‘too much’. 
Participants seemed to be overwhelmed with the strength and quantity of medication. This 
seemed to indicate that users of ARVs felt overburdened by the pills they have been using. 
Although clients on ARVs did not talk about pill burden directly, they indicated their 
dissatisfaction with taking ARVs as three separate tablets and showed a preference for a fixed 
dose combination (FDC) of pills. It seems that the client’s experiences of taking ARVs are 
similar to that in other studies.  
 
Pill burden has been pointed out as one of the reasons for poor adherence. Hodes et al. (2016) 
highlight the link between pill burden and ART non-adherence. Pill burden has also been 
mentioned in the South African guidelines for adherence (NDoH, 2016b), and in Van Dyk’s 
(2013) theory, it possibly falls under psychosocial barriers as treatment fatigue. In the 
cardiovascular framework (National Heart Foundation of Australia, 2011), burden of the 
therapeutic regimen is clearly listed as one of the barriers to adherence. Health care workers 
in this study indicated that the long duration of ART affects their clients’ adherence. This 
means that for clients to continue taking pills as expected for the rest of their lives, there 
should be continuous scheduled psychosocial support for people using ARV. 
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In this study, HCW mentioned pill burden and treatment fatigue as the reasons their clients 
gave for poor adherence in ARVs. This was mentioned by two lay counsellors and one nurse, 
empathising with their clients that it would be better if there was a break at some point, as 
opposed to taking pills every day and forever. Health care workers see this as a tiring and 
daunting exercise for their clients. The Australian cardiovascular framework of barriers 
highlighted that long duration of therapy is a barrier to adherence (National Heart Foundation 
of Australia, 2011). However, this is mentioned under condition-related barriers in this 
framework.  
 
In contrast to the above, it seemed that if there was improvement in the client’s health 
condition, adherence was also affected. According to the cardiovascular framework (National 
Heart Foundation of Australia, 2011), lack of symptoms is a barrier to adherence. In this 
study, one lay counsellor and two nurses mentioned this as a reason for their clients 
defaulting on treatment. All three health care workers mentioned that some of their clients 
said they saw that they were better and decided to stop taking ARVs. This factor does not 
seem to have been identified in other studies. In both the sub-Saharan Africa study (Croome 
et al., 2017) and the Botswana study (Weiser et al., 2003), there is no mention of improved 
health as a barrier to adherence. Even the South African adherence guidelines (NDoH, 
2016b) have no comment on improved health as a barrier to adherence. In addition, in the 
eight barriers identified by van Dyk (2013), there is no clear articulation of health 
improvement as a barrier to adherence. This means that it is also important to support clients 
who have recovered and are now feeling well, in order to maintain their adherence.  
 
In van Dyk’s (2013) framework, health improvement barriers to adherence relate to such 
things as lack of health care worker support; lack of information sharing with a patient; and 
poor understanding of need to adhere to treatment. In this study, all clients on ARVs 
mentioned that they felt supported by the health care workers, especially the lay counsellors 
and nurses. However, some of the clients indicated that they intentionally rejected support 
from the CCGs because of stigma and fear of being discriminated against. This indicates a 
seriously strained relationship between CCGs as health care workers in the community and 
clients. Interventions to reduce stigma in the community and to improve the upholding of 
confidentiality by the CCGs side should be considered.  
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The relationship between the client and the health care worker seems to play a critical role in 
adherence. If the relationship is negative, it may affect the client’s adherence. According to 
Dale et al. (2014), general medical mistrust was seen to be contributing to low adherence and 
thus poor health outcomes in African American males living with HIV in America.   
 
According to Campbell et al. (2015), reprimands (by health care workers of clients) are 
linked to poor adherence to ART and poor adherence to clinic times. In this study, only one 
participant on ART commented on being reprimanded by a health care worker when 
complaining about side effects. However, health care workers (nurses, in particular) 
highlighted how clients seemed fearful of them and fearful of being reprimanded. Both lay 
counsellors and nurses said that clients said they missed clinic appointments because they 
were afraid of being reprimanded for not adhering to treatment, or for missing other 
appointments.  
 
Van Dyk (2013) mentioned poor information sharing with a patient as a contributing factor to 
poor adherence. The same ART client, who said she had been reprimanded, highlighted a 
concern about her blood results not being shared with her. From the HCW’s perspectives, 
clients were not always honest (e.g. they gave them the incorrect contact information). 
Whether the clients were deliberately deceiving the HCWs is not clear, but this relationship 
of suspicion, and the fact that the HCWs seem to feel frustrated at not being able to maintain 
continuous contact with the clients, have consequences for adherence. Poor communication 
skills and lack of information sharing by the health care workers lead to patients adhering 
poorly. When the clients feel that they may have not adhered to treatment as prescribed, they 
fear coming to the clinic, thus they miss appointments. This means they will not have 
sufficient medication. When tracing clients, this attempt could be unsuccessful due to wrong 
contact information given by the clients at the facilities. Another system for tracing clients is 
the use of CCGs. This too could be unsuccessful because of the wrong directions given by the 
clients and due to the fact that most of the clients do all they can to avoid contact with CCGs.  
 
Previous literature has commented that nurses are aware of the hardships faced by the clients 
and therefore empathise with their clients on ARVs (Campbell et al., 2015). In this study, it is 
the nurses who mentioned the issue of patients fearing that they would be reprimanded and 
thus defaulting. According to the South African guidelines for HIV, TB and NCD (NDoH, 
2016b), the patient and health care provider relationship is mentioned as a barrier to 
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adherence from the cognitive perspective under patient-related barriers to adherence and 
retention in care. It is mentioned that the perception of the health care provider could be a 
barrier to adherence. Therefore, improvement of the relationship between the client and the 
health care worker should be considered.  
 
6.2 Practical problems and socio-economic issues  
In van Dyk’s (2013) framework, practical problems include transport problems to the clinic; 
shortage of food to take with ARVs; challenges related to planning ahead to have enough 
ARVs when going away or travelling for work; restrictions in getting time off from work; 
working shifts; and getting mugged and robbed of ARVs. In this study, problems related to 
transport to go the clinic were found to be most dominant amongst the practical problems and 
socio-economic issues experienced by clients. This is due to the fact that Injisuthi health 
clients are all from a rural setting; therefore, to access the clinic means travelling fairly long 
distances. This relates to the challenge of not having money to pay transport fees to go the 
clinic to collect ARVs. This barrier to adherence is also recognised by the Department of 
Health. The adherence guidelines (NDoH, 2016b) mention lack of transport money to the 
clinic as presenting behavioural and socio-demographic challenges under patient-related 
barriers. Some of the clients in my study miss their appointments due to unavailability of 
funds for transport; sometimes they had to wait until the pension (government social grant) 
date before they could go to the clinic. This was mentioned by two nurses and a CCG, but not 
by the ARV clients.  
 
While van Dyk (2013) referred to losing ARVs through robbery, in this study, a CCG 
referred to a client losing ARVs because a family member had stolen them, because s/he 
could not go to the clinic because of lack of transport money. In this case, adherence is 
affected because of insufficient medication and lack of transport funds. Lack of transport 
money as a barrier to adherence has been found in other studies as well (Knight et al., 2015; 
Lekhuleni et al., 2013). However, the challenge of having ARVs stolen by a family member 
who also needed them but was constrained by lack of transport funds seems to be unheard of 
and may need further exploration. The government is currently trying to intervene on this 
barrier through the implementation of the Central Chronic Medicine Dispensing and 
Distribution (CCMDD) programme. In this programme, the government is trying to bring 
medicine closer for clients who are on chronic medicine.  
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Van Dyk (2013) also speaks about shortage of food to take with ARVs for those that need to 
be taken with food. In this study, there was no indication that clients were on ARVs that were 
required to be taken with food. However, there is a general belief that if one is using the pills, 
there should also be sufficient food. Shortage of food was repeatedly mentioned by all the 
CCGs and two ARV clients. Both ARV clients mentioned that they would rather skip their 
ARV doses when there is no food. All the CCGs mentioned lack of food in the area and 
reiterated how this becomes a challenge for clients on ART. Issues of poverty, where there is 
a lack of food and transport money, were emphasised by the CCGs as a challenge that affects 
adherence for clients on ARVs. This is emphasised mostly by the CCGs, perhaps because of 
the fact that they work in the community and witness this at the household level.  
 
Van Dyk (2013) spoke about work-related challenges that affect adherence; these included 
being away for work, as well as working shifts and being unable to ask for time off in order 
to go to the clinic. In this study, none of the clients on ART spoke about this, perhaps because 
they were all unemployed. However, this could relate to what was said by one client on ART 
who could not attend the clinic in Bloemfontein because its times were in conflict with 
university lecture times. This affected his adherence, for he ran out of his medication until he 
came back to the Injisuthi clinic to ask for a three-month supply of medicine, which was the 
option that worked best for him.  
 
From the health care workers’ perspective, it appears that the work-related barrier is 
multifaceted. Working too far from home (e.g. as a truck driver or domestic worker), the type 
of work the person is doing, and restrictions in getting time off from work to collect 
treatment, were all challenges. This is similar to what was proposed by van Dyk (2013). From 
what the health care workers said, it appears that most of their clients who are defaulting are 
the ones who had found work as far away as in Johannesburg, Durban or even in 
Bloemfontein. Many of these clients did not take a transfer letter for them to be transferred to 
the health care facilities near their work, and did not adhere to their clinic appointments.  
 
Lastly, the individuals on ART seem to be placed in a situation where they have to choose 
between ARVs and work. Under practical problems, Van Dyk (2013) also referred to being 
away from home for holidays. In this community, being away is often due to education, 
visiting relatives or looking for work. However, travelling and being away has been reported 
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by the health care workers, especially the nurses, as one of the biggest challenges for ARV 
adherence. This is similar to what was found in other studies conducted in sub-Saharan 
Africa. Croome et al. (2017) found that being outside the house or travelling is a barrier to 
adherence to ARV treatment in the sub-Saharan region. To demonstrate its importance, 
Weiser et al. (2003) ranked travel/migration as number three and commented that it was 
responsible for 10% of poor adherence in Botswana. This demonstrates that there is a need 
for extra support for clients who indicate that they are travelling or might travel in the near 
future.  
 
6.3 Medication/therapy-related barriers 
On medication-related barriers, van Dyk (2013) mentioned a difficult treatment regime, side 
effects and problems where a pill may be too big to be swallowed by a client. In this study 
clients on ARVs reported a lot of issues in relation to medication as a barrier.  
 
Treatment side effects are known to form part of the barriers to adherence resulting from 
medicine. Side effects are mentioned as a treatment adverse effect and as a patient-related 
barrier to adherence in the South African guidelines for HIV, TB and NCD (NDoH, 2016b). 
This is also supported by a study that was conducted in Johannesburg by Knight et al. (2015), 
which also identified medication side effects as one of the reasons for sub-optimal adherence. 
Treatment side effects have been listed as one of the top barrier to adherence. In a sub-
Saharan study that identified 40 barriers to ARV adherence, side effects are listed as number 
three out of the first four (Croome et al., 2017). All clients using ARVs in this study 
experienced side effects and these were severe, according to them. Their subjective 
experience of side effects was very significant to them. Furthermore, this experience of side 
effects has affected their adherence to ART.  
 
However, the health care workers did not consider side effects as an issue affecting their 
clients’ adherence to ART. Apart from one lay counsellor, no other health care worker 
referred to side effects as an issue affecting adherence for their clients. The unempathic and 
ineffectual responses the clients received when complaining about side effects to the health 
care workers indicates a lack of skill in managing clients’ frustrations and dissatisfaction with 
ARV treatment. Lekhuleni et al. (2013) commented that side effects play a role in poor 
adherence and recommended that health care workers should employ a patient-centred 
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approach in order to teach their clients about side effects. In the cardiovascular framework 
(National of Heart Foundation of Australia, 2011, p. 99), adherence is reported to suffer if 
“health professionals have sub-optimal interpersonal skills” to support their clients on 
therapy.  
 
Regardless of how the clients on ART were managed, the experiences of side effects had an 
impact on ARV adherence. Though some of the clients continued taking ARVs, four of them 
changed their way of taking ARVs following their experiences of side effects. This included 
skipping doses and seeking alternative treatment.  
 
There might be different side effects for men and women, and depending on the type of ARV 
medication taken. In this study, two male clients identified increased urination as a severe 
side effect. This was not mentioned by women. Tenofovir is one of the drugs that are known 
to affect individuals’ renal systems (Brennan et al., 2014); however, there is no evidence that 
these two male clients were on the medication that contained Tenofovir.  
 
In the literature, side effects are frequently mentioned as a barrier to adherence and ranked as 
one of the highest barriers. However, the findings of this study also show how these side 
effects are handled by clients, how threatening they are for individuals on ART, and how 
ART clients may default in the process because of these side effects.  
 
 A particular concern for participants using ARVs, but not mentioned by the health care 
workers, was not seeing any improvement whilst on ART and well adherent to the treatment. 
This may discourage someone who is taking treatment hoping to see some benefits, which 
would act as a ‘reward’ for good adherence. It becomes a challenge for one to continue taking 
treatment while one is noticing health problems. These may also be mistaken by the clients as 
side effects of the medication. This may relate to what the National Heart Foundation of 
Australia (2011) says about medicine-induced side effects and perceived side effects. Two of 
the participants using ARVs mentioned problems related to continuing to experience illnesses 
even while being on ART for some time. In this situation, adherence to HIV treatment may 
be affected, and the user of ARVs may be confused as to whether they are working or not. 
Perhaps this could be a reason why some clients try to look for alternative treatments. 
According to the cardiovascular framework of barriers to adherence, patients may lose faith 
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in medicines if they believe that there is too little or no improvement in their health 
conditions (National Heart Foundation of Australia, 2011).  
 
6.4 Service delivery-related barriers 
Van Dyk (2013) mentioned service delivery-related barriers such as medication stock-outs, 
health care workers being on strike, poor discipline in clinics leading to early closure and bad 
service, and the fact that prisoners find it difficult to access their treatment. In this study, no 
participant mentioned challenges relating to drug stock-out or inability to access treatment 
due to strike actions. Bad service and early closure were not mentioned as a problem either. 
However, inability to access ARVs due to imprisonment seems to be a reality for some 
clients on ART at the Injisuthi clinic. This was highlighted by one nurse. It seems that some 
of the clients on ARVs would miss appointments because they got arrested. According to this 
nurse, clients stop taking their medicines when arrested because it seemed the clinician in 
prison may sometimes not trust the inmate when he/she says they are on ART. Therefore, this 
means that ARVs will be discontinued until they are released from custody.  
 
This barrier could be improved by strengthening communication between the Department of 
Health, the police and Department of Justice. Defaulting due to incarceration did not appear 
in other frameworks of barriers. There is still a need to explore this further as this could assist 
in understanding adherence among prisoners. What makes this important is the fact that 
prisons are listed in South Africa as one of the high-transmission areas (HTAs) for HIV 
(NDoH, 2014a).  
 
Another issue relating to service delivery that appeared in this study but was not covered by 
the framework from a variety of studies including van Dyk (2011; 2013) and the 
cardiovascular framework (National Heart Foundation of Australia, 2011) is clinic 
overcrowding, resulting in long queues and long waiting times. This is similar to what was 
observed in Zimbabwe by Campbell et al. (2015). Campbell et al. (2015) commented that, in 
Zimbabwe, patients would wait in a queue of over 30 patients, moving at a rate of one patient 
an hour. In the South African adherence guidelines for HIV, TB and NCD (NDoH, 2016b), 
long clinic waiting times are considered under structural barriers as a provider-related barrier 
to adherence and retention to care for people using ARVs and other chronic medications.  
90 | P a g e  
 
Injisuthi is one of the high-volume clinics in the uThukela district. This results in a high 
number of clients in a context of limited human resources. This results in bottlenecks, 
overcrowding and longer waiting times. Two of the participants on ARVs mentioned long 
waiting times as one of the difficulties experienced when coming to the clinic. One of the 
participants mentioned that, at some times, she would have to leave home as early as five 
o’clock in the morning to wait in the clinic until midday without getting her medication. This 
was confirmed by the nurses who, however, emphasised that they do all they can to make 
sure that all the clients do get their medication, no matter how crowded the clinic is. The 
nurses mentioned that some of the clients get discouraged by the long queues and decide to 
leave without medication, which has implications for adherence.  
 
It seems some of the country’s health systems and policies are not supporting adherence to 
the treatment. Some of the health care workers felt that clients would adhere better if they 
were to be given at least a three-month supply of medicine and also have ARVs available 
from the mobile clinics. This could prevent ART clients having to come to collect their 
treatment on a month-to-month basis, which often costs them time and money. During the 
time of this study, ARVs were not yet made available for patients through the public mobile 
clinics. Making ARVs available through mobile clinics may help clients who are on ART and 
reduce the long queues at clinics.  
 
6.5 Stigma and discrimination  
In van Dyk’s framework (2013), stigma leads to secrecy, fear and lies, hiding of pills, non-
disclosure, lack of support groups due to secrecy and fear of community rejection, and 
rejection of the disease. In this study, only one participant using ARVs talked about hiding 
her status and her medication. However, all participants using ARVs mentioned that they had 
disclosed their status at least to either a family member or to the entire family. They reported 
receiving support from their families and the clinic but not from the community, since they 
felt a need to keep their status a secret from the community due to fear of discrimination. This 
is in line with what is mentioned in van Dyk (2013) as a fear of community rejection.  
 
Four of the ARV clients highlighted that they would prefer not to disclose their status to the 
community because people from the community gossip, and some mentioned that they have 
heard people from the community talking badly about the people living with HIV. Two of the 
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participants described how they would lie and hide their status from the CCGs. Most of 
participants mentioned stigma as a reason for their non-disclosure to the community and to 
the CCGs. The CCGs in this study also mentioned that they often come across people who do 
not want to disclose their status. This blocks access to support they should be receiving from 
the CCGs.  
 
Non-disclosure was mentioned by all of the health care workers. From the care workers’ 
perspective, clients hide their HIV status from their husbands, and do not come for treatment 
collection when their husband is back from work. This non-disclosure in one case was 
because the husband threatened to kill his wife if he found out that she is living with HIV. All 
of the health care workers mentioned that married women did not disclose to their mothers-
in-law. This led to married women not being able to come for their treatment collection 
appointment, thus defaulting on ARVs.  
 
One of the lay counsellors mentioned that some of the clients may even opt to go back home, 
when they may have seen someone at the clinic. Specifically, she mentioned an instance 
where a person said she come for her appointment but left when she saw a woman she was 
sharing a partner with. This is supported by what was mentioned by a nurse, that clients at the 
clinic may feel that they are ‘watched’ by others. In addition to this, a nurse and a lay 
counsellor participant mentioned that “stigma is still there”.  
 
HIV-related stigma has been listed as one of the important barriers to ART adherence in sub-
Saharan countries in Africa. In Botswana ten years ago, stigma was shown to be number 
three, accounting for 15% of poor adherence to ARVs (Weiser et al., 2003). This raises a 
concern that, after all the effort put into education and awareness campaigns on HIV-related 
stigma, it is still appearing as one of the high-ranking barriers to ARV adherence. In a study 
conducted in sub-Saharan Africa, it was also found to be the third most significant barrier to 
adherence (Croome et al., 2017). This shows that stigma has been, and still is, a barrier to 
adherence. Interventions to reduce HIV-related stigma through dialogues and various 
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6.6 Health control 
In van Dyk’s (2013) framework, health control relates to such issues as having no control 
over one’s own health, having a fatalistic attitude (“Nothing I can do will make a 
difference.”), an external locus of control and poor health literacy. In this study, there was no 
indication that patients struggled with control over their own health, or had a fatalistic 
attitude or external locus of control. However, married women did experience 
disempowerment, as discussed in the section about stigma. This study also did not find poor 
health literacy to be a challenge for clients who are using ARVs, and thus a cause for poor 
adherence. 
 
6.7 Cultural aspects  
According to van Dyk (2013), cultural factors are seen as a barrier to adherence; this refers to 
the fact that some of the clients on ARVs take and use medicines from traditional healers 
without disclosing this behaviour to their health care workers. This use of traditional 
medicines while on ART was observed as a threat to ARV adherence in a sub-Saharan setting 
(Wanyama et al., 2017). In this study, two of the clients on ARVs, as well as CCGs and 
nurses spoke about the use of traditional medicines. Sometimes this happened in conjunction 
with taking ARVs and sometimes ARVs were suspended. One client mentioned stopping 
using ARVs while using traditional medicines and the other one suspected that her use of 
traditional medicines in the form of immune boosters was responsible for her high HIV viral 
load. On the health care workers’ side, lay counsellors, CCGs and nurses referred to the use 
of traditional medicines as one of the reasons for poor adherence or clients stopping ARVs. 
Both clients using ART and health care workers indicated that, usually, use of ARVs is 
suspended when traditional medication is used. This creates a problem for viruses like HIV, 
since it may lead to the HIV viral load not being suppressed and later resistance to ARVs.  
 
It is not known how widely traditional medicines are used with ARVs in South Africa. 
However, in a study that was conducted in sub-Saharan Africa (Tanzania, Zambia and 
Uganda), Wanyama et al. (2017) comment that 5.8% of the participants on ART in their 
study had consulted a traditional healer ‘in the past three months’. In that same study, 
participants said that traditional healers claimed to be able to cure HIV, something also 
mentioned by a nurse in this study. Use of traditional medicine is also mentioned as a barrier 
to adherence in the South African adherence guidelines for HIV, TB and NCDs (NDoH, 
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2016b). If use of traditional medicines goes unnoticed and users of ARVs are not supported 
accordingly in their use of alternative-medicines, this will directly affect adherence, which 
will affect health outcomes and health budgets. This is because these clients will have to be 
switched onto a new regimen when the first (and the less expensive) one is no longer 
working.  
 
The communal lifestyle in the rural and traditional setting as a context also becomes a 
challenge for an individual who is taking ARV medication. Having HIV is still stigmatised, 
therefore there is always a need for taking treatment in private. This privacy is often limited 
by this communal life, since every move is being watched by everyone in this setting.  
   
6.8 Gender and social organisation (masculinity) 
Van Dyk’s (2013) framework does not specifically mention gender or social organisation as 
barriers to adherence. However, Van Dyk (2011) found that women would hide the fact that 
they are taking ARVs from their male counterparts, for fear of rejection, losing children and 
even getting killed. This affects adherence to ARV medication. According to van Dyk (2011), 
this made 79% of her participants fail to adhere optimally. In terms of masculinity, according 
to van Dyk (2011), men seemed unwilling to seek medical help even if they were living with 
HIV. This could be based on a need to maintain a masculine identity in which a ‘real man’ is 
not sick. This was mentioned by health care workers in this study. This is similar to what was 
found by other studies. According to Skhosana et al. (2006), men delay seeking medical help 
in order to maintain their masculine image. This makes them come to health facilities very 
late and some even die of HIV because of coming so late for health services (Naidoo, 2017). 
These gender-based aspects and late health-seeking behaviour do not only affect males, but 
their female counterparts as well.  
 
Married women seem to be more at risk of defaulting on ART. Household social barriers 
seem to mostly affect women, particularly in the rural communities of Injisuthi clinic. This 
seems to be an issue particular to this context as it is not identified in the literature. Married 
women appeared to be mostly stigmatised, and often feel they must take their treatment in 
secret since they live with their in-laws and fear being discriminated against by them. Thus, 
they do not disclose their HIV status. All categories of participants pointed out household 
conflict as a barrier to adherence. In this study, it was discovered that married females often 
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fail to adhere to clinic appointments because they are either prevented by their partners from 
coming or they have not disclosed to their in-laws that they are taking ARVs. This could be 
due to the denial of HIV status by their partners and the fear of being stigmatised and 
discriminated against by their in-laws. 
 
A lay counsellor mentioned that most of her clients are married females and they often miss 
their clinic appointments because they have not disclosed to their in-laws or their husbands. 
All three nurses spoke at length about how the clients’ relationship with either their husbands 
or mothers-in-law was a barrier to adherence for young married women in the area. The 
nurses commented that the husband might be in denial and therefore prevent his wife from 
going to the clinic to collect treatment, claiming they ‘don’t want any issues relating to HIV 
in their house’. The nurses also mentioned that the husbands of the married women do not 
want them to take ARVs. Interestingly, none of the five participants on ART mentioned 
gender-related issues as a reason for non-adherence. 
 
6.9 Summary  
Ever since the discovery of AIDS in 1981, international communities and governments have 
been trying all they can to curb the scourge of the disease and promote life through research, 
education, change of policies, and prevention and treatment interventions. However, the 
success of these interventions depends among other things on the behaviours of individuals 
and the factors that influence those behaviours.  
 
In this study, 12 barriers to adherence for people using ARVs at Injisuthi clinic were 
identified through data collected from 14 research participants. The identified barriers varied 
across the different research participants (clients and health care workers). The participants 
who use ARVs mentioned ARV side effects and difficulties relating to fetching medication, 
since they are the ones who are directly involved with taking pills and therefore have direct 
experience of what it feels like taking ARVs and going to the clinic to collect them. Their 
perspective focuses on how it feels to be a user of ARVs and living with HIV. The challenges 
they indicated included side effects; clinic waiting times; use of alternative (traditional) 
treatment; taking ARVs on an empty stomach; non-disclosure and stigma; lack of support at a 
community level; pill burden; and poor treatment outcomes.  
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On the other hand the health care workers, depending on their area of intervention, gave a 
different (though sometimes overlapping perspective) on what was mentioned by the clients 
who are using ARVs. Their perspective also varied with their level of involvement with the 
clients, and with their role in helping people living with HIV and ARV users. Their duty is to 
focus on making sure that their clients take ARVs, through preparing them for ARVs, giving 
ARVs, monitoring that ARVs are taken as prescribed, as well as tracing them in the 
community and bringing them back to the facility for care should they default and lose their 
contact with the clinic.  
 
1. The lay counsellors, whose focus is to ensure that clients who test positive for HIV 
are linked to an ARV programme, and also to provide them with adherence 
counselling to ensure that they stay on ARVs, indicated non-disclosure and stigma; 
resistance to behaviour change; use of traditional medicine; health care worker/patient 
relationship; transport money; work-related challenges; side effects; treatment fatigue; 
and improved health as the main barriers to adherence for their clients at Injisuthi 
clinic. Only one lay counsellor mentioned the side effects as an issue, which is a 
major concern for the clients who are using ARVs. This shows how the priority issue 
amongst the clients who use ARVs is missed. This impacts on adherence to treatment 
since it might mean that clients are not fully supported in issues around side effects. 
 
2. The community care givers (CCGs) who work in the community to provide basic 
health care services through door-to-door household visits indicated that poverty 
(taking ARVs on an empty stomach and lack of transport money to go to the clinic); 
social issues (household conflicts with husbands); stigma and non-disclosure; 
substance abuse; use of traditional medicines and challenges relating to access to 
ARVs in mobile clinics are barriers to adherence for clients on ART at Injisuthi clinic. 
Their perspective is valuable for its focus on the issues affecting adherence at the 
level of the community, having worked there for years supporting individuals living 
with HIV. All of the CCGs pointed out poverty, stigma, non-disclosure and 
discrimination as the main challenges affecting adherence for their clients in the 
community.  
 
3. It is interesting here that the main reasons being mentioned by CCGs and lay 
counsellors are not the side effect issues, which is what the focus was with the clients. 
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CCGs may have been overwhelmed by the poverty that they witness when doing their 
work. Some of the CCGs donated their own food to the families that they visited.  
 
4. The nurses’ duty is to enrol clients on ARVs and monitor their bloods to see if the 
treatment is working. The nurses indicated that long duration on treatment/treatment 
fatigue; poor community support system; non-disclosure and stigma; poverty (no 
transport money to the clinic); work-related issues; incarceration; social issues (family 
conflicts with husbands and in-laws); clinic overcrowding (clinic waiting times); 
travelling (being away); improved health; use of traditional medicines; health care 
worker/patient relationship; and authorities (the health system) appeared to be the 
barriers experienced by their clients on ART.  
 
5. The narratives of the nurses focussed mostly on barriers relating to accessing 
treatment and person-related issues, rather than how it feels for their clients to be on 
ARVs. This may result from the fact that their duty is to issue medication and order 
their clients to take their treatment as prescribed. This approach overlooks the 
experience of what it is like to be on this prescribed treatment and might mean 
insufficient support is provided to the client about the emotional experiences of being 
on ARVs. This potentially creates the conditions for poor adherence since there is 
poor insight into, and little management of, the most important needs of the client. 
Empowering clinicians to explore the experiences of the client on ARVs is 
recommended. This should be combined with equipping clinicians with skills to 
respond adequately and efficiently to clients’ needs. This could help shift the focus 
from a health system-centred approach to one that is centred on clients’ needs. 
 
In this study, it appears that the different foci of the participants resulted in different 
perspectives of the barriers to adherence. This may also result from different experiences of 
needs. In this study, all the clients who had used ARVs and defaulted highlighted side effects 
as their main concern, while on the other hand, out of nine health care workers, only one 
referred to this as one of the barriers to adherence. Nurses and CCGs are mute on side effects. 
Only one lay counsellor referred to this. This could be because lay counsellors are trained to 
be empathic when dealing with their clients. However, the other two lay counsellors, like the 
nurses and CCGs, did not refer to side effects.  
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From the responses of the participants who use ARVs, one could clearly see how the issue of 
side effects is brushed off when they complain about them. This suggests that most of the 
services are more health system centred and less client’s need centred. Therefore, adherence 
to treatment suffers when the demands of the treatment are not adequately noticed and dealt 
with appropriately. A psychosocial support system that is more client need centred and 
empathetic would be recommended, given the rush to enrol all HIV positive patients on 
ARVs, as per the World Health Organisation’s (WHO) recommendations for 2030. Taking 
care of the needs of the users of the services, in this regard ART, may assist in reducing the 
number of defaulters and avoid challenges like the formation of resistant strains and the 
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Chapter 7: Conclusion 
 
Non-adherence to ARVs is one of the major contributing factors to treatment failure because 
of viral resistance that may occur. This study was an attempt to answer such questions as: 
Why do clients fail to adhere to ART treatment? What makes it hard for ART clients to 
adhere to treatment? What are the most common barriers to adherence for local clients? This 
study showed that taking ARVs is not always easy. There are a variety of issues involved in 
the process which contribute to ultimate failure to remain on ARVs. When the findings of this 
study are compared to findings from the previous researchers it becomes clear that most of 
the barriers that were identified in 2010/2011 were still affecting adherence in 2016. This 
study also found that there is still a big gap in the health care services when it comes to 
counselling and provision of adherence support for clients on ART. 
 
Different perspectives used in this study made it possible to gain sound insight into barriers to 
adherence. This is due to the fact that the different backgrounds that participants were coming 
from allowed for a comparison of the different perceptions of barriers. The use of multiple 
perspectives in this study was also useful to illustrate how the ART programme is more 
health system centered rather than person centered, despite the fact that the ultimate success 
of the ART programme rests largely on the behaviour of the person (i.e. adherence) who is 
taking the treatment as prescribed. 
 
This study showed that Injisuthi clinic clients on ART experience similar barriers to 
adherence as those that have been found by other researchers in other contexts. However, in 
some instances, the manifestation of the experience of these barriers differed with the 
context. For instance, male research participants reported an additional side effect of 
increased urination when using ARVs. The experience of stigma and discrimination was also 
found to be more severe for women, and especially for married women.  
 
This study also demonstrated that people do not only fail on ARVs because of the side 
effects, but also because of the responses they get from health care workers and others who 
should support them. Some of the responses from health care workers appeared to be of no 
use at all for clients on ARVs, especially when they complained about side effects. This leads 
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to clients abandoning or the prescribed way of taking pills, for an example, skipping the 
morning dosage because of side effects and taking only the afternoon one. 
 
This study confirmed most of the barriers found in other studies and also added more insight 
into some of the issues that were reported in other studies. On issues such as side effects, 
more insight is still needed in order to explore their manifestations across gender. A stronger 
psychosocial support system that integrates the experiential needs of the client on ART 
should also be considered, in order to manage other barriers that are influenced or linked to 
this, such as looking for alternative treatments and the experience of pill burden.  
 
The framework used in this study included gender and social organisation as a barrier for 
people on ARVs. This study confirmed the existence of gender issues as a barrier to 
adherence mostly affecting women through stigma, discrimination and gender-based 
violence, whilst for men, the need to maintain masculinity had a negative impact on their 
health-seeking behaviour and thus adherence. Gender and social issues were fairly dominant 
findings in this study but have not been referred to significantly in other studies. There is a 
need to explore these further, especially these dynamics in African rural communities. 
 
7.1 Strengths and limitations of the study  
There were many aspects that contributed as strengths in this study. These will be considered 
in this section. 
 
1. There were 14 people interviewed, from a variety of backgrounds, providing access to 
information from different world views. Five clients using ARVs, with an experience 
of failing on the first-line regimen, shared their experiences of how they had come to 
fail. This information was compared to information shared by the nine health care 
workers who supported people on ARVs at various levels (i.e. psychosocial, clinical 
and community levels). This means that the barriers to ARV adherence were 
examined from different perspectives. However, the number of participants per 
category was limited due to the qualitative design of the study. 
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2. Themes from the data were identified objectively from the data and later compared to 
barriers already available from the literature, as opposed to being guided by the pre-
existing information. The analysis was thus initially data driven.  
 
3. The researcher has had experience of more than 17 years working in the field of HIV, 
as an HIV youth coordinator, trainer, counsellor (including adherence counselling), 
and counsellor mentor, at a private or public institutional and community level. This 
means that, over the years, I have gained adequate awareness around how sensitive 
living with HIV is and the need for confidentiality for clients. As a former HIV lay 
counsellor and research assistant, I could draw from previous experiences the skills to 
ensure that the interviews ran smoothly, with appropriate probes where necessary.  
 
4. Clients were interviewed in their own language. This serves as strength for it allowed 
them to express themselves as deeply and as far as they could during their interviews. 
The collected data were then translated by the researcher into English. This means 
that the researcher was able to incorporate non-verbal cues into the transcribed data, 
and translated it with an understanding of what was said and how it was said. This 
therefore was able to include the implied messages apparent in what was said by the 
participants.  
 
5. This study only investigated barriers to adherence in the context of one clinic (i.e. 
Injisuthi clinic), a high-volume clinic serving the population from a rural area with 
areas far apart from each other This means that the findings of this study cannot be 
generalised to other facilities with a different setting from Injisuthi clinic. However, 
the detailed description of the data collection process, and the details provided in the 
presentation of results, mean that the findings could be transferable to similar 
participants in similar settings. 
 
6. Inclusion of men and women in this study assisted in obtaining the experiences of 
both genders of being on ART. This allowed for findings to emerge that were 
different across genders, for example, increased urination on the part of men in 
relation to ARVs. This study did not, however, explore the extent of this phenomenon 
and could not give the reasons for this phenomenon.  
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7. The analysis showed that, for some of the barriers, the perception of the barriers was 
the same for the health care workers and the individuals using ARVs, for example, in 
relation to side effects, stigma/non-disclosure, pill burden and use of traditional 
medicines. However, perceptions differed in relation to poverty, travelling, work-
related issues, social issues (conflicts at a household level) and improved health.  
 
8. As for the last research question about how challenges of living with HIV relate to 
poor adherence, the data show that stigma that is attached to HIV is still active and 
that it leads to non-disclosure and thus poor adherence. Stigma meant that clients left 
the clinic if they saw someone they knew. Non-disclosure and stigma were evident 
when participants on ART rejected support at a community level, fearing that the 
CCGs would gossip about them. As a result, the individuals on ART seemed to prefer 
to keep their HIV status to themselves.  
 
7.2 Recommendations  
There are a number of recommendations related to ARV medication adherence. Given the 
seriousness of the side effects, one would recommend the use of drugs with fewer or tolerable 
side effects. The currently used first-line regimen has fewer side effects than earlier ARVs. 
This study recommends stronger psychosocial support for people who are using ARVs in 
order to keep them on a regimen that is tolerable. This should be combined with continuous 
screening for side effects and ongoing counselling for patients using ARVs. In addition, 
packaging of the medication such that is makes less or no noise may reduce shame in 
carrying the ARVs by the clients on ART.  
 
Recommendations related to managing and reducing stigma include that there is an urgent 
need to address stigma. This could be addressed at the individual and community level. HIV-
positive individuals need to be protected and assisted to overcome stigma, while interventions 
that reduce stigma at a community level should also be conducted.  
 
There is also a need to implement strategies to alleviate poverty, so as to increase access to 
food for clients on ART, as well as strategies to minimise travelling costs for clients who are 
using ARVs. 
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In terms of gender, there is a need to implement interventions that would address gender-
based violence affecting married women on ART. Such interventions should target men in 
the communities with dialogues that would see them empowered to access HIV services 
themselves. These interventions should help men in the community know and accept their 
HIV status and take leadership in HIV prevention and treatment.  
 
In terms of access to treatment, a workplace-based distribution of ARVs programme for 
clients who are working would be recommended. This may reduce time requested to attend 
the clinic. It might also address some of the fear clients expressed about dealing with attitudes 
of health care workers at clinics. However, this should be combined with distribution of other 
medications, in order to avoid or reduce stigma.  
 
In addition, availability of ARVs in various forms at a community level is recommended for 
ease of access to ARVs. This is currently being implemented by the Department of Health. 
This is done through a model that allows all people who are using chronic medicine to collect 
their treatment in the community, in the form of clubs known as adherence clubs. However, 
the establishment of these clubs is slow and has been met with many challenges. If this is fast 
tracked, this could make a significant difference in terms of access.  
 
An intervention that shortens waiting times for clients on ARVs at the facilities is also 
recommended. Since 2016, the government has started implementing this. The Department of 
Health implemented a model in which clients who go to the public clinic for their chronic 
medicine (including ARVs) can now choose to just go straight to the clinic dispensary to 
collect their medicine and leave without sitting in the queue. 
 
A training and mentorship process to empower health care workers about on how to deal with 
and counsel their clients on ART (or any other chronic medication) about side effects is 
recommended. This study has shown that if their clients are simply ignored when 
complaining about side effects it impacts on adherence to their treatment.  
 
In terms of further research, the increase in male urination whilst on ARVs needs to be 
followed up as it interferes with adherence, and was a significant problem for two of the 
clients in the study.  
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Appendix One: Enquiry about research project permission 
 
Enquiry about research permission. 
 




Dear Dr. Lutge, 
I work for the department of health and I am intending to do a study for my Master’s Degree in 
Psychology with UKZN. My area of interest is HAST. I would like to conduct a study on ART 
(ARV) Adherence barriers to patients that are on regimen 2, due to non-adherence on regimen 
one. I am looking at conducting a qualitative study that will recruit and interview 5 (adult) clients, 
3 Lay counsellors and two ART Nurses. 
 
For a permission to conduct such a study I have asked for an advice from a provincial head 
office. Part of the response I got was that, I have to ask for permission from the DM, and also 
have been referred to you for further advice. On the kznhealth website it appears as if non 
clinical studies may not need a form that needs approval from the ethics committee. 






Lutge Elizabeth <Elizabeth.Lutge@kznhealth.gov.za> Wed, Feb 3, 2016 at 2:14 PM 
To: Cele Jabulani <Jabulani.Cele@kznhealth.gov.za> 
Cc: "ndosimagaye7@gmail.com" <ndosimagaye7@gmail.com>, Khumalo Gugu 
<gugu.khumalo@kznhealth.gov.za>, Xaba Xolani <Xolani.Xaba@kznhealth.gov.za> 
 
Dear Mr Cele 
You will need to get letters of support from the institutions that you wish to conduct your research 
in. If you are hoping to work in 4 or more facilities in the same district, then you should get 
permission from the district manager, but if in three or fewer facilities then you should get 
permission from each facility manager. You need to submit these letters, plus your letter of ethics 
approval and your full protocol, onto the website of the National Health Research Database 
(nhrd.hst.org.za/), from which it will be forwarded to us. If you have any difficulties with this 
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Appendix Three (A): Information sheet (for the participants on ART) 
 
The Study 
The purpose of this study is to establish an understanding of key barriers to adherence to antiretroviral treatment 
(ART) for clients that are living with HIV. 
 
This is a study about the experiences of the clients that are living with HIV and are using (ART) to control HIV. 
The main focus is to find out the challenges that people experience when taking ARVs.  
 
You may directly benefit from the fact that you will get an opportunity to talk to someone about the problems you 
came across when taking ARVs, and living with HIV. This may be therapeutic. The results (not exactly your 
words) will be shared with the decision makers. This may influence decisions that they take to support HIV 
positive and on ART people. This may be a benefit more people that are living with HIV and are using ART.  
 
The interview process (for individual participants on ART) 
In this interview you will be talking to a researcher for about an hour. The interview will take place in one of the 
clinic rooms. The researcher will ask you questions about living with HIV. He will also ask questions about what 
happens when you are taking ARVs, and challenges you had about taking.  
 
The aim of this study is to get to understand better the challenges that are met by the people living with HIV and 
are using ARVs. You are invited to share as much as you can and as free as possible. Whatever you say during 
the interviews will be kept confidential. When the results of the study are shared with other people, your name 
will not be mentioned.  
 
All that you talk about is not going to be looked at as not going to be judged in terms of wrong or right, good or 
bad. It is important in this study that you just share whatever happened as it is. If you do not want to answer 
some of the questions please feel free to do so.  
 
You will be talking to a researcher (Jabulani Cele) who is a male. He is a student at the University of KwaZulu 
Natal. He is a doing this research as part of his studies for Master’s Degree in Psychology. He is also 
experienced in HIV counselling and in conducting research interviews. 
 
Interviews will be conducted in either English or isiZulu (or a combination of both). It will depend on the language 
you feel more comfortable with) 
 
Recording  
In order to capture all you say, we ask for your permission to record the interviews which will be later be written 
on paper word for word on what you have said. The researcher will then analyse it so as to understand better 
what you have talked about. 
 
Participation in the study 
Your participation in this study is absolutely voluntary. Please be aware that you have the right to stop your 
participation in the study at any given stage and that is not going to have any bad results in the services you 
receive in this clinic.  
 
During the study if I feel that you are getting upset, I will ask you if you still want to continue participating.  
Should your participation in this study lead to a situation where you are feeling distressed and that you need to 
talk to someone an arrangement has been made for you to see a counsellor here at this clinic, who can be 
contacted as follows: 
 
Name of a counsellor: Ms Tholakele Ngobese 
 
Contact: 036 431 8133 (Injisuthi clinic) 
And you can also call the AIDS helpline at: 0800 012 322 
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HIV/AIDS information will also be provided by the researcher after the interviews. 
 
If you decide to leave the study and have already participated, the researcher is going to ask for your permission 
as if you would like the data that has already been collected to be used in the study or not. If you happen to be 
asked whether you want data to be used or not, you still have a right to agree or disagree. And that will again, 
not have bad consequences on the way you are treated in this clinic in future.  
 
After the interviews 
After the interviews discussions all recorded data will be transcribed word for word and translated in to English. 
Transcribed and translated data will be analysed and the research report is going to be written out of it. The 
same researcher who conducted the interviews will do the transcription and translation, the second person will 
only come into contact with the data when checking if the translations from isiZulu to English are correct This 
person will not know the names of the people who participated in the study because she will only be working with 
what is written on papers. 
 
Throughout all the stages of working with data, from transcription, translation, verification of translation analysis 
and reporting of research findings research participants will not be referred to by names. Instead I will use codes. 
For an example I will be saying participant “A” or participant “B”. 
 
The findings of this study will appear in a thesis for examination for the researcher’s degree of Masters in 
Psychology. It will be publically available in the UKZN library. Since information from this study is of a high value, 
findings from this study may be shared with other researchers, in AIDS seminars, AIDS conferences, HAST (HIV, 
AIDS, STI and TB), Meetings and with the provincial department of health. When information from this study is 
shared in any form or platform, there is going to be no mention of names, but rather pseudonyms and labels 
such as “research participant A or B” as I have mentioned before. 
 
A summary of the results of this study may be made available to you should you wish to get them.  
 
Storage and dispersal of research data  
All data (audio, transcribed and translated) and information from this study will be stored for five years for future 
reference. It will be stored with researcher’s supervisor, kept in lockable device (a filling cabinet). When the 
period of 5 years is finished it will be destroyed and incinerated. Electronic data will be protected with a password 
to ensure that no one else get to it except the researcher (me) and my supervisor. All electronic data will be 
deleted from the systems and storage devices including backups, when the period of 5 years has lapsed.  
 
HIV/AIDS information 
It may be possible that during your participation in this study you need further information and support. If you 
need any information on HIV and AIDS and other health matters relating to HIV, you could refer to the pamphlets 
provided by the researcher, go to any nearest government clinic, and speak to an HIV counsellor in this clinic. 
 
And you can also call the AIDS helpline at: 0800 012 322 
.  
For counselling and advice you can call the helpline, go to any government clinic that is accessible to you, or 
come to this clinic to see any HIV/AIDS counsellor, or ask for Ms Tholakele Ngobese. 
 
Name of a counsellor: Ms Tholakele Ngobese 
Contact: 036 431 8133 (Injisuthi clinic) 
If you have any concerns about this study you can also contact Ms Phume Ximba of the Humanities and Social 
Science Research Ethics Committee (031 260 3587, email ximbap@ukzn.ac.za) 
If you have any questions about this study, then please talk to: 
The researcher - Mr. Jabulani Cele (cell:  email: ndosimagaye7@gmail.com), 
The Operational Manager of Injisuthi clinic - Mrs. G Ganes (Tel: 036 431 8133) or  
Talk to the researcher’s supervisor - Dr Mary van der Riet (Tel: 033 260 6163 email: vanderriet@ukzn.ac.za). 
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Appendix Three (B): Information sheet (for the participants on ART) 
 
Ucwaningo 
Inhloso yalolucwaningo ukuthola ukuqonda kabanzi ngezithiyo nezinselelo ngqangi ekusebenziseni imishanguzo 
ngendlela kubantu abaphila nesandulela ngculaza abasebenzisa imishanguzo elwisana nesandulela ngculaza. 
 
Lolu ucwaningo olumayelana nempilo yabantu abaphila negciwane eliyisandulela ngculaza (HIV) asebenzisa 
imishanguzo (amaphilisi ama ARV) ukulawula igciwane lengculaza. Lolucwaningo lugxile kakhuluekutholeni 
izinselelo abantu ababhekana nazo uma besebenzisa amaphilisi okunqanda ukudlondlobala kwesandulela 
ngculaza egazini.  
 
Ongakuzuza mathupha kulolucwaningo ukuthi uzothola ithuba loxoxela umuntu ngezinkinga oye 
wahlangabezana nazo ngenkathi uthatha imishanguzo (ARVs), nangokuphila nesandulela ngculaza. Lokhu 
kungase kwelaphe umphefumulo. Imiphumela (hhayi amazwi akho enjengoba enjalo) izofinyelela kubathathi 
zinqumo. Lokhu kungaba nomthelela ezinqumeni abazithathayo ukweseka abantu abaphila nesandulela 
ngculaza nabasebenzisa imishanguzo elwisana nesandulela ngculaza.  
 
Inqubo yengxoxo yocwaningo (kwababamba iqhaza abasebenzisa imishanguzo) 
Kulengxoxo uzebe uxoxa nomcwaningi isikhathi esingangehora. Ingxoxo izokwenzelwa kwelinye lamagumbi 
asemtholampilo. Umcwaningi uzokubuza imibuzo emayelana nokuphila nesandulela ngculaza. Uzokubuza 
emayelana nokuthi kwenzakalani uma uthatha amaphilisi nezinselelo obe nazo ekuthatheni kwakho amaphilisi.  
 
Njengoba inhloso yalolucwaningo ukuthola ukuqonda kabanzi ngezithiyo nezinselelo ngqangi ekusebenziseni 
imishanguzo ngendlela kubantu abaphila nesandulela ngculaza abasebenzisa imishanguzo elwisana 
nesandulela ngculaza. Kanjalo siyakucela ukuba uxoxe nje ukhululeke wenabe ngakho konke okusemandleni 
usho konke ofisa ukukusho. Konke ozokusho kulengxoxo kuzogcinwa kuyimfihlo, akuyikutshelwa muntu. Uma 
kwethulwa imiphumela yalolucwaningo kwabanye abantu, aliyukuvezwa igama lakho. 
 
Konke ozokusho kulengxoxo akuzukwahlulelwa ngokuthi kuhle noma kubi, kulungile noma akulungile. 
Kubalulekile kulolucwaningo ukuthi ukhulume nje ngokwenzeka njengoba kunjalo. Uma ungathandi ukuphendula 
eminye yemibuzo sicela ukhululeke ukuba ungayiphenduli.  
 
Uzobe ukhuluma nomcwaningi (uJabulani Cele) ongowesilisa. Ungumfundi eNyuvesi yaKwaZulu Natali. Wenza 
ucwaningo njengenxenye yeziqu zakhe zemfundo ephakeme (Masters) ezifundweni ngempilo yabantu 
(Psychology). Unesipiliyoni sokwaluleka abaphila nesandulela ngculaza nasekwenzeni ucwaningo.   
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Ingxoxo yocwaningo ingaba ngesiNgisi noma ngesiZulu noma kuxutshwe. Kuzoya ngokuthi yiluphi ulimi wena 
ozizwa ukhululekile kulona. 
 
Ukuqopha 
Ukuze bambeke kahle konke ozobe ukushilo kungasali lutho, singathanda ukucela imvumo yakho ukuba 
lengxoxo yocwaningo iqoshwe ngesiqophamazwi, okuzothi ngemuva kwalokho kubhalwe ephepheni igama 
negama lozobe ukushilo. Umcwaningi uyobe esekuhlaziyake lokhu ukuze aqonde kabanzi obukhuluma ngakho.  
 
 
Ukubamba iqhaza ocwaningweni 
Ukubamba iqhaza kwakho kulolucwaningo kuya ngokuzikhethela kwakho. Sicela ukukwazisa ngokuthi 
unelungelo lokuhoxa nomanini kulolucwaningo kantu ukuhoxa kwakho akuyikuba namthelela omubi empathweni 
ozoyithola kulomtholampilo ngomuso.  
 
Ngesikhathi ucwaningo luqhubeka uma uzizwa uphatheka kabi, ngizokubuza ukuthi uyafisa yini ukuqhubeka 
nokubamba iqhaza ocwaningweni.  
Uma ukubamba kwakho iqhaza ocwaningweni kuholela esimweni lapho uzizwa uphatheka kabi ufisa sengathi 
kungakhona oxoxa naye kuhleliwe ukuba ungakhuluma nomaluleki kuwo wona lo mtholampilo ongaxhumana 
naye kanjena: 
 
Igama lomaluleki:  Ms Tholakele Ngobese 
Inombolo yocingo: 036 431 8133 (Injisuthi clinic) 
Ungashayela nalenombolo yosizo olumayelana nengculaza: 0800 012 322 (imahhala uma uyishayela ocingweni 
lakwa telkom) 
 
Ulwazi mayelana nesandulela ngculaza nengculaza luzotholakala emapheshananeni azonikezelwa 
ngumcwaningi ngemuva kwengxoxo yakho naye.  
Uma unquma ukuhoxa ocwaningweni kanti usuke wathi ukubamba iqhaza kukhona nobese kucoshelelwe oke 
wakusho umcwaningi uyocela imvumo kuwena ukuba uyafisa yini ukuba obese kucoshiwe okumayelana 
nocwaningo kusetshenziswe ocwaningweni noma cha. Nalapho unelungelo lokuba uvume noma wenqabe. 
Nalokho akuyikuba namthelela empathweni oyoyithola ngomuso kulomtholampilo.  
 
Ngemuva kwezingxoxo zocwaningo 
Ngemuva kwezingxoxo zocwaningo konke okuqoshiwe kuzobhalwa phansi ephepheni igama negama bese 
kuguqulelwa esiNgisini. Osekubhalwe ephepheni kwase kuguqulelwa esiNgisini kuzobe sekuhlaziywa bese 
kubhalwa umbiko wocwaningo ususelwa kukho. Umcwaningo obuxoxa naye nguyena ozobhala phansi ozobe 
ukushilo bese ekuguqulela esingisini, umuntu wesibili uyongena nje kuphela lapho esezoqinisekisa ukuthi 
kuguqulelwe ngakho yini esiNgisini obekushiwo ngesiZulu ephepheni. Lo muntu wesibili akazukuwazi amagama 
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abantu ababambe iqhaza kulolucwaningo ngoba yena uzosebenza nje kuphela ngalokhu okuzobe kubhalwe 
emaphepheni. 
 
Kuzona zonke izigaba zokusebenza ngolwazi olucoshwe kwenziwa ucwaningo, kusukela ekubhalweni kwalo 
phansi kuya ekutolikweni naseku bhekweni kwamaphutha kuhlaziywa nasekubhalweni kombiko wocwaningo, 
abebebambe iqhaza ocwaningweni abezukuhlonzwa ngamagama abo. Esikhundleni samagama 
kuyosetshenziswa amakhodi. Okwesibonelo ngizothi umbambiqhaza “A” noma “B”  
 
Okutholakele kulolucwaningo kuyovela embhalweni wezivivinyo lapho umcwaningi eyobe ehlolelwa khona iziqu 
zakhe zemfundo ephakeme (Masters) will appear in a thesis for examination for the researcher’s degree of 
Masters in Psychology. Lolulwazi luzotholakala kunoma bani oludingayo emtapweni wolwazi weyunivesi 
yaKwaZulu Natali. Ngokuthi lolulwazi lubaluleke kakhulu, imiphumela yalolucwaningo iyonikezwa kwabanye 
abacwaningi ezingqungutheleni zengculazi, nasemihlanganweni emayelana nengculaza, nasemihlanganweni 
yezikhulu ezibhekelele isandulela ngculaza nengculaza nezifo zofuba (TB) nezocansi, bese lwedluliselwa 
nakubaphathi bomnyango wezempilo wezifunda saKwaZulu Natal. Uma ulwazi oluvele kulolucwaningo 
lunikezelwa noma kubani nangasiphi isikhathi, akuyikudalulwa gama lamuntu, Kodwa kuyomane kusetshenziswe 
amakhodi noma amagamambumbulu njengokuthi umbambiqhaza “A” noma “B” njengoba bese ngike ngachaza 
ngaphambilini. 
Imiphumela yalolucwaningo efingqiwe ungase uyithole uma kwenzeka uyidinga.  
.  
Ukubekwa nokulahlwa kolwazi oluqoqelwe ucwaningo 
Lonke ulwazi (oluqoqwe ngesiqopha mazwi, olubhalwe phansi noluguqulelwe eSingisini) nolwazi olutholakale 
kulolu cwaningo luzobekwa iminyaka emihlanu ukuze lisetshenziswe makuvela isidingo ngenkathi ezayo. Konke 
lokhu kuzobekwa kuMphathi kaMcwaningi, eNyuvesi lugcinwe entweni ekhiywayo, (ekhabetheni lokubeka 
amafayela). Uma sesiphelile isiskhathi esiyinyaka emihlanu, luyobe selucinwa, okungamaphepha kushiswe 
ngomlilo. Ulwazi olugcinwe ngamaKhompuyutha nolungekho emaphepheni luyovikelwa ngenombolo eyimfihlo 
ukuqinisekisa ukuthi akekho omunye umuntu okwazi ukufinyelelela kulo, ngaphandle koMcwaningi noMphathi 
wakhe kuphela. Lonke ulwazi olubekwe emaKhompuyutheni nolugcine kwezinye izinto zokugcina ulwazi 
luyocinwa uma isikhathi esingangegeminyaka emihlanu sesidlulile.  
Ulwazi mayelana nengculazi nesandulela sayo 
Kungenzeka ukuthi ngokubamba kwakho iqhaza kulolu cwaningo uzizwe udinga olunye ulwazi nokwesekwa. 
Uma noma luphi ulwazi mayelana nesandulela ngculazi nengculazi nokunye okumayelana nempilo ungabheka 
kulamapheshana olwazi ozowanikezelwa uMcwaningi, ungaya kunoma muphi uMtholampilo kaHulumeni, 
ukhulume nomaluleki oluleka ngesandulela ngculazi nengculazi. 
 
Ungashayela kule lenombolo yosizo olumayelana nengculaza: 0800 012 322 (imahhala uma uyishayela 
ocingweni lakwa telkom) 
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Uma udinga izaluleko nokwalulekwa ungashayela lenombolo engenhla, ungaya kunoma muphi umtholampilo 
oseduze nawe, noma ubonane nanoma yimuphi umaluleki wasemtholampilo kahulumeni, noma uze kulo 
mtholampilo ucele umaluleki ongu Tholakele Ngobese.  
 
Igama likameluleki      :     uTholakele Ngobese 
Inombolo yomtholampilo  : 036 431 8133 (Injisuthi clinic) 
Uma unakuphi onganasiqinisekiso kukona mayelana nalolu cwaningo ungaxhumana Ms Phume Ximba wekomidi 
elibhekele ubulungiswa uma kwenziwa ucwaningo ngezimpilo zabantu (Humanities and Social Science 
Research Ethics Committee) (ucingo: 031 260 3587, email/umbikonyazi: ximbap@ukzn.ac.za) 
Uma unanoma yimuphi umbuzo mayelana nalolucwaningo ungathintana no: 
 Mcwaningi - Mnu. Jabulani Cele (cell:XXXXXXXXXX), 
Umphathi waseMtholampilo Injisuthi - Mrs. G Ganes (Tel: 036 431 8133) noma 
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Appendix Three (C): Information sheet for Health Care Workers (clinic nurses, counsellors and CCGs)  
 
The Study 
The purpose of this study is to establish an understanding of key barriers to adherence to antiretroviral treatment 
(ART) for clients that are living with HIV. 
 
This is a study about the experiences of the clients that are living with HIV and are using (ART) to control HIV. 
The main focus is to find out the challenges that were met during the first line regimen, which might have 
contributed to poor adherence to ART and change of ART regimen.  
 
Direct benefits of participating in this study may be that you would get an opportunity to share your experiences 
on helping clients that are living with HIV and their experiences of taking antiretroviral drugs (ARVs) and the 
challenges you met, which may be therapeutic to you as a health care worker.  
Moreover, because the results (and not exactly your words) will be shared with the decision makers, the results 
of the study may influence decisions taken around supporting HIV positive and on ART individuals, thus 
benefiting more people that are living with HIV and are using ART.  
(Brennan, 2014) 
 
The Health Care Worker’s interviews 
This Interview is expected to take about 30 to 45 minutes. It will take place in one of the counselling consulting 
rooms in the afternoon when the clinic workload is a bit lower. It will be in a private and confidential space. 
Interviews will be conducted by the researcher (Jabulani Cele) who is a male and familiar with health care facility 
setting and has experience working with HIV positive clients. 
 
You are going to be asked to share your experiences about clients that are taking ARVs. Challenges that are met 
by clients are going to be explored. Reasons for clients to stop ARVs are going to be discussed. There will be no 
personal questions about your own HIV status. You are encouraged to share as much as you can; your answers 
are not going to be judged in terms of right and wrong good or bad. During the discussions you are encouraged 
not to mention names (yours and that of the clients you work with) but rather refer to clients as “a client” or 
“another client” and then share the experience around the client. .  
 
Please take off your name tag and not put it on during the interviews, and you are also encouraged not to 
mention your name during the interview so that when data is transcribed and analysed it is not possible to link 
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Recording  
I would ask for your permission to record the interview. This will help me to capture all you have said during the 
interview. This data will then be transcribed and analysed by the researcher so as to understand better your 
experiences as shared during the interview. (There is a separate consent form for audio recording) 
 
Participation in the study 
Your participation in this study is absolutely voluntary. Please be aware that you have a right to stop your 
participation in the study at any given stage. If that happens it is not going to have any bad consequences in the 
future of your career. During the study if the researcher feels that you are getting upset, will indicate that to you 
and ask you if you are still willing to continue participating in the interview.  
 
After the interview 
After the interviews all recorded data will be transcribed word for word and translated from isiZulu to English. 
Transcribed and translated data will be analysed and the research report is going to be written out of it. The 
same researcher who interviewed you will do the transcription and translation. The second person will only come 
into contact with the data when verifying the quality of translated data in a form of a written document.  
 
No name of participants will be mentioned when working with data. For an example during transcription (writing it 
down word for word), translation, verification of translation analysis and reporting of research findings research 
participants will not be referred to by names or any identifiable features. Coding will be used. For example 
Participant “A” or participant “B” 
 
Findings of this study will appear in a thesis for examination for the researcher’s degree of Masters in 
Psychology. It will be publically available in the UKZN library. Since information from this study is of a high value, 
findings from this study may be shared with other researchers, in AIDS seminars, AIDS conferences, HAST (HIV, 
AIDS, STI and TB) Meetings and with the provincial department of health. When information from this study is 
shared in any form or platform, there is going to be no mention of names, but rather pseudonyms and labels 
such as “research participant A”. 
 
A summary of the results of this study may be made available to you should you wish to get them.  
 
Storage of Information 
All data (audio, transcribed and translated) and information from this study will be stored for five years for future 
references. It will be stored with researcher’s supervisor, kept in lockable device (a filling cabinet). When the 
period of 5 years has lapsed it will be destroyed and incinerated. Electronic data will be protected with a 
password to ensure that access is limited to only the researcher (me) and my supervisor. All electronic data will 
be deleted from the systems and storage devices including backups, when the period of 5 years has lapsed.  
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HIV/AIDS information 
It may be possible that your participation in this study triggers some of the issues and resulting in you needing 
further information. If you need any information on HIV and AIDS and other health matters relating to HIV, you 
could refer to the pamphlets provided by the researcher, go to any nearest government clinic, call a toll free 
number for HIV/AIDS line provided above, or speak to an HIV counsellor in this clinic. For counselling and 
advices you can call the helpline, go to any government clinic that is accessible to you, or talk to any HIV/AIDS 
counsellor. 
 
AIDS help line: 0800 012 322 
If you have any concerns about this study you can also contact Ms Phume Ximba of the Humanities and Social 
Science Research Ethics Committee (031 260 3587, email ximbap@ukzn.ac.za) 
If you have any questions about this study, then please talk to: 
 
The researcher - Mr. Jabulani Cele (cell:  XXXXXXXXXXXXX), 
 
The Operational Manager of Injisuthi clinic - Mrs. G Ganes (Tel: 036 431 8133) or Talk to the researcher’s 
supervisor - Dr Mary van der Riet (Tel: 033 260 6163 email: vanderriet@ukzn.ac.za). 
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Appendix Four (A): Invitation 
 
Inviting ART clients to participate on ART adherence study 
You are cordially invited to participate in a study that investigates barriers to adherence that 
lead to client to be switched from the first line ART regimen to another set of pills. 
 
1. Have you been diagnosed with HIV, and used ARVs to control HIV, and at some stage have 
found ARVs to be no longer working/effective to control HIV anymore? And you had to be 
switched onto another set of ARVs?  
 
If so, we would like you to volunteer to participate in a study that is investigating challenges you may 
have met while you were still using first combination of pills, which may have led to being changed 
onto another combination of pills through listening to your story. 
If you would like to volunteer to participate, please read through the information regarding your 
participation below and let your counsellor know. She will pass on the information to me as the 
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Appendix Four (B): Invitation (isimemo) - IsiZulu 
 
Kumenywa abasebenzisa imishanguzo yesandulela ngculaza ukuba babambe 
iqhaza ocwaningweni olumayelana nokusetshenziswa ngendlela 
kwemishanguzo 
Uyamenywa ukuba uzobamba iqhaza ocwaningweni oluhlola izinselelo ezikhona 
ekuthatheni imishanguzo ngendlela neziholela ekutheni umuntu aze ayekiswe imishanguzo 
abeyisebenzisa afakwe kweminye.   2. Ngabe usuwathola ukuthi uphila nesandulela ngculaza 
(HIV)? Uyayisebenzisa imishanguzo ukulawula/ukuthothobalisa isandulela ngculaza? Wake waba 
nesikhathi lapho amaphilisi (imishanguzo) engasakusebenzeli khona? Wase ushintshelwa 
kwamanye amaphilisi (imishanguzo/ARVs)? 
Uma kunjalo, singathanda ukuba ubambe iqhaza ocwaningweni olubheka kabanzi izinselelo okungase 
kube wahlangana nazo ngenkathi usebenzisa imishanguzo okokuqala, okwaye kwaholela ekutheni uze 
ushintshelwe kolunye uhlobo lwamaphilisi, ngokulalela udaba lwakho.  
 
Uma ungathanda ukubamba iqhaza kulolucwaningo uyacelwa ukuba ufunde ipheshana elinolwazi 
mayelana nokubamba kwakho iqhaza kulolucwaningo bese wazisa umeluleki/ikhansela lakho. Yena 
uyobe esedlulisela lolu lwazi kimina njengomcwaningi [uJabulani Cele, otholakala kulenombolo 




121 | P a g e  
 
Appendix Five (A) 
 
Interview schedule: For participants using ARVs 
 
Semi structured questions for research participants: 
1. How did you discover that you are living with HIV? 
2. How did you go about disclosing your HIV status, if you did so?  
3. Who would you say has been supporting you since you learned about your HIV status? 
4. Would you like to share what your health condition was like before you took ARVs? 
5. Would you like to share what your CD4 count was like by that time? 
6. What has been your reason for using ARVs? What did you want them to do for you? 
7. How did you did you start using ARVs? Or what happened when you were starting on ARVs? 
8. How long have you taken ARVs before you were switched on to another type of ARVs? 
9. Tell me about your experience on ART? 
10. Where were you storing your ARVs? 
11. What did you use to remind yourself when it was time for taking your treatment? 
12. Who was supporting you at home and in the community during on ART during that period? 
13. What support did you get from the clinic? 
14. When you are to travel to somewhere, how did you ensure that taking your medication  
              continues?     
15.       When you travel, what happens to your ARV treatment? 
16.       What would you say made it difficult for you to adhere to taking ARVs? 
17. What would you say was the most difficult time for you to take your treatment? 
18. What lead you to be switched onto the treatment you are on right now? 
19. When was the easiest time for you to take you medication? 
20. How have ARVs improved your life thus far? 
21.      When do you get your treatment? 
22.       When do you know that your treatment is running out? 
23.      How do you get prepared not to run out of treatment? 
24.     When do you take your treatment? 
25.      What are some of the challenges to taking the treatment?  
26.     Is there anything you would like to say about taking your treatment? 
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Appendix five (B) 
 
Interview schedule: For participants using ARVs 
 
Semi structured questions for research participants: 
1. Wathola kanjani ukuthi usuphila nesandulela ngculaza (I HIV)?  
2. Uma kukhona osuwamazisa ngesimo sakho sokuphila negciwane, wakwenza kanjani lokhu?  
3. Ungathi ngubani oyaye akweseke selokhu wathola ukuthi usuphila nesandulela ngculazi? 
4. Ungachaza hleze ukuthi isimo sakho sezempilo sasinjani ngaphambi kokuqala ukusebenzisa       
Imishanguzo (ARVs)?    
5. Ungathanda ukuchaza ngesimo sakho samasosha omzimba ukuthi sasimi kanjani ngaleso       
sikhathi? 
6. Kwabe kuyisiphi isizathu owabe uyidingela sona imishanguzo? Imishanguzo wawufisa       
ikwenzeleni? 
7. Wayiqala kanjani imshanguzo? Noma, kwenzakalani ngenkathi uqala ukuyisebenzisa? 
8. Wabe usuyisebenzise isikhathi esingakanani imishanguzo ngaphambi kokuba ushintshelwe       
kolunye uhlobo lwamaphilisi (ama - ARVs)? 
9. Ngicela ungixoxele ngobekwenzeka ngenkathi usuthatha imishanguzo? 
10. Ubuyaye uwabeke kuphi amaphilisi akho?  
11. Yini ebiyaye ikusize ukuzikhumbuza uma sekuyisikhathi sokuthatha amaphilisi akho? 
12. Ubani ongathi ubekweseka ekhaya nasemphakathini ngaleso sikhathi? 
13. Hlobo luni lokwesekwa obuluthola emtholampilo? 
14. Uma unohambo oluya ndawana thize, ubuwenzenjani ukuqinisekisa ukuthi kuyaqhubeka ukudla 
amaphilisi ngendlela? 
15. Yini ongase uthi ibikwenza kube lukhuni ukuthatha amaphilisi ngendlela? 
16. Yisiphi isikhathi ongathi yisona okwaba nzima kakhulu kusona ukuqhubeka nokuthatha       
amaphilisi?  
17. Yikuphi ongathi kwaba yisizathu ngqangi sokuba ushintshelwe emaphilisini owasebenzisa         
manje? 
18. Kunini lapho bekuba lula khona kuwe ukuthatha/ukuphuza amaphilisi akho? 
19. Ungathi imishanguzo ilithuthukise kanjani izinga lempilo yakho kuze kube namuhla? 
20. Okwamanje uma unohambo uyaye wenze njani ngamaphilisi? 
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21. Uvame ukuwathola nini amaphilisi akho avela emtholampilo? 
22. Ubona nini ngokuvamaile ukuthi aseyaphela amaphilisi? 
23. Uyaye wenze njani ukuqinisekisa ukuthi awakupheleli amaphilisi? 
24. Uyaye uwathathe ngasikhathi sini okwamanje?  
25. Yiziphi ezinye zezingqinamba obhekana nazo ekuthatheni amaphilisi wona qobo lwawo?  
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Appendix Six (A):  Questions for Health Care Workers (Lay Counsellors, nurses and CCGs) 
 
 
1. Would you please share with me the services you offer to HIV positive clients? 
2. How long have you been working with people that are living with HIV? 
3. On average how many HIV positive clients do you offer services to per day? 
4.  Of the HIV positive clients you see per day how many would you say are on ART? 
5. Please take me through what you normally do from when the client gets in through your door 
until when she/he leaves? 
6. Would you say that your clients sometimes find it difficult to take their treatment? 
7. What do they normally mention as their reasons for difficulties for taking their treatment? 
8. What are the reasons for stopping medication you have heard more frequently from your 
clients?  
9. What do you think makes your clients stop taking their medication, apart from what they 
themselves say? 
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Appendix Six (B): Questions for Health Care Workers (Lay Counsellors, nurses and CCGs) 
 
1. Ngicela ungixoxele ngezinsiza oyaye nizinikezele kubantu abaphila negciwane lengculaza (HIV)? 
2. Sesisingakanani isikhathi usebenza nabantu abaphila negciwane lengculazi?  
3. Ngokuvamile ungathi bangakhi abantu abaphila nesandulela ngculazi oyaye ubasize ngosuku? 
4. Koyaye ubabone abaphila negciwane ngosuku ungathi bangakhi abasebenzisa imishanguzo? 
5. Ngicela ungixoxele ngovame ukwenze kusukela umuntu engena kuze kube uyophuma 
ngomnyango?  
6.  Ungasho yini ukuthi kwesinye isikhathi abantu abasebenzisa imishanguzo obasizayo babuye   
bakuthole kunzima ukuthatha amaphilisi abo? 
7. Bayeye babike kuphi njengezizathu ngqangi ngobunzima bokuthatha amaphilisi abo? 
8.  Yiziphi izizathu zokuyeka amaphilisi ovame ukuzizwa kaningi kubantu abathatha amaphilisi 
obasizayo? 
9. Ucabanga ukuthi yini eyenza abasebenzisa imishanguzo obasizayo bayiyeke, ngaphadle kwalokhu 
abakushoyo bona qobo lwabo? 
10. Kukhona olunye ulwazi onalo ongase uthande uklwedlulisa mayelana nosebenza ngabo abaphila 
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Appendix Seven (A): Informed consent  
 







I _______________________________________hereby give consent to participate in the ARV 
Adherence study voluntarily.  
1. All the information about the study I am participating in has been given to me. 
2. The nature and the purpose of the study I am involved in have been disclosed to me. 
3. I have been informed that responses will be treated in a confidential manner, even 
though the findings of the whole study would be disclosed, but this would be done 
without disclosing that it is I who responded as such.  
4. I have been informed about my choice remain anonymous, and I have been encouraged 
to do so.  
5. I understand that I can quit at any time during this study should I wish to do so without 
fear of being punished or excluded from the clinic services and care.  
6. The name and the surname of a researcher as well as the institution he is associated with 
and the name of his supervisor and the contacts of both the supervisor and the 
researcher have been shared with me. 
 























127 | P a g e  
 
 
Appendix Seven (B) Informed consent (translated version). 







Mina _______________________________________Nginika imvumo yokuba yingxenye yocwaningo 
olumayelana nokusetshenziswa kwemishanguzo yegciwane lengculaza ngendlela ngokuzikhethela 
ngingaphoqwanga.  
1. Lonke ulwazi mayelana nocwaning engizibandakanya nalo ngilunikeziwe. 
2. Ngichazeliwe ngenhloso ocwaningo nohlobo nobunjalo balo.  
3. Ngichazeliwe ngokuthi engikushilo ocwaningweni kuzogcinwa kuyimfihlo.  
4. Ngazisiwe ukuthi imiphumela iyodalulwa ngaphandle kokuveza umnikazi wezimpendulo. 
5. Ngazisiwe ngelungelo lami lokukhetha ukungazisho igama lami, ngakhuthazwa ukuba 
ngilifihle. 
6. Ngiyaqonda ukuthi ngingazikhethela noma nini ukuyeka ukuba yingxenye yalolucwaningo 
uma ngifisa ngaphandle kokwesabela ukujeziswa noma ngilahlekelwe yilungelo lami 
lokuthola usizo olutholakala emtholampilo nokunakekelwa. 
7. Igama nesi bongo sowenza ucwaningo, nomphathi wakhe nesikhungo asebenzisana naso 
kunye nezindlela zokuxhumana nabo bobabili owenza ucwaningo nomphathi wakhe 
nginikeziwe kona. 
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Appendix Eight (A): Consent form for audio recording of interview  
 






   
In order to capture all you would have said, I would ask for your permission to record interviews which will be 
later on transcribed analysed by the researcher so as to understand better you shared experiences during 
interviews. Recorded will be transcribed and translated into English by the researcher.  
 
After translation and transcription, a second person will verify the written and translated data. All recorded data 
will be deleted from all recording devices once it has been written.  
 
Recorded data is not going to have your name. Instead it will be given a code such as Participant “A” or “B” 
 
I hereby provide consent to: 
                                         Please tick in the box below to indicate your choice 
Audio-record my interview discussion    
            
       I AGREE     I DO NOT AGREE 
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Appendix Eight (B): Consent form for audio recording of an interview (isiZulu) 
 







Ukuze kubanjwe konke ozobe ukushilo, ngicela imvumo yakho ukuqopha inkulumo ngxoxo yethu. Kuzothi emva 
kwesikhathi umcwaningi ayibhale phansi igama negama, ayihlaziye ukuze aqondisise kangcono ukuthi oye 
wakhuluma ngakho mayelana noye wabhekana nakho yakho. Lokho okuzobe sekubhalwe phansi kuyobe 
sekuguqulelwa esingisini kusaguqulwa nguyena umcwaningi. 
 
Ngemuva kokuba sekubhalwe phansi kwayiswa esingisini okubhaliwe, umuntu wesibili uyobe esengenelela 
ukuqinisekisa-ke ukuthi kuguqulelwe ngokho yini esingisini kusuka esizulwini. Okuqoshiwe kuyobe 
sekuyacinywa konke uma sekubhalwe phansi. 
 
Aliyukufakwa igama lakho kokuqoshiwe. Kuyomane kusetshenziswe izinkomba (code) ezingadaluli muntu, 
njengokuthi nje, obebambe iqhaza wokuqala “A”, noma obebambe iqhaza wesibili “B”. 
 
I hereby provide consent to: 
                        Sicela ukhethe ngokukhombisa ebhokisini elingezansi, okuhambisana nawe 
 
Lapha nginikeza imvume yokuqopha inkulumo ngxoxo yami 
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Appendix Twelve: Sub-District (Estcourt Hospital) Acting CEO Letter of support 
 
 
 
